"ticker","title","summary","published","description","link","language","subject","sector","published_est","market","hour_of_day","begin_price","end_price","index_begin_price","index_end_price","return","index_return","alpha"
ELOX,Eloxx Pharmaceuticals Reports First Quarter 2023 Financial and Operating Results and Provides Business Update,Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date,2023-05-15 23:30:00.000 +0300,Topline results to include biopsy results for the Phase 2 clinical study evaluating ELX-02 for the potential treatment of Alport syndrome expected in first half of 2023; meaningful protein reduction has been observed in one patient to date,https://www.globenewswire.com/news-release/2023/05/15/2669369/0/en/Eloxx-Pharmaceuticals-Reports-First-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-05-15 18:30:00.000 +0300,market_open,15,3.5399999618530273,10.899999618530273,412.2200012207031,413.010009765625,2.07909597061821,0.0019164731031546998,2.077179497515055
TTOO,T2 Biosystems Receives FDA Breakthrough Device Designation for Candida Auris Diagnostic Test,"LEXINGTON, Mass., July  20, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.",2023-07-20 15:30:00.000 +0300,"LEXINGTON, Mass., July  20, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the Company’s Candida auris (C. auris) direct-from-blood molecular diagnostic test.",https://www.globenewswire.com/news-release/2023/07/20/2708188/32489/en/T2-Biosystems-Receives-FDA-Breakthrough-Device-Designation-for-Candida-Auris-Diagnostic-Test.html,,Product / Services Announcement,biotech,2023-07-20 10:30:00.000 +0300,pre_market,7,0.10199999809265137,0.14000000059604645,455.20001220703125,454.1700134277344,0.3725490511174118,-0.002262738909656306,0.3748117900270681
TTOO,T2 Biosystems Announces Submission for FDA Breakthrough Device Designation for Candida Auris Diagnostic Test,Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel,2023-06-05 16:00:00.000 +0300,Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel Company plans to add multidrug-resistant Candida auris detection to its FDA-cleared T2Candida Panel,https://www.globenewswire.com/news-release/2023/06/05/2682027/32489/en/T2-Biosystems-Announces-Submission-for-FDA-Breakthrough-Device-Designation-for-Candida-Auris-Diagnostic-Test.html,,Company Announcement,biotech,2023-06-05 11:00:00.000 +0300,pre_market,8,0.10199999809265137,0.13899999856948853,427.9200134277344,428.2799987792969,0.36274510949724065,0.0008412444855732,0.36190386501166744
TALS,Talaris Therapeutics to Present at the H.C. Wainwright Global Investment Conference,"BOSTON and LOUISVILLE, Ky., May  17, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.",2022-05-17 23:01:00.000 +0300,"BOSTON and LOUISVILLE, Ky., May  17, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced today announced that Scott Requadt, Chief Executive Officer of Talaris, will be presenting virtually at the H.C. Wainwright Global Investment Conference being held May 23-25, 2022.",https://www.globenewswire.com/news-release/2022/05/17/2445422/0/en/Talaris-Therapeutics-to-Present-at-the-H-C-Wainwright-Global-Investment-Conference.html,,Calendar of Events,biotech,2022-05-17 18:01:00.000 +0300,market_open,15,6.809999942779541,8.890000343322754,406.5299987792969,408.32000732421875,0.30543324787375087,0.004403140113390898,0.30103010776036
ELOX,Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis (CF) Patients, ,2023-06-14 23:53:00.000 +0300, ,https://www.globenewswire.com/news-release/2023/06/14/2688488/0/en/Eloxx-Pharmaceuticals-Announces-Final-Data-Assessment-from-Phase-2-Combination-Clinical-Trial-of-ELX-02-in-Class-1-Cystic-Fibrosis-CF-Patients.html,,Clinical Study,biotech,2023-06-14 18:53:00.000 +0300,market_open,15,5.599999904632568,6.980000019073486,437.010009765625,437.17999267578125,0.24642859606110362,0.0003889680015508,0.2460396280595528
PYPD,PolyPid Announces Reverse Share Split,"PETACH TIKVA, Israel, Sept.  20, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, such that each thirty (30) Ordinary Shares, shall be consolidated into one (1) Ordinary Share.",2023-09-20 16:15:00.000 +0300,"PETACH TIKVA, Israel, Sept.  20, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announces a reverse share split (the “Reverse Split”) of the Company’s issued and outstanding ordinary shares, no par value (“Ordinary Shares”), at the ratio of 1-for-30, such that each thirty (30) Ordinary Shares, shall be consolidated into one (1) Ordinary Share.",https://www.globenewswire.com/news-release/2023/09/20/2746559/0/en/PolyPid-Announces-Reverse-Share-Split.html,,Stock Market News,biotech,2023-09-20 11:15:00.000 +0300,pre_market,8,6.03000020980835,7.5,442.7099914550781,444.010009765625,0.24378105125113606,0.002936500950145798,0.24084455030099025
ORPHA.CO,Change in management,"The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.",2023-05-30 20:41:00.000 +0300,"The board of directors and CEO/CFO Anders Fink Vadsholt has today entered into a severance agreement pursuant to which Mr. Vadsholt will step down as CEO/CFO of the Company. Regardless, Mr. Vadsholt will remain available for the company until his replacement has been found and all disputes related to the US security class action case has been finally settled, however, in no event longer than until 1 October 2023.",https://www.globenewswire.com/news-release/2023/05/30/2678759/0/en/Change-in-management.html,,European Regulatory News,biotech,2023-05-30 15:41:00.000 +0300,market_open,12,2.259999990463257,2.700000047683716,422.0299987792969,420.17999267578125,0.1946902916270665,-0.004383589102354538,0.19907388072942103
TTOO,T2 Biosystems to Participate in the Gilmartin Group Emerging Growth Company Showcase,"LEXINGTON, Mass., Sept.  07, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to host a fireside chat on Thursday, September 21, 2023, at 10:30am ET.",2023-09-07 23:05:00.000 +0300,"LEXINGTON, Mass., Sept.  07, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in the upcoming Gilmartin Group Emerging Growth Company Showcase, taking place virtually. Members of management are scheduled to host a fireside chat on Thursday, September 21, 2023, at 10:30am ET.",https://www.globenewswire.com/news-release/2023/09/07/2739767/32489/en/T2-Biosystems-to-Participate-in-the-Gilmartin-Group-Emerging-Growth-Company-Showcase.html,,Conference Calls/ Webcasts,biotech,2023-09-07 18:05:00.000 +0300,market_open,15,0.29100000858306885,0.34299999475479126,443.1099853515625,444.8500061035156,0.17869410528514984,0.0039268371498615545,0.17476726813528828
DYAI,"Dyadic to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023","JUPITER, Fla., April  26, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.",2023-04-26 23:30:00.000 +0300,"JUPITER, Fla., April  26, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it will report its financial results for first quarter 2023 and host a corporate update conference call on Wednesday, May 10, 2023.",https://www.globenewswire.com/news-release/2023/04/26/2655687/0/en/Dyadic-to-Report-First-Quarter-2023-Financial-Results-on-Wednesday-May-10-2023.html,,Calendar of Events,biotech,2023-04-26 18:30:00.000 +0300,market_open,15,1.809999942779541,2.0999999046325684,406.7200012207031,404.3599853515625,0.16022097846461064,-0.005802556702540878,0.16602353516715151
TTOO,T2 Biosystems Reports Granting of Inducement Award,"LEXINGTON, Mass., Oct.  06, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to nine new employees.",2023-10-06 23:07:00.000 +0300,"LEXINGTON, Mass., Oct.  06, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to nine new employees.",https://www.globenewswire.com/news-release/2023/10/06/2756309/32489/en/T2-Biosystems-Reports-Granting-of-Inducement-Award.html,,Contests/Awards,biotech,2023-10-06 18:07:00.000 +0300,market_open,15,0.2240000069141388,0.2630000114440918,421.9700012207031,429.5400085449219,0.1741071577060355,0.017939681262458766,0.15616747644357673
KA,Kineta Announces New Research Agreement to Evaluate VISTA Biomarker Expression,"SEATTLE, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today a research agreement with Fred Hutchinson Cancer Center to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.",2023-09-18 16:30:00.000 +0300,"SEATTLE, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today a research agreement with Fred Hutchinson Cancer Center to evaluate VISTA expression as a potential biomarker in cancer patients from Kineta’s ongoing Phase 1/2 clinical trial evaluating KVA12123, the company’s VISTA blocking immunotherapy, alone and in combination with pembrolizumab.",https://www.globenewswire.com/news-release/2023/09/18/2744896/0/en/Kineta-Announces-New-Research-Agreement-to-Evaluate-VISTA-Biomarker-Expression.html,,Health,biotech,2023-09-18 11:30:00.000 +0300,pre_market,8,1.9299999475479126,2.2200000286102295,443.3699951171875,443.04998779296875,0.15025911344234252,-0.0007217613454744,0.1509808747878169
EVAX,Evaxion Partners With Pharmaceutical Company Afrigen Biologics to Develop Novel mRNA Vaccine Against Gonorrhea,"COPENHAGEN, Denmark, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced a collaboration with Afrigen Biologics (Afrigen). The collaboration aims at developing a prophylactic vaccine based on Evaxion’s EDEN™-discovered gonorrhea targets.",2023-09-20 15:26:00.000 +0300,"COPENHAGEN, Denmark, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced a collaboration with Afrigen Biologics (Afrigen). The collaboration aims at developing a prophylactic vaccine based on Evaxion’s EDEN™-discovered gonorrhea targets.",https://www.globenewswire.com/news-release/2023/09/20/2746452/0/en/Evaxion-Partners-With-Pharmaceutical-Company-Afrigen-Biologics-to-Develop-Novel-mRNA-Vaccine-Against-Gonorrhea.html,,Partnerships,biotech,2023-09-20 10:26:00.000 +0300,pre_market,7,0.47999998927116394,0.5529999732971191,442.7099914550781,444.010009765625,0.15208330345340007,0.002936500950145798,0.14914680250325427
EVAX,Evaxion geht Partnerschaft mit dem Pharmaunternehmen Afrigen Biologics zur Entwicklung eines neuartigen mRNA-Impfstoffs gegen Gonorrhoe ein,"KOPENHAGEN, Dänemark, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von KI-gestützten Immuntherapien spezialisiert hat, hat heute eine Zusammenarbeit mit Afrigen Biologics (Afrigen) bekanntgegeben. Ziel der Zusammenarbeit ist die Entwicklung eines prophylaktischen Impfstoffs, der auf den mittels der EDEN™-Plattform von Evaxion entdeckten Gonorrhoe-Ziele basiert.",2023-09-20 15:26:00.000 +0300,"KOPENHAGEN, Dänemark, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) („Evaxion“ oder das „Unternehmen“), ein im klinischen Stadium tätiges Biotechnologieunternehmen, das sich auf die Entwicklung von KI-gestützten Immuntherapien spezialisiert hat, hat heute eine Zusammenarbeit mit Afrigen Biologics (Afrigen) bekanntgegeben. Ziel der Zusammenarbeit ist die Entwicklung eines prophylaktischen Impfstoffs, der auf den mittels der EDEN™-Plattform von Evaxion entdeckten Gonorrhoe-Ziele basiert.",https://www.globenewswire.com/news-release/2023/09/20/2755536/0/de/Evaxion-geht-Partnerschaft-mit-dem-Pharmaunternehmen-Afrigen-Biologics-zur-Entwicklung-eines-neuartigen-mRNA-Impfstoffs-gegen-Gonorrhoe-ein.html,,Partnerships,biotech,2023-09-20 10:26:00.000 +0300,pre_market,7,0.47999998927116394,0.5529999732971191,442.7099914550781,444.010009765625,0.15208330345340007,0.002936500950145798,0.14914680250325427
EVAX,Evaxion s'associe à la société pharmaceutique Afrigen Biologics pour développer un nouveau vaccin à ARN messager contre la gonorrhée,"COPENHAGUE, Danemark,  05 oct. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique et spécialisée dans le développement d'immunothérapies reposant sur l'IA, a annoncé ce jour une collaboration avec Afrigen Biologics, ci-après « Afrigen ». Cette collaboration vise à développer un vaccin prophylactique basé sur les cibles de la gonorrhée découvertes par la plateforme EDEN™ d'Evaxion.",2023-09-20 15:26:00.000 +0300,"COPENHAGUE, Danemark,  05 oct. 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ : EVAX), ci-après « Evaxion » ou la « Société », une société de biotechnologie axée sur la recherche clinique et spécialisée dans le développement d'immunothérapies reposant sur l'IA, a annoncé ce jour une collaboration avec Afrigen Biologics, ci-après « Afrigen ». Cette collaboration vise à développer un vaccin prophylactique basé sur les cibles de la gonorrhée découvertes par la plateforme EDEN™ d'Evaxion.",https://www.globenewswire.com/news-release/2023/09/20/2755536/0/fr/Evaxion-s-associe-%C3%A0-la-soci%C3%A9t%C3%A9-pharmaceutique-Afrigen-Biologics-pour-d%C3%A9velopper-un-nouveau-vaccin-%C3%A0-ARN-messager-contre-la-gonorrh%C3%A9e.html,,Partnerships,biotech,2023-09-20 10:26:00.000 +0300,pre_market,7,0.47999998927116394,0.5529999732971191,442.7099914550781,444.010009765625,0.15208330345340007,0.002936500950145798,0.14914680250325427
SNCE,Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"RESEARCH TRIANGLE PARK, N.C., June  09, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",2023-06-09 23:51:00.000 +0300,"RESEARCH TRIANGLE PARK, N.C., June  09, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",https://www.globenewswire.com/news-release/2023/06/09/2685814/0/en/Science-37-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html,,Stock Market News,biotech,2023-06-09 18:51:00.000 +0300,market_open,15,0.25999999046325684,0.2980000078678131,429.9599914550781,429.8999938964844,0.14615391845534098,-0.0001395421894737,0.14629346064481472
ANAB,AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer,"SAN DIEGO, July  31, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The supplemental Biologics License Application (sBLA) supporting this new indication received Priority Review and was approved ahead of the Sept. 23, 2023 Prescription Drug User Fee Act action date.",2023-07-31 20:34:00.000 +0300,"SAN DIEGO, July  31, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK has received U.S. Food and Drug Administration (FDA) approval for JEMPERLI (dostarlimab-gxly) plus carboplatin and paclitaxel (chemotherapy) for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer. The supplemental Biologics License Application (sBLA) supporting this new indication received Priority Review and was approved ahead of the Sept. 23, 2023 Prescription Drug User Fee Act action date.",https://www.globenewswire.com/news-release/2023/07/31/2715235/0/en/AnaptysBio-and-GSK-Partnered-Immuno-Oncology-Agent-JEMPERLI-dostarlimab-gxly-plus-Chemotherapy-Approved-in-the-U-S-for-dMMR-MSI-H-Primary-Advanced-or-Recurrent-Endometrial-Cancer.html,,Health,biotech,2023-07-31 15:34:00.000 +0300,market_open,12,17.209999084472656,19.709999084472656,457.4100036621094,457.7900085449219,0.14526438890142476,0.0008307751902453,0.14443361371117944
TTOO,T2 Biosystems Reports Granting of Inducement Award,"LEXINGTON, Mass., Sept.  15, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to four new employees.",2023-09-15 23:05:00.000 +0300,"LEXINGTON, Mass., Sept.  15, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to four new employees.",https://www.globenewswire.com/news-release/2023/09/15/2744244/32489/en/T2-Biosystems-Reports-Granting-of-Inducement-Award.html,,Major shareholder announcements,biotech,2023-09-15 18:05:00.000 +0300,market_open,15,0.2460000067949295,0.2770000100135803,447.1400146484375,443.3699951171875,0.1260162697657689,-0.008431407182857849,0.13444767694862675
SCLX,Scilex Holding Company Provides Notice to All Lenders of Short Positions in the Restricted Dividend Shares of Scilex Holding Company,"PALO ALTO, Calif., Oct.  04, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all lenders of short positions of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.",2023-10-04 19:59:00.000 +0300,"PALO ALTO, Calif., Oct.  04, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all lenders of short positions of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.",https://www.globenewswire.com/news-release/2023/10/04/2754860/0/en/Scilex-Holding-Company-Provides-Notice-to-All-Lenders-of-Short-Positions-in-the-Restricted-Dividend-Shares-of-Scilex-Holding-Company.html,,Dividend Reports and Estimates,biotech,2023-10-04 14:59:00.000 +0300,market_open,11,1.2400000095367432,1.409999966621399,422.07000732421875,424.6600036621094,0.13709673852999948,0.006136414085213794,0.1309603244447857
ORIC,ORIC Pharmaceuticals Announces $85 Million Private Placement Financing,"Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital",2023-06-26 15:30:00.000 +0300,"Financing led by Nextech and includes participation from EcoR1 Capital, Frazier Life Sciences, Venrock Healthcare Capital Partners, and Boxer Capital",https://www.globenewswire.com/news-release/2023/06/26/2694439/0/en/ORIC-Pharmaceuticals-Announces-85-Million-Private-Placement-Financing.html,,Changes in company's own shares,biotech,2023-06-26 10:30:00.000 +0300,pre_market,7,6.489999771118164,7.289999961853027,433.2099914550781,432.6199951171875,0.12326659768079329,-0.0013619176600911914,0.12462851534088448
JSPR,Jasper Therapeutics Announces Appointment of Ronald Martell as Chief Executive Officer,"William Lis to Continue as Chairman, Board of Directors William Lis to Continue as Chairman, Board of Directors",2022-02-28 15:00:00.000 +0200,"William Lis to Continue as Chairman, Board of Directors William Lis to Continue as Chairman, Board of Directors",https://www.globenewswire.com/news-release/2022/02/28/2393128/0/en/Jasper-Therapeutics-Announces-Appointment-of-Ronald-Martell-as-Chief-Executive-Officer.html,,Directors and Officers,biotech,2022-02-28 10:00:00.000 +0200,pre_market,8,3.740000009536743,4.119999885559082,437.75,432.0299987792969,0.10160424466667521,-0.013066821749179041,0.11467106641585426
KA,Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial,Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level,2023-10-03 15:30:00.000 +0300,Cleared First Three Monotherapy Cohorts with No Dose Limiting Toxicity and No Consistent Pattern of Adverse Events at any Dose Level,https://www.globenewswire.com/news-release/2023/10/03/2753627/0/en/Kineta-Announces-Positive-KVA12123-Monotherapy-Safety-and-Biomarker-Data-from-its-Ongoing-Phase-1-2-VISTA-101-Clinical-Trial.html,,Clinical Study,biotech,2023-10-03 10:30:00.000 +0300,pre_market,7,4.489999771118164,4.940000057220459,427.30999755859375,425.05999755859375,0.10022278597805571,-0.0052654981462058464,0.10548828412426156
TALS,Talaris Therapeutics Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan,"BOSTON and LOUISVILLE, Ky., Feb.  16, 2023  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001’s ability to induce durable tolerance in living donor kidney transplant recipients. This decision was primarily attributable to the pace of enrollment and the associated timeline to critical milestones. The company will continue to enroll its FREEDOM-3 Phase 2 clinical trial evaluating FCR001’s ability to induce tolerance in scleroderma.",2023-02-16 14:00:00.000 +0200,"BOSTON and LOUISVILLE, Ky., Feb.  16, 2023  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), today announced that it has completed a review of its business and program prospects. Based on this review, Talaris has decided to discontinue its FREEDOM-1 and FREEDOM-2 clinical trials evaluating FCR001’s ability to induce durable tolerance in living donor kidney transplant recipients. This decision was primarily attributable to the pace of enrollment and the associated timeline to critical milestones. The company will continue to enroll its FREEDOM-3 Phase 2 clinical trial evaluating FCR001’s ability to induce tolerance in scleroderma.",https://www.globenewswire.com/news-release/2023/02/16/2609545/0/en/Talaris-Therapeutics-Announces-Plans-to-Explore-Strategic-Alternatives-and-Implements-Restructuring-Plan.html,,Major shareholder announcements,biotech,2023-02-16 09:00:00.000 +0200,pre_market,7,1.5800000429153442,1.7200000286102295,413.9800109863281,408.7900085449219,0.08860758347611412,-0.012536843093077874,0.101144426569192
EYEN,Eyenovia Announces Development Collaboration Agreement with Formosa Pharmaceuticals,Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs. Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs.,2023-02-15 16:51:00.000 +0200,Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs. Collaboration will combine Eyenovia’s Optejet® dispensing technology with Formosa’s APNT™ nanoparticle formulation platform for the potential development of new topical therapeutics in high-value ophthalmic indications with significant unmet medical needs.,https://www.globenewswire.com/news-release/2023/02/15/2608912/0/en/Eyenovia-Announces-Development-Collaboration-Agreement-with-Formosa-Pharmaceuticals.html,,Health,biotech,2023-02-15 11:51:00.000 +0200,market_open,9,2.700000047683716,2.9749999046325684,410.3500061035156,413.9800109863281,0.10185179707117792,0.008846118749409226,0.09300567832176869
ELOX,Eloxx Pharmaceuticals Provides Program Updates on ELX-02 and ZKN-013,Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations,2023-09-07 16:00:00.000 +0300,Investigational New Drug (IND) application submitted to U.S. Food and Drug Administration (FDA) for ELX-02 for the treatment of Alport syndrome with nonsense mutations,https://www.globenewswire.com/news-release/2023/09/07/2739454/0/en/Eloxx-Pharmaceuticals-Provides-Program-Updates-on-ELX-02-and-ZKN-013.html,,Clinical Study,biotech,2023-09-07 11:00:00.000 +0300,pre_market,8,5.260000228881836,5.639999866485596,446.2200012207031,443.1099853515625,0.0722432739674119,-0.006969691767811171,0.07921296573522307
KA,Kineta to Present Preclinical Data on VISTA Blocking KVA12123 at Immuno US 2023,"SEATTLE, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present a preclinical overview of KVA12123, the company’s novel VISTA blocking immunotherapy, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.",2023-10-09 19:10:00.000 +0300,"SEATTLE, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present at the Oxford Global Immuno US 2023, to be held on October 12-13, 2023 in San Diego, CA. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will present a preclinical overview of KVA12123, the company’s novel VISTA blocking immunotherapy, currently being evaluated in a Phase 1/2 clinical trial in patients with advanced solid tumors.",https://www.globenewswire.com/news-release/2023/10/09/2756914/0/en/Kineta-to-Present-Preclinical-Data-on-VISTA-Blocking-KVA12123-at-Immuno-US-2023.html,,Product / Services Announcement,biotech,2023-10-09 14:10:00.000 +0300,market_open,11,3.049999952316284,3.319999933242798,427.5799865722656,432.2900085449219,0.08852458529432618,0.011015534217152153,0.07750905107717403
SCLX,"Scilex Holding Company Announces that Sorrento Therapeutics, Inc.’s Bankruptcy Court Issues Temporary Restraining Order Against Brokerage Firms and Suspends Short-Sales of Dividended Scilex Stock","PALO ALTO, Calif., June  15, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that, in connection with Sorrento Therapeutics, Inc.’s ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) has entered a temporary restraining order suspending short-sales of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) that Sorrento distributed to its stockholders on or around January 19, 2023 (the “Dividended Scilex Stock”).",2023-06-15 16:03:00.000 +0300,"PALO ALTO, Calif., June  15, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that, in connection with Sorrento Therapeutics, Inc.’s ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas (the “Bankruptcy Court”) has entered a temporary restraining order suspending short-sales of common stock of Scilex Holding Company (Nasdaq: SCLX, “Scilex”) that Sorrento distributed to its stockholders on or around January 19, 2023 (the “Dividended Scilex Stock”).",https://www.globenewswire.com/news-release/2023/06/15/2688968/0/en/Scilex-Holding-Company-Announces-that-Sorrento-Therapeutics-Inc-s-Bankruptcy-Court-Issues-Temporary-Restraining-Order-Against-Brokerage-Firms-and-Suspends-Short-Sales-of-Dividended.html,,Changes in company's own shares,biotech,2023-06-15 11:03:00.000 +0300,pre_market,8,7.449999809265137,8.0,437.17999267578125,436.3299865722656,0.07382553084778065,-0.0019442932379250056,0.07576982408570565
TTOO,T2 Biosystems Receives Extension to Comply with Nasdaq Listing Requirements,"LEXINGTON, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through November 20, 2023, to evidence compliance with Nasdaq's minimum bid price and market value of listed securities (“MVLS”) requirements, as set forth in Nasdaq Listing Rules 5550(a)(2) and (b)(2) (the “Rules”).",2023-07-31 15:30:00.000 +0300,"LEXINGTON, Mass., July  31, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through November 20, 2023, to evidence compliance with Nasdaq's minimum bid price and market value of listed securities (“MVLS”) requirements, as set forth in Nasdaq Listing Rules 5550(a)(2) and (b)(2) (the “Rules”).",https://www.globenewswire.com/news-release/2023/07/31/2714891/32489/en/T2-Biosystems-Receives-Extension-to-Comply-with-Nasdaq-Listing-Requirements.html,,Stock Market News,biotech,2023-07-31 10:30:00.000 +0300,pre_market,7,0.11599999666213989,0.12399999797344208,456.9200134277344,457.4100036621094,0.06896553053016792,0.0010723763896861916,0.06789315414048173
ANAB,Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP),"SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile.",2023-10-09 15:00:00.000 +0300,"SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced positive top-line results from its global Phase 3 GEMINI-1 trial evaluating the safety and efficacy of imsidolimab (IL-36R mAb) in patients with generalized pustular psoriasis (GPP) flares. Investigational imsidolimab met its primary endpoint in the study population achieving rapid clearance of pustulation, erythema and scaling through Week 4 after a single dose of 750mg IV imsidolimab. Top-line data also demonstrate a favorable safety and tolerability profile.",https://www.globenewswire.com/news-release/2023/10/09/2756638/0/en/Anaptys-Announces-Positive-Top-Line-Phase-3-Clinical-Trial-Results-of-Imsidolimab-IL-36R-in-Generalized-Pustular-Psoriasis-GPP.html,,Product / Services Announcement,biotech,2023-10-09 10:00:00.000 +0300,pre_market,7,19.25,20.420000076293945,429.5400085449219,427.5799865722656,0.06077922474254261,-0.004563071969234895,0.0653422967117775
ANAB,"Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25","SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25.",2023-10-09 15:15:00.000 +0300,"SAN DIEGO, Oct.  09, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it will host a virtual R&D event for the investment community on rosnilimab, a PD-1 agonist antibody, at 4:15pm ET/1:15pm PT on Wednesday, Oct. 25.",https://www.globenewswire.com/news-release/2023/10/09/2756658/0/en/Anaptys-to-Provide-Overview-of-Rosnilimab-a-PD-1-Agonist-at-Virtual-R-D-Event-on-Wednesday-Oct-25.html,,Product / Services Announcement,biotech,2023-10-09 10:15:00.000 +0300,pre_market,7,19.25,20.420000076293945,429.5400085449219,427.5799865722656,0.06077922474254261,-0.004563071969234895,0.0653422967117775
JSPR,Jasper Therapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update,"REDWOOD CITY, Calif., May  12, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended March 31, 2023, and provided a business update.",2023-05-12 23:05:00.000 +0300,"REDWOOD CITY, Calif., May  12, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended March 31, 2023, and provided a business update.",https://www.globenewswire.com/news-release/2023/05/12/2668154/0/en/Jasper-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-05-12 18:05:00.000 +0300,market_open,15,1.4800000190734863,1.5700000524520874,413.4200134277344,411.5899963378906,0.0608108325802206,-0.004426532413539375,0.06523736499375998
IMNN,IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001,Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies,2023-04-19 15:30:00.000 +0300,Findings from a mouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies,https://www.globenewswire.com/news-release/2023/04/19/2650034/0/en/IMUNON-Presents-Poster-at-the-American-Association-for-Cancer-Research-Annual-Meeting-Demonstrating-Preclinical-Immune-Response-of-IMNN-001.html,,Press releases,biotech,2023-04-19 10:30:00.000 +0300,pre_market,7,1.1699999570846558,1.2400000095367432,414.2099914550781,412.2200012207031,0.059829106854422325,-0.004804302830514455,0.06463340968493678
ORPHA.CO,Major shareholder announcement,Company announcement        ,2023-05-17 19:51:00.000 +0300,Company announcement        ,https://www.globenewswire.com/news-release/2023/05/17/2671372/0/en/Major-shareholder-announcement.html,,European Regulatory News,biotech,2023-05-17 14:51:00.000 +0300,market_open,11,1.121999979019165,1.2000000476837158,412.3500061035156,415.2300109863281,0.06951877907585811,0.006984369686390907,0.06253440938946721
ORIC,ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Updates,"Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer",2023-03-16 22:05:00.000 +0200,"Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer",https://www.globenewswire.com/news-release/2023/03/16/2629174/0/en/ORIC-Pharmaceuticals-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Operational-Updates.html,,Earnings Releases and Operating Results,biotech,2023-03-16 17:05:00.000 +0200,market_open,15,4.599999904632568,4.989999771118164,386.82000732421875,396.1099853515625,0.08478258142849843,0.024016281090541478,0.06076630033795695
DYAI,Dyadic’s C1 Platform Selected by the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital as Part of VIC’s $5.88 Million Award by U.S. DoD to Develop a Self-Assembling Vaccine (SAV) Platform for Rapid Production of Prophylactic Vaccines for Infectious Diseases,"JUPITER, Fla., Oct.  05, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital, as part of VIC’s collaboration with Voltron Therapeutics, Inc. (“Voltron”), to use Dyadic’s proprietary C1 protein production platform to express vaccine antigens for influenza A and other infectious diseases.",2023-10-05 15:30:00.000 +0300,"JUPITER, Fla., Oct.  05, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center (“VIC”) at Massachusetts General Hospital, as part of VIC’s collaboration with Voltron Therapeutics, Inc. (“Voltron”), to use Dyadic’s proprietary C1 protein production platform to express vaccine antigens for influenza A and other infectious diseases.",https://www.globenewswire.com/news-release/2023/10/05/2755390/0/en/Dyadic-s-C1-Platform-Selected-by-the-Vaccine-and-Immunotherapy-Center-VIC-at-Massachusetts-General-Hospital-as-Part-of-VIC-s-5-88-Million-Award-by-U-S-DoD-to-Develop-a-Self-Assembl.html,,Health,biotech,2023-10-05 10:30:00.000 +0300,pre_market,7,2.0199999809265137,2.140000104904175,424.6600036621094,424.3599853515625,0.05940600253006966,-0.0007064906229916,0.0601124931530613
BIOR,Biora Therapeutics Reduces Debt and Largest Shareholder Increases Equity Exposure,"Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023",2023-09-19 15:00:00.000 +0300,"Funds managed by Athyrium Capital Management increase their equity exposure through a convertible notes exchange at a price representing a 44% premium to the closing price on September 18, 2023",https://www.globenewswire.com/news-release/2023/09/19/2745527/0/en/Biora-Therapeutics-Reduces-Debt-and-Largest-Shareholder-Increases-Equity-Exposure.html,,Interim information,biotech,2023-09-19 10:00:00.000 +0300,pre_market,7,2.0899999141693115,2.2100000381469727,443.6300048828125,442.67999267578125,0.05741632961997332,-0.0021414516524467307,0.05955778127242005
ECOR,electroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC,"ROCKAWAY, N.J., June  14, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.",2023-06-14 15:00:00.000 +0300,"ROCKAWAY, N.J., June  14, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.",https://www.globenewswire.com/news-release/2023/06/14/2688000/0/en/electroCore-to-Participate-in-the-Healthcare-Virtual-Conference-Presented-by-Maxim-Group-LLC.html,,Conference Calls/ Webcasts,biotech,2023-06-14 10:00:00.000 +0300,pre_market,7,4.369999885559082,4.630000114440918,436.6600036621094,437.010009765625,0.05949662143951577,0.000801552925801,0.0586950685137148
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"WESTLAKE VILLAGE, Calif., June  05, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 58,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis’ common stock to seven newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 1, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",2023-06-05 23:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., June  05, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 58,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 17,000 shares of Arcutis’ common stock to seven newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of June 1, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",https://www.globenewswire.com/news-release/2023/06/05/2682346/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Changes in company's own shares,biotech,2023-06-05 18:00:00.000 +0300,market_open,15,8.130000114440918,8.5600004196167,428.2799987792969,427.1000061035156,0.05289056569777815,-0.002755189780387874,0.055645755478166026
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"WESTLAKE VILLAGE, Calif., July  05, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 60,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to seven newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 3, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",2023-07-05 23:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., July  05, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 60,250 restricted stock units of Arcutis’ common stock as well as options to purchase an aggregate of 18,000 shares of Arcutis’ common stock to seven newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of July 3, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",https://www.globenewswire.com/news-release/2023/07/05/2699890/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Stock Market News,biotech,2023-07-05 18:00:00.000 +0300,market_open,15,8.779999732971191,9.289999961853027,441.9100036621094,443.1300048828125,0.05808658819961599,0.002760745877198913,0.05532584232241708
ADXN,Addex Announces Plan to Implement ADS Ratio Change, Ad Hoc Announcement Pursuant to Art. 53 LR,2023-10-06 23:00:00.000 +0300, Ad Hoc Announcement Pursuant to Art. 53 LR,https://www.globenewswire.com/news-release/2023/10/06/2756301/0/en/Addex-Announces-Plan-to-Implement-ADS-Ratio-Change.html,,European Regulatory News,biotech,2023-10-06 18:00:00.000 +0300,market_open,15,0.4099999964237213,0.4399999976158142,421.9700012207031,429.5400085449219,0.07317073525310204,0.017939681262458766,0.05523105399064328
RAD.AX,Radiopharm Theranostics Expands Supply Agreement With TerThera for Terbium-161 Isotope Use in Prostate Cancer,"Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer",2023-08-24 15:00:00.000 +0300,"Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer Agreement will supply Tb-161 for RAD 402, a potential next generation radiopharmaceutical for treatment of advanced prostate cancer",https://www.globenewswire.com/news-release/2023/08/24/2731100/0/en/Radiopharm-Theranostics-Expands-Supply-Agreement-With-TerThera-for-Terbium-161-Isotope-Use-in-Prostate-Cancer.html,,Business Contracts,biotech,2023-08-24 10:00:00.000 +0300,pre_market,7,0.08799999952316284,0.09300000220537186,443.0299987792969,444.69000244140625,0.05681821260570511,0.0037469328638766396,0.05307127974182847
ELOX,Eloxx Pharmaceuticals Reports Drug Response in All Patients Treated with ELX-02 in Phase 2 Clinical Study for Alport Syndrome,All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02,2023-08-14 15:00:00.000 +0300,All three patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy demonstrating the disease modifying effect of ELX-02,https://www.globenewswire.com/news-release/2023/08/14/2724338/0/en/Eloxx-Pharmaceuticals-Reports-Drug-Response-in-All-Patients-Treated-with-ELX-02-in-Phase-2-Clinical-Study-for-Alport-Syndrome.html,,Clinical Study,biotech,2023-08-14 10:00:00.000 +0300,pre_market,7,4.75,4.989999771118164,445.6499938964844,444.70001220703125,0.05052626760382401,-0.0021316766576098883,0.0526579442614339
ELOX,Eloxx Pharmaceuticals Reports Second Quarter 2023 Financial and Operating Results and Provides Business Update,"Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02",2023-08-14 15:30:00.000 +0300,"Announced today that all 3 patients (100% response rate) treated with ELX-02 showed an improvement in podocyte foot process effacement post-treatment in kidney biopsies assessed by electron microscopy, demonstrating the disease-modifying effect of ELX-02",https://www.globenewswire.com/news-release/2023/08/14/2724500/0/en/Eloxx-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-and-Operating-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-14 10:30:00.000 +0300,pre_market,7,4.75,4.989999771118164,445.6499938964844,444.70001220703125,0.05052626760382401,-0.0021316766576098883,0.0526579442614339
PYPD,PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections,Recruitment to Resume Imminently,2023-05-22 16:00:00.000 +0300,Recruitment to Resume Imminently,https://www.globenewswire.com/news-release/2023/05/22/2673448/0/en/PolyPid-Announces-FDA-Agreement-on-the-Design-of-SHIELD-II-Phase-3-Trial-Evaluating-D-PLEX-for-Prevention-of-Abdominal-Colorectal-Surgical-Site-Infections.html,,Business Contracts,biotech,2023-05-22 11:00:00.000 +0300,pre_market,8,11.399999618530273,12.0,418.6199951171875,418.6400146484375,0.05263161417079772,0.0000478226828233,0.052583791487974374
SPRY,Single and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunology,"SAN DIEGO, Oct.  03, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today the publication of its full pharmacokinetic and pharmacodynamic results from one of its four primary registration studies of neffy (epinephrine nasal spray) in the Journal of Allergy and Clinical Immunology (JACI). JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology. The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.",2023-10-03 16:03:00.000 +0300,"SAN DIEGO, Oct.  03, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, announced today the publication of its full pharmacokinetic and pharmacodynamic results from one of its four primary registration studies of neffy (epinephrine nasal spray) in the Journal of Allergy and Clinical Immunology (JACI). JACI is the official scientific publication of the American Academy of Allergy, Asthma and Immunology and the most cited journal in the field of allergy and clinical immunology. The clinical study evaluated single and repeat doses of neffy compared to single and repeat doses of approved injection products in healthy subjects.",https://www.globenewswire.com/news-release/2023/10/03/2753749/0/en/Single-and-Repeat-Dose-Clinical-Study-of-neffy-epinephrine-nasal-spray-Published-in-the-Journal-of-Allergy-and-Clinical-Immunology.html,,Clinical Study,biotech,2023-10-03 11:03:00.000 +0300,pre_market,8,3.8399999141693115,4.019999980926514,427.30999755859375,425.05999755859375,0.04687501843242637,-0.0052654981462058464,0.052140516578632216
ARQT,Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy Over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (AD),"WESTLAKE VILLAGE, Calif., Sept.  07, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced interim results from the INTEGUMENT-OLE long-term open-label study of roflumilast cream 0.15% in adults and children ages 6 years and older with atopic dermatitis. In the study, roflumilast cream was well-tolerated, with no new safety signals observed during treatment up to 56 weeks in duration. Efficacy was not only maintained but improved over time, with 46.1% and 51.0% of participants who rolled over from the roflumilast cream treatment arm in INTEGUMENT-1 or -2 achieving validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) success, defined as vIGA-AD value of 0 or 1 plus a 2-grade improvement from baseline, at Weeks 28 and 56, respectively.",2023-09-07 15:15:00.000 +0300,"WESTLAKE VILLAGE, Calif., Sept.  07, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced interim results from the INTEGUMENT-OLE long-term open-label study of roflumilast cream 0.15% in adults and children ages 6 years and older with atopic dermatitis. In the study, roflumilast cream was well-tolerated, with no new safety signals observed during treatment up to 56 weeks in duration. Efficacy was not only maintained but improved over time, with 46.1% and 51.0% of participants who rolled over from the roflumilast cream treatment arm in INTEGUMENT-1 or -2 achieving validated Investigator Global Assessment-Atopic Dermatitis (vIGA-AD) success, defined as vIGA-AD value of 0 or 1 plus a 2-grade improvement from baseline, at Weeks 28 and 56, respectively.",https://www.globenewswire.com/news-release/2023/09/07/2739327/0/en/Arcutis-Announces-Positive-Long-Term-Results-of-Roflumilast-Cream-0-15-Showing-Durable-and-Improved-Efficacy-Over-Time-and-Favorable-Safety-Profile-in-Treatment-of-Mild-to-Moderate.html,,Clinical Study,biotech,2023-09-07 10:15:00.000 +0300,pre_market,7,7.75,8.100000381469727,446.2200012207031,443.1099853515625,0.045161339544480844,-0.006969691767811171,0.05213103131229201
DBVT,DBV Technologies to Participate in Upcoming Investor Conference,"Montrouge, France, September 5, 2023",2023-09-05 23:30:00.000 +0300,"Montrouge, France, September 5, 2023",https://www.globenewswire.com/news-release/2023/09/05/2737908/0/en/DBV-Technologies-to-Participate-in-Upcoming-Investor-Conference.html,,European Regulatory News,biotech,2023-09-05 18:30:00.000 +0300,market_open,15,1.6699999570846558,1.75,450.7300109863281,449.239990234375,0.04790421854561094,-0.0033057944126962547,0.05121001295830719
DBVT,DBV Technologies invitée à participer à une prochaine Conférence Investisseur,"Montrouge, France, le 5 septembre (23 :00 CET) 2023",2023-09-05 23:30:00.000 +0300,"Montrouge, France, le 5 septembre (23 :00 CET) 2023",https://www.globenewswire.com/news-release/2023/09/05/2737908/0/fr/DBV-Technologies-invit%C3%A9e-%C3%A0-participer-%C3%A0-une-prochaine-Conf%C3%A9rence-Investisseur.html,,European Regulatory News,biotech,2023-09-05 18:30:00.000 +0300,market_open,15,1.6699999570846558,1.75,450.7300109863281,449.239990234375,0.04790421854561094,-0.0033057944126962547,0.05121001295830719
ORPHA.CO,Updated financial calendar for 2022,Company announcement Orphazyme A/SNo. 34/2022 www.orphazyme.comCompany Registration No. 32266355,2022-09-19 20:41:00.000 +0300,Company announcement Orphazyme A/SNo. 34/2022 www.orphazyme.comCompany Registration No. 32266355,https://www.globenewswire.com/news-release/2022/09/19/2518652/0/en/Updated-financial-calendar-for-2022.html,,European Regulatory News,biotech,2022-09-19 15:41:00.000 +0300,market_open,12,1.2200000286102295,1.3009999990463257,382.260009765625,388.54998779296875,0.06639341683325024,0.016454711104099858,0.049938705729150386
ANAB,AnaptysBio Announces Stock Repurchase Plan,"SAN DIEGO, Jan.  13, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share. With cash, cash equivalents and investments greater than $575 million as of December 31, 2022, notwithstanding the potential full execution of the Stock Repurchase Plan, the company reiterates its previous guidance that it anticipates having approximately 4 years of capital to execute against its non-risk adjusted research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.",2023-01-13 16:00:00.000 +0200,"SAN DIEGO, Jan.  13, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized a Stock Repurchase Plan under which the Company may repurchase up to $50,000,000 of the Company’s outstanding common stock, par value $0.001 per share. With cash, cash equivalents and investments greater than $575 million as of December 31, 2022, notwithstanding the potential full execution of the Stock Repurchase Plan, the company reiterates its previous guidance that it anticipates having approximately 4 years of capital to execute against its non-risk adjusted research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.",https://www.globenewswire.com/news-release/2023/01/13/2588623/0/en/AnaptysBio-Announces-Stock-Repurchase-Plan.html,,Stock Market News,biotech,2023-01-13 11:00:00.000 +0200,pre_market,9,23.06999969482422,24.010000228881836,396.9599914550781,393.6199951171875,0.04074558068886786,-0.00841393694525156,0.04915951763411942
PYPD,PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders’ Equity Non-Compliance,"PETACH TIKVA, Israel, April  14, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(1) requires listed companies to maintain stockholders’ equity of at least $10,000,000, and the Company’s stockholders’ equity was $5,829,000 as of December 31, 2022. In accordance with Nasdaq rules, the Company has 45 calendar days, or until May 25, 2023, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance. The notification letter has no immediate effect on the Company’s listing on the Nasdaq Capital Market, and during the grace period, as may be extended, the Company’s ordinary shares will continue to trade on Nasdaq under the symbol “PYPD”.",2023-04-14 23:01:00.000 +0300,"PETACH TIKVA, Israel, April  14, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received a letter from the Listing Qualifications staff of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Market. Nasdaq Listing Rule 5450(b)(1) requires listed companies to maintain stockholders’ equity of at least $10,000,000, and the Company’s stockholders’ equity was $5,829,000 as of December 31, 2022. In accordance with Nasdaq rules, the Company has 45 calendar days, or until May 25, 2023, to submit a plan to regain compliance. If the plan is accepted, Nasdaq can grant an extension of up to 180 calendar days from the date of the letter to evidence compliance. The notification letter has no immediate effect on the Company’s listing on the Nasdaq Capital Market, and during the grace period, as may be extended, the Company’s ordinary shares will continue to trade on Nasdaq under the symbol “PYPD”.",https://www.globenewswire.com/news-release/2023/04/14/2647341/0/en/PolyPid-Announces-Receipt-of-Nasdaq-Notification-of-Minimum-Stockholders-Equity-Non-Compliance.html,,Stock Market News,biotech,2023-04-14 18:01:00.000 +0300,market_open,15,12.600000381469727,13.199999809265137,412.80999755859375,412.4599914550781,0.047619000764301825,-0.0008478624684131,0.0484668632327149
SNCE,Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"RESEARCH TRIANGLE PARK, N.C., May  05, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",2023-05-05 23:53:00.000 +0300,"RESEARCH TRIANGLE PARK, N.C., May  05, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",https://www.globenewswire.com/news-release/2023/05/05/2662873/0/en/Science-37-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html,,Changes in company's own shares,biotech,2023-05-05 18:53:00.000 +0300,market_open,15,0.26899999380111694,0.2840000092983246,408.9100036621094,412.6300048828125,0.05576214067981647,0.009097359290278056,0.04666478138953841
PYPD,"PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds","PETACH TIKVA, Israel, March  31, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the closing of an underwritten public offering (the “Public Offering”) of ordinary shares, no par value, (“Ordinary Shares”) with gross proceeds of approximately $7.1 million, which includes the full exercise of the underwriter's option to purchase additional Ordinary Shares. The Company also announced the closing of a concurrent private placement of pre-funded warrants with certain of its existing shareholders with gross proceeds of $4.35 million.",2023-03-31 19:00:00.000 +0300,"PETACH TIKVA, Israel, March  31, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today the closing of an underwritten public offering (the “Public Offering”) of ordinary shares, no par value, (“Ordinary Shares”) with gross proceeds of approximately $7.1 million, which includes the full exercise of the underwriter's option to purchase additional Ordinary Shares. The Company also announced the closing of a concurrent private placement of pre-funded warrants with certain of its existing shareholders with gross proceeds of $4.35 million.",https://www.globenewswire.com/news-release/2023/03/31/2638897/0/en/PolyPid-Announces-Closing-of-Underwritten-Public-Offering-Including-Full-Exercise-of-Overallotment-Option-and-Concurrent-Private-Placement-with-11-4-Million-in-Aggregate-Gross-Proc.html,,Financing Agreements,biotech,2023-03-31 14:00:00.000 +0300,market_open,11,13.050000190734863,13.800000190734863,404.6600036621094,409.3900146484375,0.05747126352783344,0.011688852230322419,0.04578241129751102
ORIC,ORIC Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational Updates,"Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October 20-24, 2023",2023-08-10 23:05:00.000 +0300,"Initial Phase 1b clinical data for ORIC-114 in EGFR/HER2-mutated cancers to be presented at the ESMO Congress being held October 20-24, 2023",https://www.globenewswire.com/news-release/2023/08/10/2723134/0/en/ORIC-Pharmaceuticals-Reports-Second-Quarter-2023-Financial-Results-and-Operational-Updates.html,,Earnings Releases and Operating Results,biotech,2023-08-10 18:05:00.000 +0300,market_open,15,7.619999885559082,7.929999828338623,448.19000244140625,445.9100036621094,0.040682407799904605,-0.005087125475528537,0.04576953327543314
DYAI,Dyadic Provides Phase 1 Clinical Trial Update for its Recombinant Protein RBD Vaccine Candidate,"JUPITER, Fla., July  24, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.",2023-07-24 15:30:00.000 +0300,"JUPITER, Fla., July  24, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today provided an update regarding its Phase 1 Clinical Trial for its DYAI-100 COVID-19 recombinant protein receptor binding domain (RBD) booster vaccine candidate.",https://www.globenewswire.com/news-release/2023/07/24/2709514/0/en/Dyadic-Provides-Phase-1-Clinical-Trial-Update-for-its-Recombinant-Protein-RBD-Vaccine-Candidate.html,,Clinical Study,biotech,2023-07-24 10:30:00.000 +0300,pre_market,7,1.8600000143051147,1.9500000476837158,452.17999267578125,453.3699951171875,0.04838711434753648,0.0026317007843810036,0.045755413563155475
SCLX,"Scilex Holding Company Announces the Consummation of the Previously Announced Purchase of all of the Scilex Common Shares, Preferred Shares and Warrants Owned by Sorrento Therapeutics, Inc.","PALO ALTO, Calif., Sept.  21, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”).",2023-09-21 23:05:00.000 +0300,"PALO ALTO, Calif., Sept.  21, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the consummation of the previously announced purchase of securities from Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”).",https://www.globenewswire.com/news-release/2023/09/21/2747659/0/en/Scilex-Holding-Company-Announces-the-Consummation-of-the-Previously-Announced-Purchase-of-all-of-the-Scilex-Common-Shares-Preferred-Shares-and-Warrants-Owned-by-Sorrento-Therapeuti.html,,Management statements,biotech,2023-09-21 18:05:00.000 +0300,market_open,15,1.690000057220459,1.75,435.70001220703125,431.3900146484375,0.0355029235195547,-0.009892121730182031,0.045395045249736726
OCUP,Ocuphire Pharma Announces Financial Results for Second Quarter 2023 and Provides Corporate Update,End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR),2023-08-11 15:00:00.000 +0300,End-of-Phase 2 Meeting with FDA Scheduled for Q4 2023 for Oral APX3330 in Diabetic Retinopathy (DR),https://www.globenewswire.com/news-release/2023/08/11/2723507/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-Second-Quarter-2023-and-Provides-Corporate-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-11 10:00:00.000 +0300,pre_market,7,4.139999866485596,4.300000190734863,445.9100036621094,443.9700012207031,0.038647422562622026,-0.004350659158739791,0.04299808172136182
IMCR,Immunocore to present at the Bank of America Securities 2023 Health Care Conference,Immunocore to present at the Bank of America Securities 2023 Health Care Conference ,2023-05-03 23:30:00.000 +0300,Immunocore to present at the Bank of America Securities 2023 Health Care Conference ,https://www.globenewswire.com/news-release/2023/05/03/2660901/0/en/Immunocore-to-present-at-the-Bank-of-America-Securities-2023-Health-Care-Conference.html,,Conference Calls/ Webcasts,biotech,2023-05-03 18:30:00.000 +0300,market_open,15,57.04999923706055,59.0099983215332,411.3599853515625,408.0199890136719,0.03435581263249888,-0.008119400177039944,0.04247521280953882
RAD.AX,Radiopharm Theranostics Initiates Process for Nasdaq Listing,Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023,2023-02-14 15:00:00.000 +0200,Proposed listing on NASDAQ with RADX ticker symbolForm 20-F registration filed with Securities and Exchange CommissionTrading expected to commence late March 2023,https://www.globenewswire.com/news-release/2023/02/14/2607567/0/en/Radiopharm-Theranostics-Initiates-Process-for-Nasdaq-Listing.html,,Exchange announcement,biotech,2023-02-14 10:00:00.000 +0200,pre_market,8,0.12999999523162842,0.13500000536441803,412.8299865722656,411.239990234375,0.03846161781683767,-0.003851455537647329,0.042313073354485
MDAI,Spectral AI Adds Healthcare Services Leader and Population Health Expert Deepak Sadagopan to Board of Directors,"DALLAS, Oct.  02, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Deepak Sadagopan, MHCDS, to its board of directors. A high-impact healthcare executive with more than 25 years of senior leadership experience with top Fortune-rated corporations and aggressive startup environments, he brings to the board expertise in healthcare technology and analytics along with a successful track record in product launches. Currently, Mr. Sadagopan is the Chief Operating Officer of Population Health at Providence St. Joseph Health, one of the largest healthcare systems in the U.S., where he leads population health initiatives across the system to transform care.",2023-10-02 15:00:00.000 +0300,"DALLAS, Oct.  02, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Deepak Sadagopan, MHCDS, to its board of directors. A high-impact healthcare executive with more than 25 years of senior leadership experience with top Fortune-rated corporations and aggressive startup environments, he brings to the board expertise in healthcare technology and analytics along with a successful track record in product launches. Currently, Mr. Sadagopan is the Chief Operating Officer of Population Health at Providence St. Joseph Health, one of the largest healthcare systems in the U.S., where he leads population health initiatives across the system to transform care.",https://www.globenewswire.com/news-release/2023/10/02/2752696/0/en/Spectral-AI-Adds-Healthcare-Services-Leader-and-Population-Health-Expert-Deepak-Sadagopan-to-Board-of-Directors.html,,Directors and Officers,biotech,2023-10-02 10:00:00.000 +0300,pre_market,7,2.566999912261963,2.6700000762939453,427.4800109863281,426.6199951171875,0.040124724406874555,-0.0020118270960934603,0.042136551502968016
ONCT,Oncternal Therapeutics Announces its Prostate Cancer Scientific Advisory Board,"SAN DIEGO, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it develops its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534.",2023-09-07 16:00:00.000 +0300,"SAN DIEGO, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the establishment of its Prostate Cancer Scientific Advisory Board (SAB). The Prostate Cancer SAB is comprised of distinguished academic and industry leaders in the prostate cancer field, which will advise Oncternal as it develops its novel dual-acting androgen receptor inhibitor (DAARI), ONCT-534.",https://www.globenewswire.com/news-release/2023/09/07/2739424/0/en/Oncternal-Therapeutics-Announces-its-Prostate-Cancer-Scientific-Advisory-Board.html,,Directors and Officers,biotech,2023-09-07 11:00:00.000 +0300,pre_market,8,0.28999999165534973,0.30000001192092896,446.2200012207031,443.1099853515625,0.03448282949422888,-0.006969691767811171,0.04145252126204005
IMNN,IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023,Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel discussion,2023-06-12 15:30:00.000 +0300,Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel discussion,https://www.globenewswire.com/news-release/2023/06/12/2686298/0/en/IMUNON-CEO-to-Discuss-Company-s-Novel-Non-viral-DNA-Therapy-Option-at-the-Mass-General-Brigham-World-Medical-Innovation-Forum-2023.html,,Press releases,biotech,2023-06-12 10:30:00.000 +0300,pre_market,7,1.399999976158142,1.4600000381469727,429.8999938964844,430.9200134277344,0.042857187864732534,0.0023726902668800933,0.04048449759785244
SCLX,Scilex Holding Company Announces Results From Independent Market Research Study Conducted with Pain Specialists and HCPs Treating Post-Herpetic Neuralgia (PHN) Pain on ZTlido®,"PALO ALTO, Calif., July  13, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the results from a primary market research study with 80 pain specialists conducted on behalf of the Company by Syneos. The study was a primary market research analysis in which 80 US-based pain specialists and HCPs were presented with various product attributes, including efficacy, safety and tolerability, to determine comparative prescribing preferences for currently available lidocaine patches, neuropathic pain agents and ZTlido® for the treatment of PHN shingles-related pain. Respondents stated that the greatest unmet need in the treatment of PHN pain with current agents is greater efficacy, followed by better tolerability and fewer side effects.",2023-07-13 16:00:00.000 +0300,"PALO ALTO, Calif., July  13, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced the results from a primary market research study with 80 pain specialists conducted on behalf of the Company by Syneos. The study was a primary market research analysis in which 80 US-based pain specialists and HCPs were presented with various product attributes, including efficacy, safety and tolerability, to determine comparative prescribing preferences for currently available lidocaine patches, neuropathic pain agents and ZTlido® for the treatment of PHN shingles-related pain. Respondents stated that the greatest unmet need in the treatment of PHN pain with current agents is greater efficacy, followed by better tolerability and fewer side effects.",https://www.globenewswire.com/news-release/2023/07/13/2704383/0/en/Scilex-Holding-Company-Announces-Results-From-Independent-Market-Research-Study-Conducted-with-Pain-Specialists-and-HCPs-Treating-Post-Herpetic-Neuralgia-PHN-Pain-on-ZTlido.html,,Product / Services Announcement,biotech,2023-07-13 11:00:00.000 +0300,pre_market,8,5.380000114440918,5.610000133514404,446.0199890136719,447.8999938964844,0.042750932003909003,0.004215068672078892,0.03853586333183011
ARQT,Arcutis Announces ZORYVE® (Roflumilast) Cream 0.3% Has Been Included in a Preferred Position on National Formularies for CVS Caremark,"WESTLAKE VILLAGE, Calif., July  17, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5. These national formularies provide access to an additional 20 million commercial lives in the United States.",2023-07-17 15:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., July  17, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced that ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents, is now covered as a preferred tier product on CVS Caremark’s largest national commercial formularies effective July 5. These national formularies provide access to an additional 20 million commercial lives in the United States.",https://www.globenewswire.com/news-release/2023/07/17/2705601/0/en/Arcutis-Announces-ZORYVE-Roflumilast-Cream-0-3-Has-Been-Included-in-a-Preferred-Position-on-National-Formularies-for-CVS-Caremark.html,,Product / Services Announcement,biotech,2023-07-17 10:00:00.000 +0300,pre_market,7,9.4399995803833,9.800000190734863,449.2799987792969,449.1300048828125,0.03813565957139005,-0.0003338539371704,0.038469513508560434
MDAI,Spectral AI to Present at 2023 Cantor Fitzgerald Global Healthcare Conference,"DALLAS, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced today that the Company will present at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place September 26-28, 2023 in New York City. The Company will also host 1x1 meetings during the event.",2023-09-20 23:15:00.000 +0300,"DALLAS, Sept.  20, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, announced today that the Company will present at the 2023 Cantor Fitzgerald Global Healthcare Conference taking place September 26-28, 2023 in New York City. The Company will also host 1x1 meetings during the event.",https://www.globenewswire.com/news-release/2023/09/20/2746865/0/en/Spectral-AI-to-Present-at-2023-Cantor-Fitzgerald-Global-Healthcare-Conference.html,,Calendar of Events,biotech,2023-09-20 18:15:00.000 +0300,market_open,15,4.0,4.099999904632568,444.010009765625,438.6400146484375,0.02499997615814209,-0.012094310936868528,0.037094287095010614
IMNN,IMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla,Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology,2023-08-14 15:30:00.000 +0300,Renowned scientist will advise on the development of IMUNON’s FixPlas and IndiPlas modalities in immuno-oncology,https://www.globenewswire.com/news-release/2023/08/14/2724408/0/en/IMUNON-Expands-Scientific-Advisory-Board-with-the-Addition-of-Dr-Sachet-Shukla.html,,Press releases,biotech,2023-08-14 10:30:00.000 +0300,pre_market,7,1.159999966621399,1.2000000476837158,445.6499938964844,444.70001220703125,0.03448282949422888,-0.0021316766576098883,0.03661450615183877
VIR,Vir Biotechnology to Participate in the BofA Securities 2023 Health Care Conference,"SAN FRANCISCO, May  03, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m. ET.",2023-05-03 23:05:00.000 +0300,"SAN FRANCISCO, May  03, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, at 8:00 a.m. PT / 11:00 a.m. ET.",https://www.globenewswire.com/news-release/2023/05/03/2660796/0/en/Vir-Biotechnology-to-Participate-in-the-BofA-Securities-2023-Health-Care-Conference.html,,Calendar of Events,biotech,2023-05-03 18:05:00.000 +0300,market_open,15,24.729999542236328,25.389999389648438,411.3599853515625,408.0199890136719,0.02668822723934534,-0.008119400177039944,0.03480762741638528
EYEN,Eyenovia Reveals Positive Evidence That Optejet® Delivery Technology Decreased Inflammation From Preserved Glaucoma Solutions Compared to Drops,Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response,2023-01-12 15:00:00.000 +0200,Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response Academic study found the Optejet® to be comparable to non-preserved drops in lessening the proinflammatory response,https://www.globenewswire.com/news-release/2023/01/12/2587812/0/en/Eyenovia-Reveals-Positive-Evidence-That-Optejet-Delivery-Technology-Decreased-Inflammation-From-Preserved-Glaucoma-Solutions-Compared-to-Drops.html,,Product / Services Announcement,biotech,2023-01-12 10:00:00.000 +0200,pre_market,8,1.8799999952316284,1.9500000476837158,395.5199890136719,396.6700134277344,0.03723407054767728,0.00290762653217698,0.0343264440155003
FBIO,"Fortress Biotech Appoints Lucy Lu, M.D., to its Board of Directors","MIAMI, Dec.  19, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors. Dr. Lu is an accomplished executive with over 20 years of experience in a wide range of financial and drug development matters in the biotech and healthcare sectors as an investment banker, equity research analyst and executive at several biotech companies.",2022-12-19 15:00:00.000 +0200,"MIAMI, Dec.  19, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lucy Lu, M.D., has been appointed to its Board of Directors. Dr. Lu is an accomplished executive with over 20 years of experience in a wide range of financial and drug development matters in the biotech and healthcare sectors as an investment banker, equity research analyst and executive at several biotech companies.",https://www.globenewswire.com/news-release/2022/12/19/2576277/28889/en/Fortress-Biotech-Appoints-Lucy-Lu-M-D-to-its-Board-of-Directors.html,,Directors and Officers,biotech,2022-12-19 10:00:00.000 +0200,pre_market,8,8.699999809265137,9.0,383.2699890136719,383.4700012207031,0.03448278130022205,0.0005218572097074,0.03396092409051468
ORPHA.CO,New CEO appointed,"As mentioned in announcement 11/2023 the Company and CEO/CFO Anders Fink Vadsholt entered into a severance agreement at May 30th 2023, where Mr. Vadsholt would step down as CEO/CFO of the Company no later than October 1st 2023, or when a replacement had been found.",2023-09-20 21:52:00.000 +0300,"As mentioned in announcement 11/2023 the Company and CEO/CFO Anders Fink Vadsholt entered into a severance agreement at May 30th 2023, where Mr. Vadsholt would step down as CEO/CFO of the Company no later than October 1st 2023, or when a replacement had been found.",https://www.globenewswire.com/news-release/2023/09/20/2746819/0/da/New-CEO-appointed.html,,European Regulatory News,biotech,2023-09-20 16:52:00.000 +0300,market_open,13,1.0499999523162842,1.0720000267028809,444.010009765625,438.6400146484375,0.020952452748273794,-0.012094310936868528,0.033046763685142325
KA,Kineta to Participate in Upcoming Investor Conferences,"SEATTLE, Aug.  31, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in September 2023.",2023-08-31 16:30:00.000 +0300,"SEATTLE, Aug.  31, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in September 2023.",https://www.globenewswire.com/news-release/2023/08/31/2735375/0/en/Kineta-to-Participate-in-Upcoming-Investor-Conferences.html,,Trade Show,biotech,2023-08-31 11:30:00.000 +0300,pre_market,8,1.9500000476837158,2.0160000324249268,451.010009765625,451.6499938964844,0.03384614519348768,0.0014190020553910847,0.032427143138096595
ANAB,AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials,"SAN DIEGO, Oct.  05, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s study PERLA, a head-to-head trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancer, met its primary endpoint of objective response rate (ORR) of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as assessed by blinded independent central review per RECIST v1.1.",2022-10-05 16:00:00.000 +0300,"SAN DIEGO, Oct.  05, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s study PERLA, a head-to-head trial of JEMPERLI vs. Keytruda in patients with metastatic non-squamous non-small cell lung cancer, met its primary endpoint of objective response rate (ORR) of dostarlimab plus chemotherapy versus pembrolizumab plus chemotherapy as assessed by blinded independent central review per RECIST v1.1.",https://www.globenewswire.com/news-release/2022/10/05/2528780/0/en/AnaptysBio-and-GSK-partnered-immuno-oncology-agents-JEMPERLI-dostarlimab-gxly-and-cobolimab-show-positive-progress-in-two-separate-non-small-cell-lung-cancer-trials.html,,Health,biotech,2022-10-05 11:00:00.000 +0300,pre_market,8,26.969999313354492,27.5,377.9700012207031,373.3900146484375,0.019651490550208213,-0.012117328246881933,0.03176881879709015
DYAI,Dyadic Announced an MoU with Bangladesh’s State-Owned Pharmaceutical Company to Facilitate Biopharmaceutical Research and Biomanufacturing Capacity,"JUPITER, Fla. and DHAKA, Bangladesh, June  21, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it has entered into a Memorandum of Understanding (“MoU”) with Essential Drugs Company Limited (EDCL), the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.",2023-06-21 15:33:00.000 +0300,"JUPITER, Fla. and DHAKA, Bangladesh, June  21, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that it has entered into a Memorandum of Understanding (“MoU”) with Essential Drugs Company Limited (EDCL), the state owned pharmaceutical company under the Ministry of Health and Family Welfare of Bangladesh to facilitate biopharmaceutical research, pre-clinical development, cGMP production, clinical trials, regulatory and other relevant areas of interest in Bangladesh.",https://www.globenewswire.com/news-release/2023/06/21/2692028/0/en/Dyadic-Announced-an-MoU-with-Bangladesh-s-State-Owned-Pharmaceutical-Company-to-Facilitate-Biopharmaceutical-Research-and-Biomanufacturing-Capacity.html,,Business Contracts,biotech,2023-06-21 10:33:00.000 +0300,pre_market,7,2.059999942779541,2.119999885559082,437.17999267578125,436.1600036621094,0.029126186624346982,-0.0023331100021960816,0.031459296626543065
FBIO,Fortress Biotech Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights,"Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023",2023-08-14 23:01:00.000 +0300,"Total net revenue was $17.4 million in the second quarter of 2023, a 40% increase from $12.4 million in the first quarter of 2023",https://www.globenewswire.com/news-release/2023/08/14/2724965/28889/en/Fortress-Biotech-Reports-Second-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html,,Earnings Releases and Operating Results,biotech,2023-08-14 18:01:00.000 +0300,market_open,15,7.800000190734863,8.100000381469727,444.70001220703125,448.1099853515625,0.038461561974218274,0.007668030247194434,0.03079353172702384
ARQT,Arcutis Announces Second Quarter 2023 Financial Results and Provides Business Update,"WESTLAKE VILLAGE, Calif., Aug.  08, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended June 30, 2023, and provided a business update.",2023-08-08 23:02:00.000 +0300,"WESTLAKE VILLAGE, Calif., Aug.  08, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported financial results for the quarter ended June 30, 2023, and provided a business update.",https://www.globenewswire.com/news-release/2023/08/08/2721101/0/en/Arcutis-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-08 18:02:00.000 +0300,market_open,15,9.529999732971191,9.829999923706055,448.0799865722656,448.75,0.03147955919630771,0.0014952987140975918,0.029984260482210118
DYAI,Dyadic Receives U.S. Patent for Manufacturing Seasonal and Pandemic Influenza Vaccines from its Proprietary C1 Protein Production Platform,"JUPITER, Fla., April  18, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/640,483, titled ""PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA"" (the “Patent”), and is expected to provide patent protection through 2038.",2023-04-18 15:30:00.000 +0300,"JUPITER, Fla., April  18, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that the company has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application 16/640,483, titled ""PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA"" (the “Patent”), and is expected to provide patent protection through 2038.",https://www.globenewswire.com/news-release/2023/04/18/2649016/0/en/Dyadic-Receives-U-S-Patent-for-Manufacturing-Seasonal-and-Pandemic-Influenza-Vaccines-from-its-Proprietary-C1-Protein-Production-Platform.html,,Patents,biotech,2023-04-18 10:30:00.000 +0300,pre_market,7,1.8200000524520874,1.8799999952316284,413.94000244140625,415.5799865722656,0.032967000577117045,0.003961888489121118,0.029005112087995926
ARQT,"New Campaign from Arcutis Aims to Educate, Raise Awareness, and Provide Encouragement for Those Living with Seborrheic Dermatitis",Arcutis announced the launch of an educational campaign designed to elevate understanding and connection for those living with seborrheic dermatitis.,2023-09-25 16:00:00.000 +0300,Arcutis announced the launch of an educational campaign designed to elevate understanding and connection for those living with seborrheic dermatitis.,https://www.globenewswire.com/news-release/2023/09/25/2748693/0/en/New-Campaign-from-Arcutis-Aims-to-Educate-Raise-Awareness-and-Provide-Encouragement-for-Those-Living-with-Seborrheic-Dermatitis.html,,Health,biotech,2023-09-25 11:00:00.000 +0300,pre_market,8,5.380000114440918,5.519999980926514,430.4200134277344,429.1700134277344,0.026022279462375866,-0.002904140051586773,0.028926419513962638
IMNN,Preclinical Data Showing Strong Immunogenicity and Protection with IMUNON’s PlaCCine DNA-Based Vaccines Modality Available Online on bioRxiv,"LAWRENCEVILLE, N.J., Aug.  07, 2023  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that a manuscript titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer,” is available on the preprint server bioRxiv [here]. The study used IMUNON’s proprietary formulation against the spike proteins from two SARS-CoV-2 variants, both alone and in combination. These results add to the growing body of preclinical data confirming the efficacy and superior desirable features of the IMUNON’s PlaCCine vaccine modality.",2023-08-07 15:30:00.000 +0300,"LAWRENCEVILLE, N.J., Aug.  07, 2023  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces that a manuscript titled “Strong immunogenicity & protection in mice with PlaCCine: A COVID-19 DNA vaccine formulated with a functional polymer,” is available on the preprint server bioRxiv [here]. The study used IMUNON’s proprietary formulation against the spike proteins from two SARS-CoV-2 variants, both alone and in combination. These results add to the growing body of preclinical data confirming the efficacy and superior desirable features of the IMUNON’s PlaCCine vaccine modality.",https://www.globenewswire.com/news-release/2023/08/07/2719692/0/en/Preclinical-Data-Showing-Strong-Immunogenicity-and-Protection-with-IMUNON-s-PlaCCine-DNA-Based-Vaccines-Modality-Available-Online-on-bioRxiv.html,,Press releases,biotech,2023-08-07 10:30:00.000 +0300,pre_market,7,1.2300000190734863,1.2699999809265137,446.80999755859375,448.7099914550781,0.0325202936851642,0.004252353140856508,0.028267940544307694
SCLX,"Scilex Holding Company Presented Oral and Poster Presentations on Elyxyb at the 2023 Annual Brain Week Conference Held in Las Vegas, NV","PALO ALTO, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution). The conference was held from September 6-8, 2023 in Las Vegas, NV.",2023-09-12 16:00:00.000 +0300,"PALO ALTO, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual Brain Week Conference on the benefits of Elyxyb (celecoxib oral solution). The conference was held from September 6-8, 2023 in Las Vegas, NV.",https://www.globenewswire.com/news-release/2023/09/12/2741728/0/en/Scilex-Holding-Company-Presented-Oral-and-Poster-Presentations-on-Elyxyb-at-the-2023-Annual-Brain-Week-Conference-Held-in-Las-Vegas-NV.html,,Calendar of Events,biotech,2023-09-12 11:00:00.000 +0300,pre_market,8,2.4100000858306885,2.4700000286102295,448.45001220703125,446.95001220703125,0.024896240930572414,-0.0033448544077807063,0.02824109533835312
SCLX,"Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) at the 2023 Annual PAINWeek Conference Held in Las Vegas, NV","PALO ALTO, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual PAINWeek Conference on the benefits of ZTlido (lidocaine topical system). The conference was held from September 5-8, 2023 in Las Vegas, NV.",2023-09-12 16:00:00.000 +0300,"PALO ALTO, Calif., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it presented oral and poster presentations at the 2023 Annual PAINWeek Conference on the benefits of ZTlido (lidocaine topical system). The conference was held from September 5-8, 2023 in Las Vegas, NV.",https://www.globenewswire.com/news-release/2023/09/12/2741736/0/en/Scilex-Holding-Company-Presented-Oral-and-Poster-Presentations-on-ZTlido-lidocaine-topical-system-at-the-2023-Annual-PAINWeek-Conference-Held-in-Las-Vegas-NV.html,,Research Analysis and Reports,biotech,2023-09-12 11:00:00.000 +0300,pre_market,8,2.4100000858306885,2.4700000286102295,448.45001220703125,446.95001220703125,0.024896240930572414,-0.0033448544077807063,0.02824109533835312
OCUP,Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September,"ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis",2023-09-07 16:00:00.000 +0300,"ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis ESCRS presentations will feature clinical data on APX3330 in diabetic retinopathy; Nyxol® data in presbyopia, dim light vision disturbance and reversal of pharmacologically induced mydriasis",https://www.globenewswire.com/news-release/2023/09/07/2739442/0/en/Ocuphire-Pharma-to-Present-at-ESCRS-2023-and-MODLive-Conferences-in-September.html,,Calendar of Events,biotech,2023-09-07 11:00:00.000 +0300,pre_market,8,3.819999933242798,3.9000000953674316,446.2200012207031,443.1099853515625,0.02094245118395111,-0.006969691767811171,0.02791214295176228
KA,Kineta Reports Second Quarter 2023 Financial Results and Provides Corporate Update,Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023,2023-08-11 23:01:00.000 +0300,Initial Clinical Data Readout from Ongoing Phase 1/2 Study of VISTA-Targeting KVA12123 in Advanced Solid Tumors Anticipated by End of 2023,https://www.globenewswire.com/news-release/2023/08/11/2723846/0/en/Kineta-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-11 18:01:00.000 +0300,market_open,15,1.899999976158142,1.9600000381469727,443.9700012207031,445.6499938964844,0.031578980390385335,0.0037840229546187384,0.027794957435766595
FBIO,"Helocyte, Inc. Announces Positive Data from Stem Cell Transplant Donor Vaccination Trial to be Presented at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR",Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant ,2023-02-16 15:30:00.000 +0200,Results demonstrate the potential benefit of vaccinating donors with Triplex to enhance CMV protective immunity and reduce CMV events in recipients of allogeneic hematopoietic cell transplant ,https://www.globenewswire.com/news-release/2023/02/16/2609775/28889/en/Helocyte-Inc-Announces-Positive-Data-from-Stem-Cell-Transplant-Donor-Vaccination-Trial-to-be-Presented-at-the-2023-Tandem-Meetings-Transplantation-Cellular-Therapy-Meetings-of-ASTC.html,,Clinical Study,biotech,2023-02-16 10:30:00.000 +0200,pre_market,8,11.100000381469727,11.25,413.9800109863281,408.7900085449219,0.013513478682458597,-0.012536843093077874,0.02605032177553647
CHRS,Coherus Announces Resubmission of Biologics License Application (BLA) Supplement for UDENYCA® ONBODY™,– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler –,2023-10-05 15:30:00.000 +0300,– Resubmission follows the satisfactory resolution of the FDA’s review of inspection findings at the third-party filler –,https://www.globenewswire.com/news-release/2023/10/05/2755393/33333/en/Coherus-Announces-Resubmission-of-Biologics-License-Application-BLA-Supplement-for-UDENYCA-ONBODY.html,,Product / Services Announcement,biotech,2023-10-05 10:30:00.000 +0300,pre_market,7,3.1700000762939453,3.25,424.6600036621094,424.3599853515625,0.0252365683850654,-0.0007064906229916,0.02594305900805704
PYPD,PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections,"Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains ",2023-06-29 15:00:00.000 +0300,"Potent Antibacterial Efficacy of D-PLEX100 in In-vivo and Phase 2 Clinical Studies against a Wide Range of Bacteria Tested, including Resistant Strains ",https://www.globenewswire.com/news-release/2023/06/29/2696940/0/en/PolyPid-Announces-New-Publication-Highlighting-Potent-Antibacterial-Activity-of-D-PLEX-against-Susceptible-and-Resistant-Bacteria-for-the-Prevention-of-Surgical-Site-Infections.html,,Health,biotech,2023-06-29 10:00:00.000 +0300,pre_market,7,10.829999923706055,11.100000381469727,436.3900146484375,435.9599914550781,0.024930790366181,-0.0009854102498331,0.025916200616014073
IMCR,Immunocore announces strategic priorities including pipeline expansion for 2023 -2024,Immunocore announces strategic priorities including pipeline expansion for 2023 -2024,2023-01-09 14:00:00.000 +0200,Immunocore announces strategic priorities including pipeline expansion for 2023 -2024,https://www.globenewswire.com/news-release/2023/01/09/2585008/0/en/Immunocore-announces-strategic-priorities-including-pipeline-expansion-for-2023-2024.html,,Press releases,biotech,2023-01-09 09:00:00.000 +0200,pre_market,7,54.560001373291016,56.279998779296875,388.0799865722656,390.3699951171875,0.031524878348845806,0.0059008674091866505,0.025624010939659155
OCUP,Ocuphire Announces APX3330 Phase 2 Data Presentations at Retina Meetings,"Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting",2023-02-16 15:30:00.000 +0200,"Topline Data from ZETA-1 Phase 2 Trial of Oral APX3330 in Diabetic Retinopathy Presented on February 11th at 20th Angiogenesis, Exudation, and Degeneration 2023 Meeting",https://www.globenewswire.com/news-release/2023/02/16/2609773/0/en/Ocuphire-Announces-APX3330-Phase-2-Data-Presentations-at-Retina-Meetings.html,,Calendar of Events,biotech,2023-02-16 10:30:00.000 +0200,pre_market,8,3.8299999237060547,3.880000114440918,413.9800109863281,408.7900085449219,0.01305488034748606,-0.012536843093077874,0.025591723440563936
ONCT,Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),"SAN DIEGO, June  30, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Yisrael Katz, M.D. who is joining Oncternal as VP, Clinical Development.",2023-06-30 23:30:00.000 +0300,"SAN DIEGO, June  30, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Yisrael Katz, M.D. who is joining Oncternal as VP, Clinical Development.",https://www.globenewswire.com/news-release/2023/06/30/2698092/0/en/Oncternal-Therapeutics-Reports-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Changes in company's own shares,biotech,2023-06-30 18:30:00.000 +0300,market_open,15,0.3400000035762787,0.3499999940395355,441.44000244140625,443.2799987792969,0.029411736347271383,0.00416816855680145,0.025243567790469934
ELOX,Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement,"Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study",2023-06-06 15:30:00.000 +0300,"Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study Company continuing to prepare for advancement of clinical assets, including ELX-02 pivotal study in Alport Syndrome and ZKN-013 Phase 1 study",https://www.globenewswire.com/news-release/2023/06/06/2682826/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html,,Exchange Members,biotech,2023-06-06 10:30:00.000 +0300,pre_market,7,6.699999809265137,6.860000133514404,427.1000061035156,426.6700134277344,0.02388064609017005,-0.0010067728158192376,0.02488741890598929
TTOO,T2 Biosystems Praises CDC’s Actions Aimed at Optimizing U.S. Hospital Sepsis Programs,The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements,2023-08-28 15:30:00.000 +0300,The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements The U.S. Centers for Disease Control and Prevention Releases 2023 Hospital Sepsis Program Core Elements,https://www.globenewswire.com/news-release/2023/08/28/2732593/32489/en/T2-Biosystems-Praises-CDC-s-Actions-Aimed-at-Optimizing-U-S-Hospital-Sepsis-Programs.html,,Other News,biotech,2023-08-28 10:30:00.000 +0300,pre_market,7,0.36800000071525574,0.3790000081062317,439.9700012207031,442.239990234375,0.029891324373902205,0.00515941770432929,0.024731906669572916
CHRS,"Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.",–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® –,2023-07-03 15:30:00.000 +0300,–$995 per carton (two 40 mg/0.8 mL autoinjectors) represents a discount of more than 85% compared to Humira® –,https://www.globenewswire.com/news-release/2023/07/03/2698528/33333/en/Coherus-Launches-YUSIMRY-a-Biosimilar-of-Humira-at-995-per-Carton-in-U-S.html,,Product / Services Announcement,biotech,2023-07-03 10:30:00.000 +0300,pre_market,7,4.269999980926514,4.369999885559082,443.2799987792969,442.9200134277344,0.02341918151738965,-0.0008120947314425,0.02423127624883214
ORIC,ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones,"Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer",2023-01-09 15:00:00.000 +0200,"Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer",https://www.globenewswire.com/news-release/2023/01/09/2585167/0/en/ORIC-Pharmaceuticals-Provides-Corporate-Update-and-Highlights-Key-Upcoming-Milestones.html,,Other News,biotech,2023-01-09 10:00:00.000 +0200,pre_market,8,5.650000095367432,5.820000171661377,388.0799865722656,390.3699951171875,0.030088508570704695,0.0059008674091866505,0.024187641161518045
ORIC,ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),"SOUTH SAN FRANCISCO and SAN DIEGO, Sept.  01, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2023 (the “Grant Date”), ORIC granted a total of 19,380 non-qualified stock options and 3,220 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2023.",2023-09-01 23:30:00.000 +0300,"SOUTH SAN FRANCISCO and SAN DIEGO, Sept.  01, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on September 1, 2023 (the “Grant Date”), ORIC granted a total of 19,380 non-qualified stock options and 3,220 restricted stock units to three new non-executive employees who began their employment with ORIC in August 2023.",https://www.globenewswire.com/news-release/2023/09/01/2736350/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,,Stock Market News,biotech,2023-09-01 18:30:00.000 +0300,market_open,15,9.100000381469727,9.279999732971191,453.1700134277344,451.19000244140625,0.019780147687465638,-0.004369245377361826,0.024149393064827464
ORIC,ORIC Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Updates,"Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer",2023-05-08 23:05:00.000 +0300,"Initial Phase 1b data for three ongoing clinical trials expected in second half of 2023: ORIC-533 in multiple myeloma, ORIC-114 in EGFR/HER2-mutated cancers, and ORIC-944 in prostate cancer",https://www.globenewswire.com/news-release/2023/05/08/2663846/0/en/ORIC-Pharmaceuticals-Reports-First-Quarter-2023-Financial-Results-and-Operational-Updates.html,,Earnings Releases and Operating Results,biotech,2023-05-08 18:05:00.000 +0300,market_open,15,5.099999904632568,5.21999979019165,412.9700012207031,412.739990234375,0.02352938976529794,-0.000556967783733,0.02408635754903098
DYAI,Dyadic Announces Collaboration to Commercialize Animal-Free Alternative Proteins Using Dapibus™,"JUPITER, Fla., May  08, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a co-development and marketing agreement with Fermbox Bio Inc (“Fermbox”).",2023-05-08 15:30:00.000 +0300,"JUPITER, Fla., May  08, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a co-development and marketing agreement with Fermbox Bio Inc (“Fermbox”).",https://www.globenewswire.com/news-release/2023/05/08/2663306/0/en/Dyadic-Announces-Collaboration-to-Commercialize-Animal-Free-Alternative-Proteins-Using-Dapibus.html,,Health,biotech,2023-05-08 10:30:00.000 +0300,pre_market,7,1.649999976158142,1.690000057220459,412.6300048828125,412.9700012207031,0.02424247372139546,0.0008239738600376,0.023418499861357862
KA,Kineta Announces Participation at October Investor Conferences,"SEATTLE, Sept.  28, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in October 2023.",2023-09-28 16:30:00.000 +0300,"SEATTLE, Sept.  28, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today its participation in the following upcoming investor conferences in October 2023.",https://www.globenewswire.com/news-release/2023/09/28/2751321/0/en/Kineta-Announces-Participation-at-October-Investor-Conferences.html,,Calendar of Events,biotech,2023-09-28 11:30:00.000 +0300,pre_market,8,2.740000009536743,2.799999952316284,426.04998779296875,425.4800109863281,0.02189778925938227,-0.0013378167420992743,0.023235606001481543
ELOX,Eloxx Pharmaceuticals Granted Extension by Nasdaq to Regain Compliance with the Market Value of Listed Securities Continued Listing Requirement,"WATERTOWN, Mass., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to extend the exception granted on June 2, 2023 to Eloxx Pharmaceuticals, Inc. (the “Company”) to regain compliance with Listing Rule 5550(b)(2), which requires a listed company to have at least $35 million in market value of listed securities in order to qualify for continued listing on the Nasdaq Capital Market, until October 9, 2023, following a request for an extension and update submitted by the Company on July 27, 2023.",2023-08-03 16:26:00.000 +0300,"WATERTOWN, Mass., Aug.  03, 2023  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that it has determined to extend the exception granted on June 2, 2023 to Eloxx Pharmaceuticals, Inc. (the “Company”) to regain compliance with Listing Rule 5550(b)(2), which requires a listed company to have at least $35 million in market value of listed securities in order to qualify for continued listing on the Nasdaq Capital Market, until October 9, 2023, following a request for an extension and update submitted by the Company on July 27, 2023.",https://www.globenewswire.com/news-release/2023/08/03/2718175/0/en/Eloxx-Pharmaceuticals-Granted-Extension-by-Nasdaq-to-Regain-Compliance-with-the-Market-Value-of-Listed-Securities-Continued-Listing-Requirement.html,,Stock Market News,biotech,2023-08-03 11:26:00.000 +0300,pre_market,8,7.090000152587891,7.21999979019165,450.1300048828125,448.0400085449219,0.01833563255373262,-0.004643094917511081,0.0229787274712437
EVAX,Evaxion announces Executive Management Changes to strengthen the AI-strategy,"COPENHAGEN, Denmark, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced:",2023-08-29 15:30:00.000 +0300,"COPENHAGEN, Denmark, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced:",https://www.globenewswire.com/news-release/2023/08/29/2733405/0/en/Evaxion-announces-Executive-Management-Changes-to-strengthen-the-AI-strategy.html,,Management Changes,biotech,2023-08-29 10:30:00.000 +0300,pre_market,7,0.8799999952316284,0.8999999761581421,442.760009765625,442.6499938964844,0.02272725117600642,-0.0002484774295647,0.02297572860557117
ICCC,"ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023","PORTLAND, Maine, May  11, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2023.",2023-05-11 23:05:00.000 +0300,"PORTLAND, Maine, May  11, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2023.",https://www.globenewswire.com/news-release/2023/05/11/2667278/0/en/ImmuCell-Announces-Unaudited-Financial-Results-for-the-Quarter-Ended-March-31-2023.html,,Earnings Releases and Operating Results,biotech,2023-05-11 18:05:00.000 +0300,market_open,15,4.849999904632568,4.960000038146973,411.95001220703125,412.1300048828125,0.022680440345851472,0.0004369284390039,0.022243511906847587
SPRY,ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis,"Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting",2022-11-10 15:00:00.000 +0200,"Data from Pivotal Clinical Trials to be Presented in Five Poster Presentations at the 2022 American College of Allergy, Asthma and Immunology Annual Scientific Meeting",https://www.globenewswire.com/news-release/2022/11/10/2553122/0/en/ARS-Pharmaceuticals-Announces-Presentation-of-Clinical-Data-Supporting-neffy-epinephrine-nasal-spray-for-the-Treatment-of-Allergic-Reactions-Type-I-including-Anaphylaxis.html,,Trade Show,biotech,2022-11-10 10:00:00.000 +0200,pre_market,8,6.059999942779541,6.420000076293945,374.1300048828125,388.04998779296875,0.059405963187069435,0.03720627249481463,0.022199690692254803
TTOO,T2 Biosystems Announces Clinical Collaboration with Vanderbilt University Medical Center to Implement and Evaluate the T2Bacteria Panel for Clinical Use,"LEXINGTON, Mass., June  09, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced a collaborative relationship with Vanderbilt University Medical Center’s (VUMC) Learning Healthcare System (LHS) Platform, which unites clinical research and clinical operations to evaluate and implement new approaches to care that can improve the health of patients and the community. Through this collaboration, VUMC will implement and evaluate the FDA-cleared T2Bacteria® Panel in a clinical setting and conduct a prospective study to assess the impact of the direct-from-blood T2Bacteria Panel to improve antibiotic usage and clinical interventions for patients with a bloodstream infection.",2023-06-09 16:15:00.000 +0300,"LEXINGTON, Mass., June  09, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced a collaborative relationship with Vanderbilt University Medical Center’s (VUMC) Learning Healthcare System (LHS) Platform, which unites clinical research and clinical operations to evaluate and implement new approaches to care that can improve the health of patients and the community. Through this collaboration, VUMC will implement and evaluate the FDA-cleared T2Bacteria® Panel in a clinical setting and conduct a prospective study to assess the impact of the direct-from-blood T2Bacteria Panel to improve antibiotic usage and clinical interventions for patients with a bloodstream infection.",https://www.globenewswire.com/news-release/2023/06/09/2685564/32489/en/T2-Biosystems-Announces-Clinical-Collaboration-with-Vanderbilt-University-Medical-Center-to-Implement-and-Evaluate-the-T2Bacteria-Panel-for-Clinical-Use.html,,Clinical Study,biotech,2023-06-09 11:15:00.000 +0300,pre_market,8,0.08299999684095383,0.08500000089406967,429.1300048828125,429.9599914550781,0.024096435292019235,0.0019341145173297286,0.022162320774689506
TTOO,T2 Biosystems Announces Conversion of Approximately Twenty Percent of CRG Term Loan into Equity,"LEXINGTON, Mass., July  06, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems common stock and Series B convertible preferred stock.",2023-07-06 15:00:00.000 +0300,"LEXINGTON, Mass., July  06, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the conversion of approximately 20% of its term loan with entities affiliated with CRG Servicing LLC (“CRG”) into T2 Biosystems common stock and Series B convertible preferred stock.",https://www.globenewswire.com/news-release/2023/07/06/2700253/32489/en/T2-Biosystems-Announces-Conversion-of-Approximately-Twenty-Percent-of-CRG-Term-Loan-into-Equity.html,,Prospectus/Announcement of Prospectus,biotech,2023-07-06 10:00:00.000 +0300,pre_market,7,0.07400000095367432,0.07500000298023224,443.1300048828125,439.4200134277344,0.013513540725275752,-0.008372241586437477,0.02188578231171323
FBIO,Fortress Biotech to Present at the BTIG Virtual Biotechnology Conference 2023,"MIAMI, Aug.  03, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on Tuesday, August 8, 2023 at 12:00 PM ET. The Company will also attend virtual one-on-one meetings during the conference.",2023-08-03 15:30:00.000 +0300,"MIAMI, Aug.  03, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference on Tuesday, August 8, 2023 at 12:00 PM ET. The Company will also attend virtual one-on-one meetings during the conference.",https://www.globenewswire.com/news-release/2023/08/03/2718058/28889/en/Fortress-Biotech-to-Present-at-the-BTIG-Virtual-Biotechnology-Conference-2023.html,,Calendar of Events,biotech,2023-08-03 10:30:00.000 +0300,pre_market,7,8.699999809265137,8.850000381469727,450.1300048828125,448.0400085449219,0.017241445458980986,-0.004643094917511081,0.021884540376492068
FBIO,Fortress Biotech Announces Closing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,"MIAMI, Feb.  10, 2023  (GLOBE NEWSWIRE) --  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued 16.6 million shares of its common stock in the registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share was $0.835.  ",2023-02-10 19:50:00.000 +0200,"MIAMI, Feb.  10, 2023  (GLOBE NEWSWIRE) --  Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced the closing of its previously announced registered direct offering and concurrent private placement. The Company issued 16.6 million shares of its common stock in the registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share was $0.835.  ",https://www.globenewswire.com/news-release/2023/02/10/2606152/28889/en/Fortress-Biotech-Announces-Closing-of-13-9-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html,,Stock Market News,biotech,2023-02-10 14:50:00.000 +0200,market_open,12,11.100000381469727,11.399999618530273,405.8599853515625,408.0400085449219,0.027026957364917194,0.005371367644117475,0.02165558972079972
IMCR,Immunocore to present at upcoming investor conferences,Immunocore to present at upcoming investor conferences,2023-09-01 23:00:00.000 +0300,Immunocore to present at upcoming investor conferences,https://www.globenewswire.com/news-release/2023/09/01/2736335/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html,,Calendar of Events,biotech,2023-09-01 18:00:00.000 +0300,market_open,15,56.29999923706055,57.27000045776367,453.1700134277344,451.19000244140625,0.017229151578115887,-0.004369245377361826,0.021598396955477713
MDWD,MediWound to Report Second Quarter 2023 Financial Results,"Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time",2023-08-07 15:00:00.000 +0300,"Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Wednesday, August 16th at 8:30 am Eastern Time",https://www.globenewswire.com/news-release/2023/08/07/2719647/30505/en/MediWound-to-Report-Second-Quarter-2023-Financial-Results.html,,Calendar of Events,biotech,2023-08-07 10:00:00.000 +0300,pre_market,7,9.010000228881836,9.239999771118164,446.80999755859375,448.7099914550781,0.02552714055423189,0.004252353140856508,0.021274787413375382
CHRS,Coherus BioSciences to Participate at Upcoming September Investor Conferences,"REDWOOD CITY, Calif., Sept.  01, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:",2023-09-01 23:01:00.000 +0300,"REDWOOD CITY, Calif., Sept.  01, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus“, Nasdaq: CHRS) today announced that senior management will participate in the following investor conferences:",https://www.globenewswire.com/news-release/2023/09/01/2736337/33333/en/Coherus-BioSciences-to-Participate-at-Upcoming-September-Investor-Conferences.html,,Calendar of Events,biotech,2023-09-01 18:01:00.000 +0300,market_open,15,5.360000133514404,5.449999809265137,453.1700134277344,451.19000244140625,0.016790983863599666,-0.004369245377361826,0.021160229240961493
EYEN,"Eyenovia Announces FDA Approval of Mydcombi™, the First Ophthalmic Spray for Mydriasis, Which Also Leverages the Company’s Proprietary Optejet® Device Platform",Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis,2023-05-08 15:00:00.000 +0300,Represents the first FDA approved fixed-combination of tropicamide and phenylephrine for mydriasis,https://www.globenewswire.com/news-release/2023/05/08/2663251/0/en/Eyenovia-Announces-FDA-Approval-of-Mydcombi-the-First-Ophthalmic-Spray-for-Mydriasis-Which-Also-Leverages-the-Company-s-Proprietary-Optejet-Device-Platform.html,,Product / Services Announcement,biotech,2023-05-08 10:00:00.000 +0300,pre_market,7,4.599999904632568,4.699999809265137,412.6300048828125,412.9700012207031,0.021739110153428578,0.0008239738600376,0.02091513629339098
KA,Kineta to Present New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy,"SEATTLE, Sept.  25, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, to be held on October 1-4, 2023 in Toronto, ON, Canada. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of advanced solid tumors.",2023-09-25 16:30:00.000 +0300,"SEATTLE, Sept.  25, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present a poster on the Company’s anti-CD27 agonist antibody program at the American Association for Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy, to be held on October 1-4, 2023 in Toronto, ON, Canada. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting new preclinical data on the company’s anti-CD27 agonist antibodies in development for the treatment of advanced solid tumors.",https://www.globenewswire.com/news-release/2023/09/25/2748721/0/en/Kineta-to-Present-New-Preclinical-Data-on-Lead-Anti-CD27-Agonist-Antibody-at-AACR-Special-Conference-on-Tumor-Immunology-and-Immunotherapy.html,,Health,biotech,2023-09-25 11:30:00.000 +0300,pre_market,8,2.299999952316284,2.3399999141693115,430.4200134277344,429.1700134277344,0.017391288122742862,-0.002904140051586773,0.020295428174329635
EVAX,"Revolutionizing Vaccine Discovery: New Data Validates Evaxion AI Platform, Offering Promise to Reduce Risk and Cost in Infectious Disease Vaccine Development","COPENHAGEN, Denmark, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (""Evaxion"" or the ""Company""), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDENTM. Data will be shared at the Vaccines Europe conference in Berlin, Germany, taking place from September 14th to 15th.",2023-09-11 15:17:00.000 +0300,"COPENHAGEN, Denmark, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (""Evaxion"" or the ""Company""), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, has achieved a groundbreaking milestone in vaccine discovery with the validation of its AI-powered vaccine discovery platform, EDENTM. Data will be shared at the Vaccines Europe conference in Berlin, Germany, taking place from September 14th to 15th.",https://www.globenewswire.com/news-release/2023/09/11/2740790/0/en/Revolutionizing-Vaccine-Discovery-New-Data-Validates-Evaxion-AI-Platform-Offering-Promise-to-Reduce-Risk-and-Cost-in-Infectious-Disease-Vaccine-Development.html,,Research Analysis and Reports,biotech,2023-09-11 10:17:00.000 +0300,pre_market,7,0.6819999814033508,0.699999988079071,445.5199890136719,448.239990234375,0.02639297238495757,0.006105228245145371,0.0202877441398122
CHRS,Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023,List price of $995 per carton for two 40 mg/0.8 mL autoinjectors List price of $995 per carton for two 40 mg/0.8 mL autoinjectors,2023-06-01 15:30:00.000 +0300,List price of $995 per carton for two 40 mg/0.8 mL autoinjectors List price of $995 per carton for two 40 mg/0.8 mL autoinjectors,https://www.globenewswire.com/news-release/2023/06/01/2680331/33333/en/Coherus-Announces-Industry-Wide-Lowest-List-Price-for-Adalimumab-Biosimilar-YUSIMRY-adalimumab-aqvh-Launching-in-July-2023.html,,Product / Services Announcement,biotech,2023-06-01 10:30:00.000 +0300,pre_market,7,4.090000152587891,4.170000076293945,417.8500061035156,418.0899963378906,0.01955988281698128,0.0005743454131135,0.018985537403867783
CHRS,"Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients",–  YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  –,2023-06-01 15:33:00.000 +0300,–  YUSIMRY™ (adalimumab-aqvh) will be the first biologic product offered by the Mark Cuban Cost Plus Drug Company  –,https://www.globenewswire.com/news-release/2023/06/01/2680351/33333/en/Mark-Cuban-Cost-Plus-Drug-Company-joins-forces-with-Coherus-to-make-YUSIMRY-a-HUMIRA-biosimilar-available-to-patients.html,,Product / Services Announcement,biotech,2023-06-01 10:33:00.000 +0300,pre_market,7,4.090000152587891,4.170000076293945,417.8500061035156,418.0899963378906,0.01955988281698128,0.0005743454131135,0.018985537403867783
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"WESTLAKE VILLAGE, Calif., Sept.  15, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 39,000 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 14, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",2023-09-15 23:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., Sept.  15, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 39,000 restricted stock units of Arcutis’ common stock to six newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of September 14, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",https://www.globenewswire.com/news-release/2023/09/15/2744239/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Product / Services Announcement,biotech,2023-09-15 18:00:00.000 +0300,market_open,15,6.739999771118164,6.809999942779541,447.1400146484375,443.3699951171875,0.010385782498292867,-0.008431407182857849,0.018817189681150717
IMNN,"IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023","LAWRENCEVILLE, N.J., May  04, 2023  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. EDT on Thursday, May 11, 2023 to discuss financial results for the first quarter ended March 31, 2023 and provide an update on its clinical development of IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines.",2023-05-04 15:30:00.000 +0300,"LAWRENCEVILLE, N.J., May  04, 2023  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. EDT on Thursday, May 11, 2023 to discuss financial results for the first quarter ended March 31, 2023 and provide an update on its clinical development of IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines.",https://www.globenewswire.com/news-release/2023/05/04/2661505/0/en/IMUNON-to-Hold-First-Quarter-2023-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-May-11-2023.html,,Press releases,biotech,2023-05-04 10:30:00.000 +0300,pre_market,7,1.2599999904632568,1.2799999713897705,408.0199890136719,406.92999267578125,0.015873000855468576,-0.002671428771236258,0.018544429626704835
DYAI,Dyadic Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress,"JUPITER, Fla., Aug.  09, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and produce biopharmaceuticals and alternative proteins for human and animal health, today announced its financial results for the second quarter of 2023, and highlighted recent company developments.",2023-08-09 23:00:00.000 +0300,"JUPITER, Fla., Aug.  09, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and produce biopharmaceuticals and alternative proteins for human and animal health, today announced its financial results for the second quarter of 2023, and highlighted recent company developments.",https://www.globenewswire.com/news-release/2023/08/09/2722067/0/en/Dyadic-Announces-Second-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,,Earnings Releases and Operating Results,biotech,2023-08-09 18:00:00.000 +0300,market_open,15,1.7799999713897705,1.7999999523162842,449.0299987792969,445.75,0.011235944521335181,-0.00730463173554921,0.018540576256884392
FBIO,Helocyte Announces $3.22 Million Grant from the National Cancer Institute for Triplex Phase 2 Clinical Trial Program,Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients,2023-06-15 15:00:00.000 +0300,Multicenter randomized placebo-controlled trials will evaluate the ability of the cytomegalovirus (“CMV”) vaccine to enhance protective virus-specific immunity in stem cell donors to reduce the risk of CMV events in high-risk transplant recipients,https://www.globenewswire.com/news-release/2023/06/15/2688861/28889/en/Helocyte-Announces-3-22-Million-Grant-from-the-National-Cancer-Institute-for-Triplex-Phase-2-Clinical-Trial-Program.html,,Clinical Study,biotech,2023-06-15 10:00:00.000 +0300,pre_market,7,9.300000190734863,9.449999809265137,437.17999267578125,436.3299865722656,0.016128990909022856,-0.0019442932379250056,0.018073284146947862
CHRS,Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day,- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments -,2023-10-02 16:00:00.000 +0300,- Bipartisan resolution highlights the challenges patients with rare cancers face and raises awareness and supports efforts to improve early diagnosis and development of effective treatments -,https://www.globenewswire.com/news-release/2023/10/02/2752800/33333/en/Coherus-Applauds-Congressional-Designation-of-September-30th-as-Rare-Cancer-Day.html,,Health,biotech,2023-10-02 11:00:00.000 +0300,pre_market,8,3.740000009536743,3.799999952316284,427.4800109863281,426.6199951171875,0.016042765408167188,-0.0020118270960934603,0.01805459250426065
CHRS,"Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023","REDWOOD CITY, Calif., July  26, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.",2023-07-26 23:05:00.000 +0300,"REDWOOD CITY, Calif., July  26, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) today announced its second quarter 2023 financial results will be released after market close on Wednesday, August 02, 2023. Starting at 5:00 pm ET on August 02, 2023, Coherus’ management team will host a conference call and webcast to discuss financial results and provide a general business update.",https://www.globenewswire.com/news-release/2023/07/26/2711653/33333/en/Coherus-BioSciences-to-Report-Second-Quarter-2023-Financial-Results-on-August-02-2023.html,,Conference Calls/ Webcasts,biotech,2023-07-26 18:05:00.000 +0300,market_open,15,4.440000057220459,4.53000020980835,454.4700012207031,455.510009765625,0.020270304375678942,0.002288398666861222,0.01798190570881772
SCPH,scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update,"Commercial launch planned for February 20, 2023 Commercial launch planned for February 20, 2023",2023-01-30 15:00:00.000 +0200,"Commercial launch planned for February 20, 2023 Commercial launch planned for February 20, 2023",https://www.globenewswire.com/news-release/2023/01/30/2597485/0/en/scPharmaceuticals-Provides-FUROSCIX-furosemide-injection-Commercial-Update.html,,Product / Services Announcement,biotech,2023-01-30 10:00:00.000 +0200,pre_market,8,5.690000057220459,5.75,405.67999267578125,402.79998779296875,0.010544805303367736,-0.007099203645258875,0.01764400894862661
SCLX,"Scilex Holding Company Generates Record Monthly Revenue In August 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales For The One Month Ended August 2023, And Year-To-Date As Of August 31 2023, Based On Currently Available Information","PALO ALTO, Calif., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announces record revenue for the month of August 2023 and is providing certain preliminary unaudited financial results for the month ended August 31, 2023, and year-to-date as of August 31, 2023, based on currently available information.",2023-09-11 16:00:00.000 +0300,"PALO ALTO, Calif., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announces record revenue for the month of August 2023 and is providing certain preliminary unaudited financial results for the month ended August 31, 2023, and year-to-date as of August 31, 2023, based on currently available information.",https://www.globenewswire.com/news-release/2023/09/11/2740873/0/en/Scilex-Holding-Company-Generates-Record-Monthly-Revenue-In-August-2023-And-Provides-Certain-Preliminary-Unaudited-Financial-Results-For-Gross-And-Net-Sales-For-The-One-Month-Ended-.html,,Pre-Release Comments,biotech,2023-09-11 11:00:00.000 +0300,pre_market,8,2.5399999618530273,2.5999999046325684,445.5199890136719,448.239990234375,0.023622025071121953,0.006105228245145371,0.017516796825976583
QGEN,FBI approves QIAGEN’s NGS-based ForenSeq MainstAY workflow for the U.S. National DNA Index System (NDIS),NDIS approval provides access to federal government funding for accredited public crime laboratories in the U.S. to implement next-generation sequencing (NGS) for routine casework // NGS-based ForenSeq MainstAY workflow from QIAGEN provides a cost-effective alternative to traditional capillary electrophoresis // Combination of ForenSeq MainstAY and ForenSeq Kintelligence from QIAGEN enables end-to-end workflow for forensic investigative genetic genealogy (FIGG) NDIS approval provides access to federal government funding for accredited public crime laboratories in the U.S. to implement next-generation sequencing (NGS) for routine casework // NGS-based ForenSeq MainstAY workflow from QIAGEN provides a cost-effective alternative to traditional capillary electrophoresis // Combination of ForenSeq MainstAY and ForenSeq Kintelligence from QIAGEN enables end-to-end workflow for forensic investigative genetic genealogy (FIGG),2023-06-20 23:05:00.000 +0300,NDIS approval provides access to federal government funding for accredited public crime laboratories in the U.S. to implement next-generation sequencing (NGS) for routine casework // NGS-based ForenSeq MainstAY workflow from QIAGEN provides a cost-effective alternative to traditional capillary electrophoresis // Combination of ForenSeq MainstAY and ForenSeq Kintelligence from QIAGEN enables end-to-end workflow for forensic investigative genetic genealogy (FIGG) NDIS approval provides access to federal government funding for accredited public crime laboratories in the U.S. to implement next-generation sequencing (NGS) for routine casework // NGS-based ForenSeq MainstAY workflow from QIAGEN provides a cost-effective alternative to traditional capillary electrophoresis // Combination of ForenSeq MainstAY and ForenSeq Kintelligence from QIAGEN enables end-to-end workflow for forensic investigative genetic genealogy (FIGG),https://www.globenewswire.com/news-release/2023/06/20/2691593/8690/en/FBI-approves-QIAGEN-s-NGS-based-ForenSeq-MainstAY-workflow-for-the-U-S-National-DNA-Index-System-NDIS.html,,Company Announcement,biotech,2023-06-20 18:05:00.000 +0300,market_open,15,45.310001373291016,46.06999969482422,437.45001220703125,437.17999267578125,0.016773301666267462,-0.0006172580265519,0.017390559692819323
ARQT,FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11,Arcutis today announced the FDA has approved an sNDA to expand the indication of ZORYVE (roflumilast) cream 0.3%.,2023-10-06 15:00:00.000 +0300,Arcutis today announced the FDA has approved an sNDA to expand the indication of ZORYVE (roflumilast) cream 0.3%.,https://www.globenewswire.com/news-release/2023/10/06/2756044/0/en/FDA-Approves-Arcutis-ZORYVE-roflumilast-Cream-0-3-for-Treatment-of-Psoriasis-in-Children-Ages-6-to-11.html,,Product / Services Announcement,biotech,2023-10-06 10:00:00.000 +0300,pre_market,7,4.429999828338623,4.480000019073486,424.5,421.9700012207031,0.011286725208207239,-0.005959950010122203,0.01724667521832944
OCUP,Ocuphire to Present at American Society of Retina Specialists Annual Meeting and OIS Retina Innovation Summit,ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy,2023-07-26 15:00:00.000 +0300,ASRS presentations will feature data from ZETA-1 Phase 2 trial evaluating APX3330 in diabetic retinopathy,https://www.globenewswire.com/news-release/2023/07/26/2711269/0/en/Ocuphire-to-Present-at-American-Society-of-Retina-Specialists-Annual-Meeting-and-OIS-Retina-Innovation-Summit.html,,Health,biotech,2023-07-26 10:00:00.000 +0300,pre_market,7,3.9800000190734863,4.039999961853027,455.44000244140625,454.4700012207031,0.015075362435176206,-0.0021298112056547308,0.017205173640830938
SCLX,"Scilex Holding Company to Present Data on ELYXYB™ (celecoxib oral solution) at the 65th Annual Scientific Meeting of the American Headache Society, in Austin, TX.","PALO ALTO, Calif., June  16, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it will be presenting data on ELYXYB™ (celecoxib oral solution) for acute treatment of migraine with or without aura in adults at the 65th Annual Scientific Meeting of American Headache Society (AHS) to be held on June 14-18, 2023 in Austin, Texas.",2023-06-16 16:00:00.000 +0300,"PALO ALTO, Calif., June  16, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that it will be presenting data on ELYXYB™ (celecoxib oral solution) for acute treatment of migraine with or without aura in adults at the 65th Annual Scientific Meeting of American Headache Society (AHS) to be held on June 14-18, 2023 in Austin, Texas.",https://www.globenewswire.com/news-release/2023/06/16/2689744/0/en/Scilex-Holding-Company-to-Present-Data-on-ELYXYB-celecoxib-oral-solution-at-the-65th-Annual-Scientific-Meeting-of-the-American-Headache-Society-in-Austin-TX.html,,Calendar of Events,biotech,2023-06-16 11:00:00.000 +0300,pre_market,8,7.78000020980835,7.920000076293945,442.6000061035156,443.0199890136719,0.017994840965312058,0.000948899467611,0.01704594149770106
DYAI,"Dyadic and bYoRNA Announce a Collaboration Targeting the Production of Abundant, Low-Cost mRNA From C1-Cells","JUPITER, Fla. and PARIS, Sept.  26, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (""bYoRNA"") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (""mRNA""). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health.",2023-09-26 15:30:00.000 +0300,"JUPITER, Fla. and PARIS, Sept.  26, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI) and bYoRNA SAS (""bYoRNA"") today announced that they entered into a development and commercialization agreement to work on disruptive bioproduction technologies that will help exploit the therapeutic potential of messenger RNA (""mRNA""). Dyadic is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products and alternative proteins for human and animal health. bYoRNA is a French biotechnology company focused on producing affordable therapeutic mRNA, at scale, for human and animal health.",https://www.globenewswire.com/news-release/2023/09/26/2749502/0/en/Dyadic-and-bYoRNA-Announce-a-Collaboration-Targeting-the-Production-of-Abundant-Low-Cost-mRNA-From-C1-Cells.html,,Partnerships,biotech,2023-09-26 10:30:00.000 +0300,pre_market,7,2.0799999237060547,2.0999999046325684,432.2300109863281,429.0899963378906,0.009615375798129148,-0.007264684470363678,0.016880060268492827
ARQT,Arcutis Launches First Television Ad for ZORYVE® (Roflumilast) Cream 0.3%,"WESTLAKE VILLAGE, Calif., Aug.  29, 2023  (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of The Cream That Can, the first commercial direct-to-consumer ad for ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents. The Cream That Can campaign invites individuals with psoriasis to reimagine a steroid-free cream for their psoriasis.",2023-08-29 15:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., Aug.  29, 2023  (GLOBE NEWSWIRE) --  Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the launch of The Cream That Can, the first commercial direct-to-consumer ad for ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous psoriasis in adults and adolescents. The Cream That Can campaign invites individuals with psoriasis to reimagine a steroid-free cream for their psoriasis.",https://www.globenewswire.com/news-release/2023/08/29/2733332/0/en/Arcutis-Launches-First-Television-Ad-for-ZORYVE-Roflumilast-Cream-0-3.html,,Product / Services Announcement,biotech,2023-08-29 10:00:00.000 +0300,pre_market,7,8.020000457763672,8.149999618530273,442.760009765625,442.6499938964844,0.0162093707414639,-0.0002484774295647,0.01645784817102865
ELOX,Eloxx Pharmaceuticals Highlights Recent Alport Syndrome Natural History Data Presented at 60th ERA Congress,"Data from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure",2023-06-21 16:00:00.000 +0300,"Data from RaDaR natural history study indicates that Alport syndrome patients with autosomal recessive COL4A4 mutations have severest disease, with a more rapid progression to kidney failure",https://www.globenewswire.com/news-release/2023/06/21/2692112/0/en/Eloxx-Pharmaceuticals-Highlights-Recent-Alport-Syndrome-Natural-History-Data-Presented-at-60th-ERA-Congress.html,,Clinical Study,biotech,2023-06-21 11:00:00.000 +0300,pre_market,8,4.960000038146973,5.03000020980835,437.17999267578125,436.1600036621094,0.014112937726413529,-0.0023331100021960816,0.016446047728609612
JSPR,Jasper Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference,"REDWOOD CITY, Calif., March  10, 2022  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022.",2022-03-10 15:00:00.000 +0200,"REDWOOD CITY, Calif., March  10, 2022  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that the Company is participating in the 32nd Annual Oppenheimer Healthcare investor conference, to be held virtually from March 15-17, 2022.",https://www.globenewswire.com/news-release/2022/03/10/2400877/0/en/Jasper-Therapeutics-to-Participate-in-the-Oppenheimer-32nd-Annual-Healthcare-Conference.html,,Calendar of Events,biotech,2022-03-10 10:00:00.000 +0200,pre_market,8,3.390000104904175,3.4000000953674316,427.4100036621094,422.5199890136719,0.0029498496028924183,-0.01144103929842344,0.01439088890131586
EYEN,"Eyenovia to Report Fourth Quarter and Full-Year 2022 Results on Thursday, March 30",Company to host an investor conference call and webcast at 4:30 pm ET Company to host an investor conference call and webcast at 4:30 pm ET,2023-03-23 14:00:00.000 +0200,Company to host an investor conference call and webcast at 4:30 pm ET Company to host an investor conference call and webcast at 4:30 pm ET,https://www.globenewswire.com/news-release/2023/03/23/2633055/0/en/Eyenovia-to-Report-Fourth-Quarter-and-Full-Year-2022-Results-on-Thursday-March-30.html,,Conference Calls/ Webcasts,biotech,2023-03-23 09:00:00.000 +0200,pre_market,7,2.7300000190734863,2.7899999618530273,392.1099853515625,395.0899963378906,0.02197800086459484,0.007599936491431791,0.01437806437316305
ORIC,ORIC Pharmaceuticals Announces Multiple Presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting,ORIC-944 preclinical poster presentation to highlight comprehensive biomarker strategy for ongoing Phase 1 trial in metastatic prostate cancer,2023-03-14 22:30:00.000 +0200,ORIC-944 preclinical poster presentation to highlight comprehensive biomarker strategy for ongoing Phase 1 trial in metastatic prostate cancer,https://www.globenewswire.com/news-release/2023/03/14/2627208/0/en/ORIC-Pharmaceuticals-Announces-Multiple-Presentations-at-the-2023-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html,,Health,biotech,2023-03-14 17:30:00.000 +0200,market_open,15,4.570000171661377,4.650000095367432,390.5,391.7300109863281,0.017505453107449564,0.0031498360725432137,0.01435561703490635
VIR,Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results,"– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza –",2023-05-04 23:05:00.000 +0300,"– Multiple data readouts anticipated in 2023 from ongoing Phase 2 programsin hepatitis B and D, and influenza –",https://www.globenewswire.com/news-release/2023/05/04/2662074/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-First-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-05-04 18:05:00.000 +0300,market_open,15,25.260000228881836,25.5,406.92999267578125,405.1300048828125,0.009501178501326877,-0.004423335279694849,0.013924513781021726
IMCR,Immunocore to present at upcoming investor conferences,Immunocore to present at upcoming investor conferences,2023-02-28 14:00:00.000 +0200,Immunocore to present at upcoming investor conferences,https://www.globenewswire.com/news-release/2023/02/28/2616858/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html,,Press releases,biotech,2023-02-28 09:00:00.000 +0200,pre_market,7,54.209999084472656,54.88999938964844,397.7300109863281,397.2300109863281,0.012543816946319657,-0.0012571342020685167,0.013800951148388174
SCPH,scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business Update,"Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure",2023-03-22 22:05:00.000 +0200,"Announced launch and commercial availability of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure",https://www.globenewswire.com/news-release/2023/03/22/2632699/0/en/scPharmaceuticals-Inc-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Update.html,,Conference Calls/ Webcasts,biotech,2023-03-22 17:05:00.000 +0200,market_open,15,6.940000057220459,6.920000076293945,398.7300109863281,392.1099853515625,-0.0028818416083016387,-0.01660277744930671,0.013720935841005071
ORIC,ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences,"SOUTH SAN FRANCISCO and SAN DIEGO, Aug.  30, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in the first half of September:",2023-08-30 23:30:00.000 +0300,"SOUTH SAN FRANCISCO and SAN DIEGO, Aug.  30, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in the first half of September:",https://www.globenewswire.com/news-release/2023/08/30/2734804/0/en/ORIC-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html,,Conference Calls/ Webcasts,biotech,2023-08-30 18:30:00.000 +0300,market_open,15,9.0,9.149999618530273,449.510009765625,451.010009765625,0.016666624281141493,0.0033369668470388495,0.013329657434102644
DYAI,Dyadic to Present at World Vaccine Congress Washington 2023,"JUPITER, Fla., March  30, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.",2023-03-30 15:30:00.000 +0300,"JUPITER, Fla., March  30, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that its Chief Executive Officer, Mark Emalfarb will be presenting at the upcoming World Vaccine Congress in Washington, D.C.",https://www.globenewswire.com/news-release/2023/03/30/2637625/0/en/Dyadic-to-Present-at-World-Vaccine-Congress-Washington-2023.html,,Calendar of Events,biotech,2023-03-30 10:30:00.000 +0300,pre_market,7,1.4900000095367432,1.5199999809265137,401.3500061035156,404.0899963378906,0.02013420885755418,0.0068269345775674554,0.013307274279986726
EYEN,Eyenovia to Present at Upcoming H.C. Wainwright 25th Annual Global Investment Conference,"NEW YORK, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place on September 11-13, 2023 at the Lotte New York Palace Hotel.",2023-09-07 15:00:00.000 +0300,"NEW YORK, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), a commercial-stage ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation at the H.C. Wainwright 25th Annual Global Investment Conference, which is taking place on September 11-13, 2023 at the Lotte New York Palace Hotel.",https://www.globenewswire.com/news-release/2023/09/07/2739251/0/en/Eyenovia-to-Present-at-Upcoming-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,,Calendar of Events,biotech,2023-09-07 10:00:00.000 +0300,pre_market,7,1.8700000047683716,1.8799999952316284,446.2200012207031,443.1099853515625,0.005347588469389063,-0.006969691767811171,0.012317280237200233
CHRS,Coherus Completes Surface Oncology Acquisition,"– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment –",2023-09-08 16:05:00.000 +0300,"– Clinical-stage product candidates, casdozokitug and CHS-114, significantly advancenext-generation immuno-oncology portfolio focused on the tumor microenvironment –",https://www.globenewswire.com/news-release/2023/09/08/2740124/33333/en/Coherus-Completes-Surface-Oncology-Acquisition.html,,Mergers and Acquisitions,biotech,2023-09-08 11:05:00.000 +0300,pre_market,8,4.889999866485596,4.949999809265137,444.8500061035156,444.8999938964844,0.012269927283794078,0.0001123699950161,0.01215755728877801
FBIO,"Fortress Biotech Announces Timing of Regular Monthly Dividend for October, November and December 2022 for its 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock","MIAMI, Oct.  05, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced its board of directors has declared the regular monthly dividend of $0.1953125 per share of the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) for the months of October, November and December 2022. The dividend will be payable on the last day of each month (October 31, November 30, and December 31) to holders of record as of the close of business on the fifteenth of that same month (October 15, November 15, December 15). Dividends will be paid in cash.",2022-10-05 15:30:00.000 +0300,"MIAMI, Oct.  05, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Common Stock: Nasdaq: FBIO) (Preferred Stock: Nasdaq: FBIOP) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced its board of directors has declared the regular monthly dividend of $0.1953125 per share of the Company’s 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (the “Series A Preferred Stock”) for the months of October, November and December 2022. The dividend will be payable on the last day of each month (October 31, November 30, and December 31) to holders of record as of the close of business on the fifteenth of that same month (October 15, November 15, December 15). Dividends will be paid in cash.",https://www.globenewswire.com/news-release/2022/10/05/2528702/28889/en/Fortress-Biotech-Announces-Timing-of-Regular-Monthly-Dividend-for-October-November-and-December-2022-for-its-9-375-Series-A-Cumulative-Redeemable-Perpetual-Preferred-Stock.html,,Stock Market News,biotech,2022-10-05 10:30:00.000 +0300,pre_market,7,13.199999809265137,13.199999809265137,377.9700012207031,373.3900146484375,0.0,-0.012117328246881933,0.012117328246881933
ECOR,electroCore Expands Intellectual Property Portfolio for Non-Invasive Vagus Nerve Stimulation (nVNS) Technology,"ROCKAWAY, N.J., Sept.  26, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.",2023-09-26 15:00:00.000 +0300,"ROCKAWAY, N.J., Sept.  26, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to non-invasive nerve stimulation with mobile devices.",https://www.globenewswire.com/news-release/2023/09/26/2749414/0/en/electroCore-Expands-Intellectual-Property-Portfolio-for-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Technology.html,,Patents,biotech,2023-09-26 10:00:00.000 +0300,pre_market,7,5.324999809265137,5.349999904632568,432.2300109863281,429.0899963378906,0.004694853758291818,-0.007264684470363678,0.011959538228655496
ELOX,Eloxx Pharmaceuticals Announces Publication Demonstrating the Power of its TURBO-ZM™ Platform to Target the Human Ribosome for Therapeutic Benefit,Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications,2023-07-10 16:00:00.000 +0300,Publication titled “A Novel Class of Ribosome Modulating Agents Exploits Cancer Ribosome Heterogeneity to Selectively Target the CMS2 Subtype of Colorectal Cancer” published in Cancer Research Communications,https://www.globenewswire.com/news-release/2023/07/10/2701816/0/en/Eloxx-Pharmaceuticals-Announces-Publication-Demonstrating-the-Power-of-its-TURBO-ZM-Platform-to-Target-the-Human-Ribosome-for-Therapeutic-Benefit.html,,Product / Services Announcement,biotech,2023-07-10 11:00:00.000 +0300,pre_market,8,3.619999885559082,3.6600000858306885,438.54998779296875,438.17999267578125,0.011049779429876614,-0.0008436783205708,0.011893457750447376
SCLX,"Scilex Holding Company Enters into Non-Binding Term Sheets for the Purchase of all of the Scilex Common Shares, Preferred Shares, and Warrants Currently Owned by Sorrento Therapeutics, Inc. and is Declared the New Successful Bidder","PALO ALTO, Calif., Sept.  13, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer (as defined below) (the “Securities Transfer Term Sheet”) (which the official committee of unsecured creditors and the official committee of equity security holders in Sorrento’s bankruptcy cases have each signed as “Consenting Parties” thereto) and the Note (as defined below) (the “Note Term Sheet” and together with the Securities Transfer Term Sheet, the “Scilex Term Sheets”). After a hearing before the Bankruptcy Court in Sorrento’s bankruptcy cases on September 12, 2023, such court entered a final order approving the Scilex Term Sheets. The Scilex Term Sheets are subject to entry into definitive documentation relating thereto. The transactions contemplated by the Scilex Term Sheets are expected to close on or about September 19, 2023.  ",2023-09-13 16:00:00.000 +0300,"PALO ALTO, Calif., Sept.  13, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced that on September 11, 2023, Scilex, Oramed Pharmaceuticals Inc. (Nasdaq: ORMP, “Oramed”) and Sorrento executed non-binding term sheets relating to, among other things, the Securities Transfer (as defined below) (the “Securities Transfer Term Sheet”) (which the official committee of unsecured creditors and the official committee of equity security holders in Sorrento’s bankruptcy cases have each signed as “Consenting Parties” thereto) and the Note (as defined below) (the “Note Term Sheet” and together with the Securities Transfer Term Sheet, the “Scilex Term Sheets”). After a hearing before the Bankruptcy Court in Sorrento’s bankruptcy cases on September 12, 2023, such court entered a final order approving the Scilex Term Sheets. The Scilex Term Sheets are subject to entry into definitive documentation relating thereto. The transactions contemplated by the Scilex Term Sheets are expected to close on or about September 19, 2023.  ",https://www.globenewswire.com/news-release/2023/09/13/2742513/0/en/Scilex-Holding-Company-Enters-into-Non-Binding-Term-Sheets-for-the-Purchase-of-all-of-the-Scilex-Common-Shares-Preferred-Shares-and-Warrants-Currently-Owned-by-Sorrento-Therapeutic.html,,Major shareholder announcements,biotech,2023-09-13 11:00:00.000 +0300,pre_market,8,2.440000057220459,2.4700000286102295,445.989990234375,446.2200012207031,0.012295069953377443,0.0005157312750612,0.011779338678316202
ICCC,ImmuCell Appoints Bryan K. Gathagan to Board of Directors,"PORTLAND, Maine, June  21, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors.",2023-06-21 23:05:00.000 +0300,"PORTLAND, Maine, June  21, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Bryan K. Gathagan has been appointed to its Board of Directors.",https://www.globenewswire.com/news-release/2023/06/21/2692501/0/en/ImmuCell-Appoints-Bryan-K-Gathagan-to-Board-of-Directors.html,,Directors and Officers,biotech,2023-06-21 18:05:00.000 +0300,market_open,15,5.679999828338623,5.730000019073486,436.1600036621094,434.94000244140625,0.008802850747530415,-0.002797141439975438,0.011599992187505853
BIOR,Biora Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference,"SAN DIEGO, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.",2023-09-11 15:01:00.000 +0300,"SAN DIEGO, Sept.  11, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced it will present at the upcoming H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York City.",https://www.globenewswire.com/news-release/2023/09/11/2740775/0/en/Biora-Therapeutics-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,,Calendar of Events,biotech,2023-09-11 10:01:00.000 +0300,pre_market,7,2.869999885559082,2.9200000762939453,445.5199890136719,448.239990234375,0.017421669940284035,0.006105228245145371,0.011316441695138665
SCPH,scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"BURLINGTON, Mass., Feb.  06, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on February 1, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 142,500 shares of its common stock to 38 new employees.",2023-02-06 15:00:00.000 +0200,"BURLINGTON, Mass., Feb.  06, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on February 1, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 142,500 shares of its common stock to 38 new employees.",https://www.globenewswire.com/news-release/2023/02/06/2601997/0/en/scPharmaceuticals-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Stock Market News,biotech,2023-02-06 10:00:00.000 +0200,pre_market,8,8.029999732971191,8.069999694824219,412.3500061035156,409.7900085449219,0.0049813154649043685,-0.0062083121636988476,0.011189627628603215
KA,"Kineta, Inc. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","SEATTLE, April  24, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has closed its previously announced registered direct offering for the purchase and sale of 1,425,179 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.21 per share of common stock (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 1,425,179 shares of common stock with an exercise price of $4.08 per share which are immediately exercisable for a period of five and one-half years following issuance.",2023-04-24 23:01:00.000 +0300,"SEATTLE, April  24, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has closed its previously announced registered direct offering for the purchase and sale of 1,425,179 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.21 per share of common stock (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company issued unregistered warrants to purchase up to 1,425,179 shares of common stock with an exercise price of $4.08 per share which are immediately exercisable for a period of five and one-half years following issuance.",https://www.globenewswire.com/news-release/2023/04/24/2653302/0/en/Kineta-Inc-Announces-Closing-of-6-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html,,Financing Agreements,biotech,2023-04-24 18:01:00.000 +0300,market_open,15,3.940000057220459,3.990000009536743,411.989990234375,412.6300048828125,0.012690343043181961,0.001553471355149685,0.011136871688032277
PYPD,PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares,"PETACH TIKVA, Israel, March  28, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that it has commenced an underwritten public offering of its ordinary shares, no par value (the “Ordinary Shares”). In addition, PolyPid intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of Ordinary Shares offered in the offering at the public offering price, less underwriting discounts and commissions. All of the Ordinary Shares in the offering are being offered by PolyPid. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",2023-03-28 23:05:00.000 +0300,"PETACH TIKVA, Israel, March  28, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that it has commenced an underwritten public offering of its ordinary shares, no par value (the “Ordinary Shares”). In addition, PolyPid intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of Ordinary Shares offered in the offering at the public offering price, less underwriting discounts and commissions. All of the Ordinary Shares in the offering are being offered by PolyPid. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.",https://www.globenewswire.com/news-release/2023/03/28/2636208/0/en/PolyPid-Announces-Proposed-Underwritten-Public-Offering-of-Ordinary-Shares.html,,Changes in company's own shares,biotech,2023-03-28 18:05:00.000 +0300,market_open,15,14.100000381469727,14.25,395.7699890136719,395.6000061035156,0.010638270529935837,-0.0004294992416678,0.011067769771603647
SCPH,"scPharmaceuticals to Announce First Quarter 2023 Financial Results on Wednesday, May 10, 2023",Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET,2023-05-02 15:00:00.000 +0300,Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET,https://www.globenewswire.com/news-release/2023/05/02/2659075/0/en/scPharmaceuticals-to-Announce-First-Quarter-2023-Financial-Results-on-Wednesday-May-10-2023.html,,Conference Calls/ Webcasts,biotech,2023-05-02 10:00:00.000 +0300,pre_market,7,9.729999542236328,9.819999694824219,415.510009765625,414.7699890136719,0.009249759180071362,-0.0017809938017390855,0.011030752981810447
CHRS,"CIMERLI® (ranibizumab-eqrn) Sales Exceed 100,000 Doses in First Year of Launch",– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* –,2023-10-04 15:30:00.000 +0300,– CIMERLI® is the #1 ranibizumab biosimilar with 25% ranibizumab market share* –,https://www.globenewswire.com/news-release/2023/10/04/2754586/33333/en/CIMERLI-ranibizumab-eqrn-Sales-Exceed-100-000-Doses-in-First-Year-of-Launch.html,,Product / Services Announcement,biotech,2023-10-04 10:30:00.000 +0300,pre_market,7,3.3499999046325684,3.390000104904175,421.5899963378906,422.07000732421875,0.011940358629948591,0.0011385729986425292,0.010801785631306062
DYAI,Dyadic Announces Expanded Licensing Agreement to Develop and Commercialize Vaccines and Biologics for African Continent,"JUPITER, Fla., April  12, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"", ""we"", ""us"", ""our"", or the ""Company"") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced it signed an expanded licensing agreement for its C1-cell protein expression platform with South Africa’s Rubic One Health (“Rubic”) to develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.",2023-04-12 15:00:00.000 +0300,"JUPITER, Fla., April  12, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (""Dyadic"", ""we"", ""us"", ""our"", or the ""Company"") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced it signed an expanded licensing agreement for its C1-cell protein expression platform with South Africa’s Rubic One Health (“Rubic”) to develop, manufacture, commercialize and distribute affordable vaccines and biologics for human and animal health in underserved African countries.",https://www.globenewswire.com/news-release/2023/04/12/2645288/0/en/Dyadic-Announces-Expanded-Licensing-Agreement-to-Develop-and-Commercialize-Vaccines-and-Biologics-for-African-Continent.html,,Licensing Agreements,biotech,2023-04-12 10:00:00.000 +0300,pre_market,7,1.9199999570846558,1.9500000476837158,409.7200012207031,411.8699951171875,0.015625047536257475,0.005247471175629138,0.010377576360628337
ORPHA.CO,Orphazyme Announces Publication of 2022 Financial Results and Annual Report,Company announcement                                                    ,2023-04-25 23:20:00.000 +0300,Company announcement                                                    ,https://www.globenewswire.com/news-release/2023/04/25/2654492/0/en/Orphazyme-Announces-Publication-of-2022-Financial-Results-and-Annual-Report.html,,European Regulatory News,biotech,2023-04-25 18:20:00.000 +0300,market_open,15,0.9010000228881836,0.8999999761581421,410.5799865722656,406.0799865722656,-0.0011099297498748369,-0.01096010557545274,0.009850175825577904
ORPHA.CO,Notice to convene Annual General Meeting,Company announcement                                                 ,2023-04-25 23:27:00.000 +0300,Company announcement                                                 ,https://www.globenewswire.com/news-release/2023/04/25/2654499/0/en/Notice-to-convene-Annual-General-Meeting.html,,European Regulatory News,biotech,2023-04-25 18:27:00.000 +0300,market_open,15,0.9010000228881836,0.8999999761581421,410.5799865722656,406.0799865722656,-0.0011099297498748369,-0.01096010557545274,0.009850175825577904
VIR,"Vir Biotechnology to Provide Business Update and Report Third Quarter 2023 Financial Results on November 2, 2023","Vir Biotechnology will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023.",2023-10-05 23:30:00.000 +0300,"Vir Biotechnology will provide a corporate update and report financial results for the third quarter ended September 30, 2023, on November 2, 2023.",https://www.globenewswire.com/news-release/2023/10/05/2755808/0/en/Vir-Biotechnology-to-Provide-Business-Update-and-Report-Third-Quarter-2023-Financial-Results-on-November-2-2023.html,,Calendar of Events,biotech,2023-10-05 18:30:00.000 +0300,market_open,15,8.880000114440918,8.970000267028809,424.3599853515625,424.5,0.010135152187839471,0.0003299430984792,0.00980520908936023
EYEN,"Eyenovia to Report Second Quarter 2023 Results on Thursday, August 10",Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT,2023-08-07 15:00:00.000 +0300,Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT,https://www.globenewswire.com/news-release/2023/08/07/2719644/0/en/Eyenovia-to-Report-Second-Quarter-2023-Results-on-Thursday-August-10.html,,Calendar of Events,biotech,2023-08-07 10:00:00.000 +0300,pre_market,7,2.1500000953674316,2.180000066757202,446.80999755859375,448.7099914550781,0.013953474446076041,0.004252353140856508,0.009701121305219534
MDWD,MediWound’s NexoBrid® Highlighted in 20 Oral and Poster Presentations at the 20th European Burns Association Congress,"YAVNE, Israel, Sept.  11, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently concluded 20th European Burns Association (EBA) Congress held in Nantes, France on September 6-9, 2023.",2023-09-11 15:00:00.000 +0300,"YAVNE, Israel, Sept.  11, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its successful participation at the recently concluded 20th European Burns Association (EBA) Congress held in Nantes, France on September 6-9, 2023.",https://www.globenewswire.com/news-release/2023/09/11/2740747/30505/en/MediWound-s-NexoBrid-Highlighted-in-20-Oral-and-Poster-Presentations-at-the-20th-European-Burns-Association-Congress.html,,Calendar of Events,biotech,2023-09-11 10:00:00.000 +0300,pre_market,7,7.179999828338623,7.293000221252441,445.5199890136719,448.239990234375,0.01573821665953514,0.006105228245145371,0.009632988414389771
MYNZ,Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania,Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania,2023-10-04 15:01:00.000 +0300,Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania,https://www.globenewswire.com/news-release/2023/10/04/2754535/0/en/Mainz-Biomed-Announces-Live-Launch-of-ColoAlert-with-Bioclinica-in-Romania.html,,Product / Services Announcement,biotech,2023-10-04 10:01:00.000 +0300,pre_market,7,2.869999885559082,2.9000000953674316,421.5899963378906,422.07000732421875,0.010453035193242005,0.0011385729986425292,0.009314462194599476
SCPH,scPharmaceuticals Inc. Announces Addition to Russell 2000® and Russell 3000® Indexes,"BURLINGTON, Mass., June  23, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it expects to be added to the small cap Russell 2000® and broad market Russell 3000® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective when the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.",2023-06-23 15:00:00.000 +0300,"BURLINGTON, Mass., June  23, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that it expects to be added to the small cap Russell 2000® and broad market Russell 3000® Indexes at the conclusion of the Russell US Indexes annual reconstitution, effective when the US market opens on June 26, 2023, according to a preliminary list of additions posted on May 19, 2023.",https://www.globenewswire.com/news-release/2023/06/23/2693627/0/en/scPharmaceuticals-Inc-Announces-Addition-to-Russell-2000-and-Russell-3000-Indexes.html,,Stock Market News,biotech,2023-06-23 10:00:00.000 +0300,pre_market,7,10.369999885559082,10.380000114440918,436.510009765625,432.92999267578125,0.0009643422364702,-0.008201454742735375,0.009165796979205592
QGEN,Bio-Rad and QIAGEN announce patent settlement and cross-licensing agreement,"Hercules, Calif., and Venlo, the Netherlands, July  26, 2023  (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.",2023-07-26 23:15:00.000 +0300,"Hercules, Calif., and Venlo, the Netherlands, July  26, 2023  (GLOBE NEWSWIRE) -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.",https://www.globenewswire.com/news-release/2023/07/26/2711680/8690/en/Bio-Rad-and-QIAGEN-announce-patent-settlement-and-cross-licensing-agreement.html,,Company Announcement,biotech,2023-07-26 18:15:00.000 +0300,market_open,15,46.709999084472656,47.2400016784668,454.4700012207031,455.510009765625,0.011346662478748028,0.002288398666861222,0.009058263811886805
TALS,Talaris Therapeutics to Participate at the 5th Annual Evercore ISI HealthCONx Conference,"BOSTON and LOUISVILLE, Ky., Nov.  22, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2022 at 4:20 PM ET.",2022-11-22 14:00:00.000 +0200,"BOSTON and LOUISVILLE, Ky., Nov.  22, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, today announced that Scott Requadt, Chief Executive Officer of Talaris, will participate in a fireside chat at the 5th Annual Evercore ISI HealthCONx Conference being held virtually on Tuesday, November 29, 2022 at 4:20 PM ET.",https://www.globenewswire.com/news-release/2022/11/22/2560659/0/en/Talaris-Therapeutics-to-Participate-at-the-5th-Annual-Evercore-ISI-HealthCONx-Conference.html,,Conference Calls/ Webcasts,biotech,2022-11-22 09:00:00.000 +0200,pre_market,7,1.4199999570846558,1.440000057220459,394.5899963378906,396.6300048828125,0.014084577986089954,0.0051699449146070066,0.008914633071482946
DBVT,DBV Technologies présente ses résultats financiers du premier semestre 2023 et fait le point sur ses activités,"Montrouge, France, le 25 juillet (22h30 CET)",2023-07-25 23:30:00.000 +0300,"Montrouge, France, le 25 juillet (22h30 CET)",https://www.globenewswire.com/news-release/2023/07/25/2710899/0/fr/DBV-Technologies-pr%C3%A9sente-ses-r%C3%A9sultats-financiers-du-premier-semestre-2023-et-fait-le-point-sur-ses-activit%C3%A9s.html,,European Regulatory News,biotech,2023-07-25 18:30:00.000 +0300,market_open,15,1.6399999856948853,1.659999966621399,453.9200134277344,455.44000244140625,0.01219511042741837,0.003348583381891053,0.008846527045527318
DBVT,DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update,"Montrouge, France, July 25, 2023",2023-07-25 23:30:00.000 +0300,"Montrouge, France, July 25, 2023",https://www.globenewswire.com/news-release/2023/07/25/2710899/0/en/DBV-Technologies-to-Report-First-Half-2023-Financial-Results-and-Provide-a-Corporate-Update.html,,European Regulatory News,biotech,2023-07-25 18:30:00.000 +0300,market_open,15,1.6399999856948853,1.659999966621399,453.9200134277344,455.44000244140625,0.01219511042741837,0.003348583381891053,0.008846527045527318
IMNN,IMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus,CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models,2023-08-24 23:05:00.000 +0300,CRADA will evaluate the immunogenicity and efficacy of two DNA-based Lassa virus vaccine candidates in animal models,https://www.globenewswire.com/news-release/2023/08/24/2731585/0/en/IMUNON-Enters-into-CRADA-for-Preclinical-Studies-of-PlaCCine-Modality-in-Preventive-Vaccines-Against-Lassa-Virus.html,,Press releases,biotech,2023-08-24 18:05:00.000 +0300,market_open,15,1.1200000047683716,1.1100000143051147,444.69000244140625,436.8900146484375,-0.008928562875609045,-0.017540281432336678,0.008611718556727634
ARQT,Arcutis to Present at Upcoming Investor Conference,"WESTLAKE VILLAGE, Calif., June  06, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.",2023-06-06 23:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., June  06, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.",https://www.globenewswire.com/news-release/2023/06/06/2683289/0/en/Arcutis-to-Present-at-Upcoming-Investor-Conference.html,,Calendar of Events,biotech,2023-06-06 18:00:00.000 +0300,market_open,15,8.520000457763672,8.619999885559082,426.6700134277344,428.0299987792969,0.011737021411106588,0.00318744066553166,0.00854958074557493
MDWD,MediWound to Report First Quarter 2023 Financial Results,"Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time",2023-05-12 15:00:00.000 +0300,"Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time Conference Call and Webcast Scheduled for Tuesday, May 30th at 8:30 am Eastern Time",https://www.globenewswire.com/news-release/2023/05/12/2667732/30505/en/MediWound-to-Report-First-Quarter-2023-Financial-Results.html,,Calendar of Events,biotech,2023-05-12 10:00:00.000 +0300,pre_market,7,10.380000114440918,10.5,412.1300048828125,413.4200134277344,0.011560682489023788,0.0031301010109387297,0.008430581478085057
OCUP,Ocuphire Pharma Announces Financial Results for First Quarter 2023 and Provides Corporate Update,End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR),2023-05-15 15:00:00.000 +0300,End-of-Phase 2 Meeting with FDA Anticipated in 2H 2023 to Confirm Phase 3 Regulatory Path for Oral APX3330 in Diabetic Retinopathy (DR),https://www.globenewswire.com/news-release/2023/05/15/2668732/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-First-Quarter-2023-and-Provides-Corporate-Update.html,,Earnings Releases and Operating Results,biotech,2023-05-15 10:00:00.000 +0300,pre_market,7,6.03000020980835,6.090000152587891,411.5899963378906,412.2200012207031,0.009950238920712737,0.001530661309599235,0.008419577611113503
SCLX,Scilex Holding Company Added to the Preliminary List of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 2023 Russell Indexes Annual Reconstitution in June 2023,"PALO ALTO, Calif., May  22, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced today that it has been added to the preliminary list of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 35th Russell indexes annual reconstitution. Preliminary membership lists (reflecting any updates) will be posted to the FTSE Russell website from May 26 – June 16, 2023. The annual reconstitution will be final after the close of market on Friday, June 23, 2023 and will become effective Monday, June 26th 2023 at the open of the equity markets. This rebalancing process is designed to capture market shifts from the previous year to ensure the Russell U.S. Indexes continue to accurately reflect the US equity market.",2023-05-22 16:00:00.000 +0300,"PALO ALTO, Calif., May  22, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced today that it has been added to the preliminary list of the Russell 3000® Index and the Small-Cap Russell 2000® Index as part of the 35th Russell indexes annual reconstitution. Preliminary membership lists (reflecting any updates) will be posted to the FTSE Russell website from May 26 – June 16, 2023. The annual reconstitution will be final after the close of market on Friday, June 23, 2023 and will become effective Monday, June 26th 2023 at the open of the equity markets. This rebalancing process is designed to capture market shifts from the previous year to ensure the Russell U.S. Indexes continue to accurately reflect the US equity market.",https://www.globenewswire.com/news-release/2023/05/22/2673437/0/en/Scilex-Holding-Company-Added-to-the-Preliminary-List-of-the-Russell-3000-Index-and-the-Small-Cap-Russell-2000-Index-as-part-of-the-2023-Russell-Indexes-Annual-Reconstitution-in-Jun.html,,Health,biotech,2023-05-22 11:00:00.000 +0300,pre_market,8,7.139999866485596,7.199999809265137,418.6199951171875,418.6400146484375,0.008403353487606407,0.0000478226828233,0.008355530804783061
OCUP,Ocuphire Presents APX3330 ZETA-1 Clinical Data in Late-Breaker Session at the American Diabetes Association’s Annual Conference,"FARMINGTON HILLS, Mich., June  27, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that a late-breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy was presented by retina specialist and ZETA-1 clinical trial investigator, Victor H. Gonzalez, M.D. at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA on Saturday, June 24, 2023.",2023-06-27 15:00:00.000 +0300,"FARMINGTON HILLS, Mich., June  27, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that a late-breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy was presented by retina specialist and ZETA-1 clinical trial investigator, Victor H. Gonzalez, M.D. at the 83rd Scientific Sessions of the American Diabetes Association (ADA) in San Diego, CA on Saturday, June 24, 2023.",https://www.globenewswire.com/news-release/2023/06/27/2695238/0/en/Ocuphire-Presents-APX3330-ZETA-1-Clinical-Data-in-Late-Breaker-Session-at-the-American-Diabetes-Association-s-Annual-Conference.html,,Clinical Study,biotech,2023-06-27 10:00:00.000 +0300,pre_market,7,3.869999885559082,3.9100000858306885,431.44000244140625,432.3500061035156,0.010335969368078622,0.002109224126089148,0.008226745241989474
ECOR,gammaCore Non-Invasive Vagus Nerve Stimulation (nVNS) Improves Attention and Working Memory in Patients with Post Traumatic Stress Disorder (PTSD),"Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD",2023-09-27 15:00:00.000 +0300,"Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD Two prospective, peer reviewed trials demonstrate the symptomatic benefit of gammaCore in patients with PTSD",https://www.globenewswire.com/news-release/2023/09/27/2750322/0/en/gammaCore-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Improves-Attention-and-Working-Memory-in-Patients-with-Post-Traumatic-Stress-Disorder-PTSD.html,,Product / Services Announcement,biotech,2023-09-27 10:00:00.000 +0300,pre_market,7,5.590000152587891,5.650000095367432,425.8800048828125,427.0899963378906,0.01073344206471337,0.0028411558213705594,0.00789228624334281
SPRY,"ARS Pharmaceuticals Announces FDA Advisory Committee for neffy® for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxis","SAN DIEGO, March  28, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Division of Pulmonology, Allergy and Critical Care Advisory Committee meeting on May 11, 2023 to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.",2023-03-28 16:39:00.000 +0300,"SAN DIEGO, March  28, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) has scheduled a Division of Pulmonology, Allergy and Critical Care Advisory Committee meeting on May 11, 2023 to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.",https://www.globenewswire.com/news-release/2023/03/28/2635830/0/en/ARS-Pharmaceuticals-Announces-FDA-Advisory-Committee-for-neffy-for-the-Treatment-of-Allergic-Reactions-Type-1-Including-Anaphylaxis.html,,Product / Services Announcement,biotech,2023-03-28 11:39:00.000 +0300,pre_market,8,6.659999847412109,6.699999809265137,396.489990234375,395.7699890136719,0.006006000415836378,-0.0018159379516176804,0.007821938367454059
BIOR,Biora Therapeutics to Present Preclinical Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes,"SAN DIEGO, June  08, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.",2023-06-08 16:00:00.000 +0300,"SAN DIEGO, June  08, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present preclinical data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion at the 59th annual meeting of the European Association for the Study of Diabetes, to be held October 2–6, 2023 in Hamburg, Germany.",https://www.globenewswire.com/news-release/2023/06/08/2684790/0/en/Biora-Therapeutics-to-Present-Preclinical-Data-on-the-BioJet-Systemic-Oral-Delivery-Platform-at-the-59th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html,,Calendar of Events,biotech,2023-06-08 11:00:00.000 +0300,pre_market,8,5.099999904632568,5.139999866485596,426.54998779296875,426.6199951171875,0.00784312992176598,0.0001641245486396,0.007679005373126375
ECOR,electroCore Announces Poster to be Presented at the American Headache Society’s 65th Annual Scientific Meeting,"ROCKAWAY, N.J., June  13, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society’s 65th Annual Scientific Meeting on June 16-17, 2023 in Austin, Texas.",2023-06-13 15:00:00.000 +0300,"ROCKAWAY, N.J., June  13, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that “SUNCT/ SUNA with neurovascular conflict: consider nVNS,” will be presented at the American Headache Society’s 65th Annual Scientific Meeting on June 16-17, 2023 in Austin, Texas.",https://www.globenewswire.com/news-release/2023/06/13/2687060/0/en/electroCore-Announces-Poster-to-be-Presented-at-the-American-Headache-Society-s-65th-Annual-Scientific-Meeting.html,,Health,biotech,2023-06-13 10:00:00.000 +0300,pre_market,7,4.054999828338623,4.099999904632568,433.79998779296875,435.32000732421875,0.011097429888765822,0.003503963978845085,0.007593465909920737
IMNN,"IMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies","Provides a look at the new manufacturing facility in Huntsville, Alabama",2023-09-26 15:30:00.000 +0300,"Provides a look at the new manufacturing facility in Huntsville, Alabama",https://www.globenewswire.com/news-release/2023/09/26/2749511/0/en/IMUNON-Releases-Enterprise-Video-Highlighting-the-Company-s-Mission-Vision-Values-Breakthroughs-and-Technologies.html,,Press releases,biotech,2023-09-26 10:30:00.000 +0300,pre_market,7,1.0299999713897705,1.0299999713897705,432.2300109863281,429.0899963378906,0.0,-0.007264684470363678,0.007264684470363678
SPRY,ARS Pharmaceuticals Highlights Progress and Reports First Quarter 2023 Financial Results,"FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions (Type I), Including Anaphylaxis",2023-05-15 16:00:00.000 +0300,"FDA Advisory Committee Votes in Support of Favorable Benefit-Risk Profile for neffy® for the Treatment of Allergic Reactions (Type I), Including Anaphylaxis",https://www.globenewswire.com/news-release/2023/05/15/2668855/0/en/ARS-Pharmaceuticals-Highlights-Progress-and-Reports-First-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-05-15 11:00:00.000 +0300,pre_market,8,8.039999961853027,8.109999656677246,411.5899963378906,412.2200012207031,0.008706429745813767,0.001530661309599235,0.007175768436214531
BIOR,Biora Therapeutics to Participate in Canaccord Genuity 43rd Annual Growth Conference,"SAN DIEGO, Aug.  02, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that management will be attending the Canaccord Genuity 43rd Annual Growth Conference in Boston.",2023-08-02 15:00:00.000 +0300,"SAN DIEGO, Aug.  02, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that management will be attending the Canaccord Genuity 43rd Annual Growth Conference in Boston.",https://www.globenewswire.com/news-release/2023/08/02/2716792/0/en/Biora-Therapeutics-to-Participate-in-Canaccord-Genuity-43rd-Annual-Growth-Conference.html,,Calendar of Events,biotech,2023-08-02 10:00:00.000 +0300,pre_market,7,3.940000057220459,3.940000057220459,456.4800109863281,453.25,0.0,-0.007075908930489545,0.007075908930489545
ORIC,ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May  05, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2023 (the “Grant Date”), ORIC granted a total of 29,800 non-qualified stock options and 4,980 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2023.",2023-05-05 23:15:00.000 +0300,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May  05, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on May 1, 2023 (the “Grant Date”), ORIC granted a total of 29,800 non-qualified stock options and 4,980 restricted stock units to two new non-executive employees who began their employment with ORIC in April 2023.",https://www.globenewswire.com/news-release/2023/05/05/2662859/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,,Stock Market News,biotech,2023-05-05 18:15:00.000 +0300,market_open,15,5.03000020980835,5.110000133514404,408.9100036621094,412.6300048828125,0.015904556733428606,0.009097359290278056,0.00680719744315055
ICCC,"ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022","Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET",2023-02-15 18:55:00.000 +0200,"Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET Conference Call Scheduled for Wednesday, February 22, 2023 at 9:00 AM ET",https://www.globenewswire.com/news-release/2023/02/15/2609049/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Year-Ended-December-31-2022.html,,Calendar of Events,biotech,2023-02-15 13:55:00.000 +0200,market_open,11,7.050000190734863,7.159999847412109,410.3500061035156,413.9800109863281,0.015602787759042624,0.008846118749409226,0.006756669009633398
ECOR,electroCore Provides Select Second Quarter 2023 Financial Guidance,"Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022",2023-07-11 15:00:00.000 +0300,"Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022 Record revenue of approximately $3,550,000 for the three months ended June 30, 2023; 65% increase over second quarter of 2022",https://www.globenewswire.com/news-release/2023/07/11/2702564/0/en/electroCore-Provides-Select-Second-Quarter-2023-Financial-Guidance.html,,Pre-Release Comments,biotech,2023-07-11 10:00:00.000 +0300,pre_market,7,4.860000133514404,4.900000095367432,439.6600036621094,440.45001220703125,0.008230444599618197,0.001796862435385453,0.006433582164232744
IMCR,Immunocore to present at upcoming investor conferences,Immunocore to present at upcoming investor conferences,2023-02-01 14:00:00.000 +0200,Immunocore to present at upcoming investor conferences,https://www.globenewswire.com/news-release/2023/02/01/2599292/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html,,Calendar of Events,biotech,2023-02-01 09:00:00.000 +0200,pre_market,7,61.27000045776367,61.459999084472656,406.4800109863281,405.2099914550781,0.003101005798750719,-0.0031244329288623173,0.0062254387276130365
ECOR,electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference,"ROCKAWAY, N.J., Sept.  07, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the H.C. Wainwright 25th Annual Global Investment Conference.",2023-09-07 15:00:00.000 +0300,"ROCKAWAY, N.J., Sept.  07, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the H.C. Wainwright 25th Annual Global Investment Conference.",https://www.globenewswire.com/news-release/2023/09/07/2739252/0/en/electroCore-to-Participate-in-the-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,,Calendar of Events,biotech,2023-09-07 10:00:00.000 +0300,pre_market,7,5.974999904632568,5.96999979019165,446.2200012207031,443.1099853515625,-0.0008368392503306,-0.006969691767811171,0.006132852517480597
IMNN,IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board,Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas™ and Indiplas™ modalities in immuno-oncology.,2023-10-06 15:30:00.000 +0300,Renowned Daner-Farber Cancer Institute researcher will advise on the development of IMUNON’s FixPlas™ and Indiplas™ modalities in immuno-oncology.,https://www.globenewswire.com/news-release/2023/10/06/2756080/0/en/IMUNON-Appoints-Dr-Patrick-Ott-to-its-Scientific-Advisory-Board.html,,Press releases,biotech,2023-10-06 10:30:00.000 +0300,pre_market,7,1.0399999618530273,1.0399999618530273,424.5,421.9700012207031,0.0,-0.005959950010122203,0.005959950010122203
OCUP,Ocuphire Presents APX3330 ZETA-1 Data at Clinical Trials at the Summit (CTS) 2023,"FARMINGTON HILLS, Mich., June  12, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that a presentation titled, Safety and Efficacy of an Oral Therapeutic APX3330 from ZETA-1 Phase 2 Trial in Patients with Diabetic Retinopathy, was delivered by David Lally, M.D. F.A.S.R.S. at the Clinical Trials at the Summit (CTS) 2023 meeting in Park City, Utah on Saturday, June 10. Dr. Lally is a member of Ocuphire’s Medical Advisory Board. APX3330 was evaluated in patients with mild to moderate non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR).",2023-06-12 15:00:00.000 +0300,"FARMINGTON HILLS, Mich., June  12, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that a presentation titled, Safety and Efficacy of an Oral Therapeutic APX3330 from ZETA-1 Phase 2 Trial in Patients with Diabetic Retinopathy, was delivered by David Lally, M.D. F.A.S.R.S. at the Clinical Trials at the Summit (CTS) 2023 meeting in Park City, Utah on Saturday, June 10. Dr. Lally is a member of Ocuphire’s Medical Advisory Board. APX3330 was evaluated in patients with mild to moderate non-proliferative diabetic retinopathy (NPDR) and mild proliferative diabetic retinopathy (PDR).",https://www.globenewswire.com/news-release/2023/06/12/2686261/0/en/Ocuphire-Presents-APX3330-ZETA-1-Data-at-Clinical-Trials-at-the-Summit-CTS-2023.html,,Clinical Study,biotech,2023-06-12 10:00:00.000 +0300,pre_market,7,3.759999990463257,3.7899999618530273,429.8999938964844,430.9200134277344,0.00797871581538869,0.0023726902668800933,0.005606025548508597
EYEN,Eyenovia Announces Addition to Russell 2000® and Russell 3000® Indexes,"NEW YORK, June  26, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the company was added to the small cap Russell 2000® and broad market Russell 3000® Indexes effective today.",2023-06-26 15:00:00.000 +0300,"NEW YORK, June  26, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage ophthalmic technology company preparing for the launch of Mydcombi™ (tropicamide+phenylephrine ophthalmic spray for mydriasis) and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that the company was added to the small cap Russell 2000® and broad market Russell 3000® Indexes effective today.",https://www.globenewswire.com/news-release/2023/06/26/2694372/0/en/Eyenovia-Announces-Addition-to-Russell-2000-and-Russell-3000-Indexes.html,,Trading information,biotech,2023-06-26 10:00:00.000 +0300,pre_market,7,2.369999885559082,2.380000114440918,433.2099914550781,432.6199951171875,0.004219506061063327,-0.0013619176600911914,0.005581423721154518
FBIO,Study Published in American Journal of Hematology Demonstrates First Reported Evidence of Safe and Successful Boosting of Cytomegalovirus Vaccine-Specific T Cell Immunity in a Stem Cell Transplant Recipient Via Vaccination of a Donor with Triplex,Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients,2023-02-15 15:30:00.000 +0200,Phase 2 clinical trial planned to evaluate efficacy of Triplex-vaccinated donors to enhance protective CMV-specific T cell immunity in stem cell transplant recipients,https://www.globenewswire.com/news-release/2023/02/15/2608720/28889/en/Study-Published-in-American-Journal-of-Hematology-Demonstrates-First-Reported-Evidence-of-Safe-and-Successful-Boosting-of-Cytomegalovirus-Vaccine-Specific-T-Cell-Immunity-in-a-Stem.html,,Clinical Study,biotech,2023-02-15 10:30:00.000 +0200,pre_market,8,10.199999809265137,10.199999809265137,412.6400146484375,410.3500061035156,0.0,-0.005549652151095731,0.005549652151095731
ONCT,Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4),"SAN DIEGO, March  27, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal as Head of IT.",2023-03-27 16:00:00.000 +0300,"SAN DIEGO, March  27, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the approval of an inducement award to one new employee, Erik S. Nelson, who joined Oncternal as Head of IT.",https://www.globenewswire.com/news-release/2023/03/27/2634811/0/en/Oncternal-Therapeutics-Reports-Inducement-Award-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Stock Market News,biotech,2023-03-27 11:00:00.000 +0300,pre_market,8,0.8700000047683716,0.8799999952316284,395.75,398.1199951171875,0.011494241848790828,0.005988616846967783,0.005505625001823045
ECOR,electroCore to Participate in the Lytham Partners Fall 2023 Virtual Investor Conference,"ROCKAWAY, N.J., Oct.  05, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.",2023-10-05 15:00:00.000 +0300,"ROCKAWAY, N.J., Oct.  05, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023.",https://www.globenewswire.com/news-release/2023/10/05/2755341/0/en/electroCore-to-Participate-in-the-Lytham-Partners-Fall-2023-Virtual-Investor-Conference.html,,Calendar of Events,biotech,2023-10-05 10:00:00.000 +0300,pre_market,7,6.320000171661377,6.349999904632568,424.6600036621094,424.3599853515625,0.004746793062713667,-0.0007064906229916,0.005453283685705305
JSPR,Jasper Therapeutics to Present Data on JSP191 Conditioning in SCID patients at the 2021 American Society of Hematology Annual Meeting,"REDWOOD CITY, Calif., Dec.  08, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting.",2021-12-08 15:30:00.000 +0200,"REDWOOD CITY, Calif., Dec.  08, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that data on JSP191 showing long-term benefits of hematopoietic stem cells (HSC) engraftment following targeted single-agent JSP191 conditioning in the treatment of severe combined immunodeficiency (SCID) will be presented at the 2021 American Society of Hematology (ASH) Annual Meeting.",https://www.globenewswire.com/news-release/2021/12/08/2348326/0/en/Jasper-Therapeutics-to-Present-Data-on-JSP191-Conditioning-in-SCID-patients-at-the-2021-American-Society-of-Hematology-Annual-Meeting.html,,Health,biotech,2021-12-08 10:30:00.000 +0200,pre_market,8,8.0,8.050000190734863,468.2799987792969,468.70001220703125,0.00625002384185791,0.0008969279679449,0.005353095873912968
BIOR,Biora Therapeutics Presents Data on the BioJet™ Systemic Oral Delivery Platform at the 59th Annual Meeting of the European Association for the Study of Diabetes,Autonomous device exceeded performance targets for oral delivery of large molecules in three recent preclinical studies,2023-10-05 15:00:00.000 +0300,Autonomous device exceeded performance targets for oral delivery of large molecules in three recent preclinical studies,https://www.globenewswire.com/news-release/2023/10/05/2755345/0/en/Biora-Therapeutics-Presents-Data-on-the-BioJet-Systemic-Oral-Delivery-Platform-at-the-59th-Annual-Meeting-of-the-European-Association-for-the-Study-of-Diabetes.html,,Health,biotech,2023-10-05 10:00:00.000 +0300,pre_market,7,2.180000066757202,2.190000057220459,424.6600036621094,424.3599853515625,0.00458715144817956,-0.0007064906229916,0.005293642071171198
ECOR,gammaCore™ Non-Invasive Vagal Nerve Stimulation Selected for Study Funded by the National Football League (NFL) and National Football League Players Association (NFLPA) on Alleviating Concussion Symptoms,"ROCKAWAY, N.J., July  06, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids and alternative care on athlete pain management and performance. The NFL and NFLPA are jointly awarding two research grants to independent medical researchers at the American Society of Pain and Neuroscience (ASPN) and Emory University.",2023-07-06 15:00:00.000 +0300,"ROCKAWAY, N.J., July  06, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its gammaCore non-invasive vagus nerve stimulation (“nVNS”) has been selected to be a part of studies on effects of cannabinoids and alternative care on athlete pain management and performance. The NFL and NFLPA are jointly awarding two research grants to independent medical researchers at the American Society of Pain and Neuroscience (ASPN) and Emory University.",https://www.globenewswire.com/news-release/2023/07/06/2700272/0/en/gammaCore-Non-Invasive-Vagal-Nerve-Stimulation-Selected-for-Study-Funded-by-the-National-Football-League-NFL-and-National-Football-League-Players-Association-NFLPA-on-Alleviating-C.html,,Product / Services Announcement,biotech,2023-07-06 10:00:00.000 +0300,pre_market,7,4.644999980926514,4.630000114440918,443.1300048828125,439.4200134277344,-0.0032292500639803574,-0.008372241586437477,0.0051429915224571205
OCUP,Ocuphire Announces APX3330 and Nyxol® Data Presentations at ASCRS 2023 and Eyecelerator,"FARMINGTON HILLS, Mich., May  02, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations featuring results from the Company’s recently completed trials of APX3330 and Nyxol® at the American Society of Cataract and refractive Surgery (ASCRS) to be held in San Diego, CA May 5-8, 2023. In addition, Ocuphire, represented by Chief Medical Advisor Jay Pepose M.D., Ph.D, will also be featured in the Marketplace Company Showcase at Eyecelerator @ ASCRS 2023 on May 4.",2023-05-02 15:30:00.000 +0300,"FARMINGTON HILLS, Mich., May  02, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced presentations featuring results from the Company’s recently completed trials of APX3330 and Nyxol® at the American Society of Cataract and refractive Surgery (ASCRS) to be held in San Diego, CA May 5-8, 2023. In addition, Ocuphire, represented by Chief Medical Advisor Jay Pepose M.D., Ph.D, will also be featured in the Marketplace Company Showcase at Eyecelerator @ ASCRS 2023 on May 4.",https://www.globenewswire.com/news-release/2023/05/02/2659176/0/en/Ocuphire-Announces-APX3330-and-Nyxol-Data-Presentations-at-ASCRS-2023-and-Eyecelerator.html,,Conference Calls/ Webcasts,biotech,2023-05-02 10:30:00.000 +0300,pre_market,7,6.019999980926514,6.039999961853027,415.510009765625,414.7699890136719,0.0033222559783854942,-0.0017809938017390855,0.00510324978012458
VIR,"Vir Biotechnology to Provide Business Update and Report Second Quarter 2023  Financial Results on August 3, 2023","SAN FRANCISCO, July  26, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on August 3, 2023.",2023-07-26 23:05:00.000 +0300,"SAN FRANCISCO, July  26, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2023 on August 3, 2023. The Company will host a conference call at 4:30 p.m. Eastern Time on August 3, 2023.",https://www.globenewswire.com/news-release/2023/07/26/2711662/0/en/Vir-Biotechnology-to-Provide-Business-Update-and-Report-Second-Quarter-2023-Financial-Results-on-August-3-2023.html,,Conference Calls/ Webcasts,biotech,2023-07-26 18:05:00.000 +0300,market_open,15,13.949999809265137,14.050000190734863,454.4700012207031,455.510009765625,0.0071684862248750396,0.002288398666861222,0.004880087558013817
OCUP,Ocuphire Announces Late Breaking Presentation on APX3330 ZETA-1 Clinical Data at American Diabetes Association Annual Conference,"FARMINGTON HILLS, Mich., June  21, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H. Gonzalez, MD will present a late breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy at the 83rd Scientific Sessions of the American Diabetes Association (ADA), in San Diego, CA, June 23-26.",2023-06-21 15:00:00.000 +0300,"FARMINGTON HILLS, Mich., June  21, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced that Victor H. Gonzalez, MD will present a late breaking poster and ePoster theater presentation titled Oral APX3330 Reduces the DRSS Worsening after 24-weeks of Daily Treatment—Efficacy and Safety Results of the ZETA-1 Phase 2 Trial in Diabetic Retinopathy at the 83rd Scientific Sessions of the American Diabetes Association (ADA), in San Diego, CA, June 23-26.",https://www.globenewswire.com/news-release/2023/06/21/2691963/0/en/Ocuphire-Announces-Late-Breaking-Presentation-on-APX3330-ZETA-1-Clinical-Data-at-American-Diabetes-Association-Annual-Conference.html,,Health,biotech,2023-06-21 10:00:00.000 +0300,pre_market,7,3.9700000286102295,3.9800000190734863,437.17999267578125,436.1600036621094,0.0025188892673024777,-0.0023331100021960816,0.00485199926949856
DBVT,DBV Technologies participera au prochain congrès de l’EAACI 2023,"Montrouge, France, 8 juin 2023",2023-06-08 23:30:00.000 +0300,"Montrouge, France, 8 juin 2023",https://www.globenewswire.com/news-release/2023/06/08/2685215/0/fr/DBV-Technologies-participera-au-prochain-congr%C3%A8s-de-l-EAACI-2023.html,,European Regulatory News,biotech,2023-06-08 18:30:00.000 +0300,market_open,15,1.8799999952316284,1.899999976158142,426.6199951171875,429.1300048828125,0.010638287753851585,0.005883478961026029,0.004754808792825556
DBVT,DBV Technologies to Participate in Upcoming EAACI Congress 2023,"Montrouge, France, June 8, 2023",2023-06-08 23:30:00.000 +0300,"Montrouge, France, June 8, 2023",https://www.globenewswire.com/news-release/2023/06/08/2685215/0/en/DBV-Technologies-to-Participate-in-Upcoming-EAACI-Congress-2023.html,,European Regulatory News,biotech,2023-06-08 18:30:00.000 +0300,market_open,15,1.8799999952316284,1.899999976158142,426.6199951171875,429.1300048828125,0.010638287753851585,0.005883478961026029,0.004754808792825556
CHRS,Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC),"REDWOOD CITY, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA.",2023-09-27 16:10:00.000 +0300,"REDWOOD CITY, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced the presentation of three abstracts from its innovative immuno-oncology pipeline at the upcoming SITC Annual Meeting taking place November 3 - 5, 2023 at the San Diego Convention Center in San Diego, CA.",https://www.globenewswire.com/news-release/2023/09/27/2750480/33333/en/Coherus-Announces-Three-Presentations-at-the-38th-Annual-Meeting-of-the-Society-for-Immunotherapy-of-Cancer-SITC.html,,Health,biotech,2023-09-27 11:10:00.000 +0300,pre_market,8,3.9800000190734863,4.010000228881836,425.8800048828125,427.0899963378906,0.007537741121753419,0.0028411558213705594,0.004696585300382859
ICCC,ImmuCell Announces Submission of CMC Technical Section to the FDA,"PORTLAND, Maine, Aug.  29, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA.",2023-08-29 15:00:00.000 +0300,"PORTLAND, Maine, Aug.  29, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, announced today that it recently submitted the Chemistry, Manufacturing and Controls (CMC) Technical Section for Re-Tain® to the FDA.",https://www.globenewswire.com/news-release/2023/08/29/2733350/0/en/ImmuCell-Announces-Submission-of-CMC-Technical-Section-to-the-FDA.html,,Government News,biotech,2023-08-29 10:00:00.000 +0300,pre_market,7,4.53000020980835,4.550000190734863,442.760009765625,442.6499938964844,0.004415006622562565,-0.0002484774295647,0.004663484052127312
EYEN,Eyenovia Announces First Commercial Sale of Mydcombi™,Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation,2023-08-03 15:00:00.000 +0300,Represents the first FDA approved and commercially available fixed combination of tropicamide and phenylephrine for pupil dilation,https://www.globenewswire.com/news-release/2023/08/03/2717937/0/en/Eyenovia-Announces-First-Commercial-Sale-of-Mydcombi.html,,Product / Services Announcement,biotech,2023-08-03 10:00:00.000 +0300,pre_market,7,2.109999895095825,2.109999895095825,450.1300048828125,448.0400085449219,0.0,-0.004643094917511081,0.004643094917511081
OCUP,"Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents",RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024,2023-09-27 15:00:00.000 +0300,RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024 RYZUMVI Expected to be Commercially Available in the U.S. in the First Half of 2024,https://www.globenewswire.com/news-release/2023/09/27/2750331/0/en/Ocuphire-Pharma-and-Viatris-Announce-FDA-Approval-of-RYZUMVI-Phentolamine-Ophthalmic-Solution-0-75-Eye-Drops-for-the-Treatment-of-Pharmacologically-Induced-Mydriasis-Produced-by-Ad.html,,Product / Services Announcement,biotech,2023-09-27 10:00:00.000 +0300,pre_market,7,4.019999980926514,4.050000190734863,425.8800048828125,427.0899963378906,0.007462738793703994,0.0028411558213705594,0.004621582972333435
SNCE,Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"RESEARCH TRIANGLE PARK, N.C., Oct.  06, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",2023-10-06 23:41:00.000 +0300,"RESEARCH TRIANGLE PARK, N.C., Oct.  06, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",https://www.globenewswire.com/news-release/2023/10/06/2756321/0/en/Science-37-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html,,Financing Agreements,biotech,2023-10-06 18:41:00.000 +0300,market_open,15,0.4000000059604645,0.4090000092983246,421.9700012207031,429.5400085449219,0.02250000800937402,0.017939681262458766,0.004560326746915255
ELOX,Eloxx Pharmaceuticals Announces Submission of Investigational New Drug (IND) Application for ZKN-013,ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB),2023-03-28 23:45:00.000 +0300,ZKN-013 in development for treatment of recessive dystrophic epidermolysis bullosa (RDEB) and junctional epidermolysis bullosa (JEB),https://www.globenewswire.com/news-release/2023/03/28/2636244/0/en/Eloxx-Pharmaceuticals-Announces-Submission-of-Investigational-New-Drug-IND-Application-for-ZKN-013.html,,Health,biotech,2023-03-28 18:45:00.000 +0300,market_open,15,2.4600000381469727,2.4700000286102295,395.7699890136719,395.6000061035156,0.004065036710645525,-0.0004294992416678,0.004494535952313337
MDWD,MediWound to Participate in Fireside Chat at Maxim Group Healthcare Virtual Conference 2023,"YAVNE, Israel, June  14, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest. The conference will take place online from June 20 to June 22, 2023.",2023-06-14 15:00:00.000 +0300,"YAVNE, Israel, June  14, 2023  (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation enzymatic therapeutics for tissue repair, today announced its participation in the upcoming Healthcare Virtual Conference Part II, organized by Maxim Group LLC and hosted by M-Vest. The conference will take place online from June 20 to June 22, 2023.",https://www.globenewswire.com/news-release/2023/06/14/2688003/30505/en/MediWound-to-Participate-in-Fireside-Chat-at-Maxim-Group-Healthcare-Virtual-Conference-2023.html,,Conference Calls/ Webcasts,biotech,2023-06-14 10:00:00.000 +0300,pre_market,7,9.680000305175781,9.729000091552734,436.6600036621094,437.010009765625,0.005061961242992267,0.000801552925801,0.0042604083171912995
EYEN,Eyenovia to Present at Upcoming H.C. Wainwright 3rd Annual Ophthalmology Virtual Conference,"NEW YORK, Aug.  09, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation and participate in a panel discussion at the H.C. Wainwright 3rd Annual Ophthalmology Day, which is taking place virtually on August 16, 2023. Presentation and panel details are below:",2023-08-09 15:00:00.000 +0300,"NEW YORK, Aug.  09, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced management will deliver a presentation and participate in a panel discussion at the H.C. Wainwright 3rd Annual Ophthalmology Day, which is taking place virtually on August 16, 2023. Presentation and panel details are below:",https://www.globenewswire.com/news-release/2023/08/09/2721562/0/en/Eyenovia-to-Present-at-Upcoming-H-C-Wainwright-3rd-Annual-Ophthalmology-Virtual-Conference.html,,Conference Calls/ Webcasts,biotech,2023-08-09 10:00:00.000 +0300,pre_market,7,2.059999942779541,2.069999933242798,448.75,449.0299987792969,0.004854364437391164,0.0006239527115251,0.0042304117258660946
SCPH,scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer,Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role,2022-12-19 15:00:00.000 +0200,Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role Appointment brings more than 20 years of life sciences finance leadership experience to the CFO role,https://www.globenewswire.com/news-release/2022/12/19/2576257/0/en/scPharmaceuticals-Inc-Announces-Appointment-of-Rachael-Nokes-as-Chief-Financial-Officer.html,,Directors and Officers,biotech,2022-12-19 10:00:00.000 +0200,pre_market,8,6.380000114440918,6.409999847412109,383.2699890136719,383.4700012207031,0.004702152418976923,0.0005218572097074,0.004180295209269551
QGEN,Neuer QuantiFERON-EBV RUO-Test von QIAGEN unterstützt Erforschung der zellvermittelten Immunreaktion auf Epstein‑Barr‑Virus,"QuantiFERON-EBV RUO ermöglicht dynamische Sicht auf Immunreaktion des Wirts und soll Forschern helfen, Epstein-Barr-Virus-Infektionen und damit verbundene bösartige Erkrankungen zu verstehen // Treibt Forschung zu onkologischen und Autoimmunerkrankungen durch Messung der T-Zell-Reaktionen auf EBV an und bietet Einblicke in Bedeutung der Viren bei diesen Erkrankungen // Portfolio an QuantiFERON-Tests zur Messung der zellvermittelten Immunreaktion über Tuberkulose hinaus erweitert",2023-10-04 23:05:00.000 +0300,"QuantiFERON-EBV RUO ermöglicht dynamische Sicht auf Immunreaktion des Wirts und soll Forschern helfen, Epstein-Barr-Virus-Infektionen und damit verbundene bösartige Erkrankungen zu verstehen // Treibt Forschung zu onkologischen und Autoimmunerkrankungen durch Messung der T-Zell-Reaktionen auf EBV an und bietet Einblicke in Bedeutung der Viren bei diesen Erkrankungen // Portfolio an QuantiFERON-Tests zur Messung der zellvermittelten Immunreaktion über Tuberkulose hinaus erweitert",https://www.globenewswire.com/news-release/2023/10/04/2754931/0/de/Neuer-QuantiFERON-EBV-RUO-Test-von-QIAGEN-unterst%C3%BCtzt-Erforschung-der-zellvermittelten-Immunreaktion-auf-Epstein-Barr-Virus.html,,Clinical Study,biotech,2023-10-04 18:05:00.000 +0300,market_open,15,39.790000915527344,40.189998626708984,422.07000732421875,424.6600036621094,0.010052719325913576,0.006136414085213794,0.003916305240699781
QGEN,"QIAGEN launches QuantiFERON-EBV RUO assay, facilitating research of cell-mediated immune response to Epstein-Barr virus","QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosis QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosis",2023-10-04 23:05:00.000 +0300,"QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosis QuantiFERON-EBV RUO to help researchers understand Epstein-Barr virus (EBV) infections and related malignancies, offering a dynamic view of the host immune response // Advancing research in oncology and autoimmune diseases through measurement of T-cell responses to EBV, providing valuable insights into the virus’ role in these conditions // Further expanding portfolio of QuantiFERON cell-mediated immune response tests beyond tuberculosis",https://www.globenewswire.com/news-release/2023/10/04/2754929/8690/en/QIAGEN-launches-QuantiFERON-EBV-RUO-assay-facilitating-research-of-cell-mediated-immune-response-to-Epstein-Barr-virus.html,,Company Announcement,biotech,2023-10-04 18:05:00.000 +0300,market_open,15,39.790000915527344,40.189998626708984,422.07000732421875,424.6600036621094,0.010052719325913576,0.006136414085213794,0.003916305240699781
CHRS,Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™,"REDWOOD CITY, Calif., July  13, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today announced a national distribution agreement for YUSIMRY™ (adalimumab-aqvh) at a price of $995 per carton of two autoinjectors, a discount of more than 85% compared to Humira® (adalimumab), currently priced at $6,922 per carton of two pens.“Coherus is pleased to work with Superior Biologics for nationwide distribution of YUSIMRY, providing patients and their plan sponsors access to a high-quality, safe, and effective treatment at significant savings compared to Humira,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer. “Superior Biologics is an ideal partner for the distribution of YUSIMRY based on their commitment to quality patient service and care, their extensive experience working with manufacturers, patients, physicians, and plan sponsors, and their nationwide reach. Through this unique distribution partnership, we can bring YUSIMRY immediately to patients throughout the United States.”",2023-07-13 15:30:00.000 +0300,"REDWOOD CITY, Calif., July  13, 2023  (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and specialty pharmacy Superior Biologics, Inc. (“Superior Biologics”) today announced a national distribution agreement for YUSIMRY™ (adalimumab-aqvh) at a price of $995 per carton of two autoinjectors, a discount of more than 85% compared to Humira® (adalimumab), currently priced at $6,922 per carton of two pens.“Coherus is pleased to work with Superior Biologics for nationwide distribution of YUSIMRY, providing patients and their plan sponsors access to a high-quality, safe, and effective treatment at significant savings compared to Humira,” said Denny Lanfear, Coherus’ Chairman and Chief Executive Officer. “Superior Biologics is an ideal partner for the distribution of YUSIMRY based on their commitment to quality patient service and care, their extensive experience working with manufacturers, patients, physicians, and plan sponsors, and their nationwide reach. Through this unique distribution partnership, we can bring YUSIMRY immediately to patients throughout the United States.”",https://www.globenewswire.com/news-release/2023/07/13/2704318/33333/en/Coherus-and-Superior-Biologics-Announce-National-Distribution-Agreement-for-YUSIMRY.html,,Product / Services Announcement,biotech,2023-07-13 10:30:00.000 +0300,pre_market,7,4.46999979019165,4.505000114440918,446.0199890136719,447.8999938964844,0.007830050535140394,0.004215068672078892,0.0036149818630615014
SCPH,scPharmaceuticals Announces Positive Type C Meeting Feedback from FDA on Potential Heart Failure Class IV Indication Expansion,Company also announces issuance of key patents covering development of alternate formulations of furosemide Company also announces issuance of key patents covering development of alternate formulations of furosemide,2023-08-01 15:00:00.000 +0300,Company also announces issuance of key patents covering development of alternate formulations of furosemide Company also announces issuance of key patents covering development of alternate formulations of furosemide,https://www.globenewswire.com/news-release/2023/08/01/2715773/0/en/scPharmaceuticals-Announces-Positive-Type-C-Meeting-Feedback-from-FDA-on-Potential-Heart-Failure-Class-IV-Indication-Expansion.html,,Health,biotech,2023-08-01 10:00:00.000 +0300,pre_market,7,8.430000305175781,8.430000305175781,457.7900085449219,456.2699890136719,0.0,-0.0033203423029728356,0.0033203423029728356
SCLX,"Scilex Holding Company Announces the Completion of its SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, Phase 2 trial which achieved its objectives to Evaluate the Safety and Efficacy of SP-103 in Subjects with Moderate to Severe Acute Lower Back Pain (LBP)","PALO ALTO, Calif., Sept.  14, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the completion of its SP-103 Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy in subjects with acute LBP. Objectives of the trial were to assess safety and tolerability of SP-103 and to provide treatment effect estimates in patient population that can be used to power future studies. The trial enrolled 75 subjects, 38 received SP-103, and 37 received placebo. Topical systems were applied to the area of most tenderness in the lower back in 12-hours ON/ 12-hours OFF regimen.",2023-09-14 16:00:00.000 +0300,"PALO ALTO, Calif., Sept.  14, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the completion of its SP-103 Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy in subjects with acute LBP. Objectives of the trial were to assess safety and tolerability of SP-103 and to provide treatment effect estimates in patient population that can be used to power future studies. The trial enrolled 75 subjects, 38 received SP-103, and 37 received placebo. Topical systems were applied to the area of most tenderness in the lower back in 12-hours ON/ 12-hours OFF regimen.",https://www.globenewswire.com/news-release/2023/09/14/2743321/0/en/Scilex-Holding-Company-Announces-the-Completion-of-its-SP-103-lidocaine-topical-system-5-4-Triple-Strength-Formulation-of-ZTlido-Phase-2-trial-which-achieved-its-objectives-to-Eval.html,,Clinical Study,biotech,2023-09-14 11:00:00.000 +0300,pre_market,8,2.2300000190734863,2.25,446.510009765625,449.07000732421875,0.00896860123562833,0.005733348643040508,0.0032352525925878227
OCUP,Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October,Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy,2023-10-06 15:00:00.000 +0300,Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Presentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy,https://www.globenewswire.com/news-release/2023/10/06/2756040/0/en/Ocuphire-Pharma-to-Present-at-Euretina-and-Retina-Society-Conferences-in-October.html,,Conference Calls/ Webcasts,biotech,2023-10-06 10:00:00.000 +0300,pre_market,7,3.450000047683716,3.440000057220459,424.5,421.9700012207031,-0.002898547920302406,-0.005959950010122203,0.003061402089819797
ORIC,ORIC Pharmaceuticals to Participate in the Jefferies Healthcare Conference,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May  31, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 10:00 a.m. ET.",2023-05-31 23:10:00.000 +0300,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May  31, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, June 7, 2023, at 10:00 a.m. ET.",https://www.globenewswire.com/news-release/2023/05/31/2679796/0/en/ORIC-Pharmaceuticals-to-Participate-in-the-Jefferies-Healthcare-Conference.html,,Conference Calls/ Webcasts,biotech,2023-05-31 18:10:00.000 +0300,market_open,15,5.03000020980835,5.039999961853027,418.2799987792969,417.8500061035156,0.001988022192360652,-0.001028002001138317,0.003016024193498969
BIOR,Biora Therapeutics Announces Submission of IND Application to the U.S. FDA for BT-600 Program,BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis,2023-09-25 15:00:00.000 +0300,BT-600 is a drug/device combination delivering a liquid formulation of tofacitinib via the NaviCap™ platform for the treatment of ulcerative colitis,https://www.globenewswire.com/news-release/2023/09/25/2748572/0/en/Biora-Therapeutics-Announces-Submission-of-IND-Application-to-the-U-S-FDA-for-BT-600-Program.html,,Health,biotech,2023-09-25 10:00:00.000 +0300,pre_market,7,2.130000114440918,2.130000114440918,430.4200134277344,429.1700134277344,0.0,-0.002904140051586773,0.002904140051586773
SCLX,"Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain","PALO ALTO, Calif., May  04, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced complete enrollment in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% triple strength formulation for ZTlido®, in subjects with acute LBP.",2023-05-04 16:00:00.000 +0300,"PALO ALTO, Calif., May  04, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced complete enrollment in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and efficacy of SP-103 (lidocaine topical system) 5.4% triple strength formulation for ZTlido®, in subjects with acute LBP.",https://www.globenewswire.com/news-release/2023/05/04/2661612/0/en/Scilex-Holding-Company-Announces-Complete-Enrollment-of-a-Phase-2-Study-to-Evaluate-the-Safety-and-Efficacy-of-SP-103-lidocaine-topical-system-5-4-Triple-Strength-Formulation-of-ZT.html,,Clinical Study,biotech,2023-05-04 11:00:00.000 +0300,pre_market,8,5.5,5.5,408.0199890136719,406.92999267578125,0.0,-0.002671428771236258,0.002671428771236258
BIOR,Biora Therapeutics Announces New Patents for its NaviCap™ Targeted Oral Delivery Platform,"SAN DIEGO, June  28, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.",2023-06-28 15:30:00.000 +0300,"SAN DIEGO, June  28, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it has been awarded a group of US and European patents related to several additional therapeutic targets for its NaviCap™ targeted oral delivery platform under development.",https://www.globenewswire.com/news-release/2023/06/28/2696172/0/en/Biora-Therapeutics-Announces-New-Patents-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html,,Patents,biotech,2023-06-28 10:30:00.000 +0300,pre_market,7,3.549999952316284,3.549999952316284,436.1700134277344,435.04998779296875,0.0,-0.0025678648240021512,0.0025678648240021512
ANAB,AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit,"SAN DIEGO, Sept.  12, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.",2023-09-12 16:15:00.000 +0300,"SAN DIEGO, Sept.  12, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer, and Dr. Paul Lizzul, chief medical officer, will present at the Stifel 2023 Immunology and Inflammation Virtual Summit later this month.",https://www.globenewswire.com/news-release/2023/09/12/2741776/0/en/AnaptysBio-to-Present-at-the-Stifel-2023-Immunology-and-Inflammation-Virtual-Summit.html,,Conference Calls/ Webcasts,biotech,2023-09-12 11:15:00.000 +0300,pre_market,8,19.690000534057617,19.670000076293945,448.45001220703125,446.95001220703125,-0.0010157672534887576,-0.0033448544077807063,0.0023290871542919487
IMNN,IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update,Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet,2023-05-11 15:00:00.000 +0300,Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet,https://www.globenewswire.com/news-release/2023/05/11/2666666/0/en/IMUNON-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,,Press releases,biotech,2023-05-11 10:00:00.000 +0300,pre_market,7,1.350000023841858,1.350000023841858,412.8500061035156,411.95001220703125,0.0,-0.002179953695480183,0.002179953695480183
SCPH,scPharmaceuticals Announces Positive Feedback from Two FDA Meetings on Key Long-Term Growth Initiatives,Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients,2023-09-19 15:00:00.000 +0300,Company advancing plans to expand the FUROSCIX franchise to include an 80mg/1ml auto-injector as an additional delivery system designed to provide greater flexibility to heart failure patients,https://www.globenewswire.com/news-release/2023/09/19/2745542/0/en/scPharmaceuticals-Announces-Positive-Feedback-from-Two-FDA-Meetings-on-Key-Long-Term-Growth-Initiatives.html,,Product / Services Announcement,biotech,2023-09-19 10:00:00.000 +0300,pre_market,7,7.099999904632568,7.099999904632568,443.6300048828125,442.67999267578125,0.0,-0.0021414516524467307,0.0021414516524467307
ANAB,AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer,"SAN DIEGO, Dec.  02, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI (dostarlimab) plus standard of care chemotherapy compared to chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer, met its primary endpoint of investigator-assessed progression-free survival (PFS). The JEMPERLI regimen showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) patient subgroup and in the overall population. A clinically relevant benefit in PFS was also observed in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroup.",2022-12-02 16:00:00.000 +0200,"SAN DIEGO, Dec.  02, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that GSK’s RUBY/ENGOT-EN6/GOG3031/NSGO Phase 3 trial of JEMPERLI (dostarlimab) plus standard of care chemotherapy compared to chemotherapy plus placebo in patients with primary advanced or recurrent endometrial cancer, met its primary endpoint of investigator-assessed progression-free survival (PFS). The JEMPERLI regimen showed a statistically significant and clinically meaningful benefit in the prespecified mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) patient subgroup and in the overall population. A clinically relevant benefit in PFS was also observed in the mismatch repair proficient (MMRp)/microsatellite stable (MSS) patient subgroup.",https://www.globenewswire.com/news-release/2022/12/02/2566746/0/en/AnaptysBio-and-GSK-partnered-immuno-oncology-agent-JEMPERLI-dostarlimab-gxly-meets-primary-endpoint-in-Phase-3-RUBY-trial-in-primary-advanced-or-recurrent-endometrial-cancer.html,,Health,biotech,2022-12-02 11:00:00.000 +0200,pre_market,9,27.280000686645508,26.989999771118164,407.3800048828125,402.25,-0.010630531826537273,-0.012592677159715298,0.0019621453331780253
IMCR,"Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023","Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023",2023-02-23 14:00:00.000 +0200,"Immunocore to Report Fourth Quarter and Full Year 2022 Earnings and Host Call on March 1, 2023",https://www.globenewswire.com/news-release/2023/02/23/2614106/0/en/Immunocore-to-Report-Fourth-Quarter-and-Full-Year-2022-Earnings-and-Host-Call-on-March-1-2023.html,,Press releases,biotech,2023-02-23 09:00:00.000 +0200,pre_market,7,57.61000061035156,58.13999938964844,398.5400085449219,401.55999755859375,0.00919977041627809,0.007577630724448267,0.0016221396918298225
OCUP,Ocuphire Pharma Announces Financial Results for Fourth Quarter and Year Ended 2022 and Provides Corporate Update,Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025,2023-03-30 15:00:00.000 +0300,Financial Profile Improved Markedly with Global License Agreement to Develop and Commercialize Nyxol for All Three Indications with Cash Runway into 2025,https://www.globenewswire.com/news-release/2023/03/30/2637588/0/en/Ocuphire-Pharma-Announces-Financial-Results-for-Fourth-Quarter-and-Year-Ended-2022-and-Provides-Corporate-Update.html,,Earnings Releases and Operating Results,biotech,2023-03-30 10:00:00.000 +0300,pre_market,7,3.5999999046325684,3.630000114440918,401.3500061035156,404.0899963378906,0.00833339183418994,0.0068269345775674554,0.0015064572566224847
ELOX,Eloxx Pharmaceuticals Reports Fourth Quarter 2022 Financial and Operating Results and Provides Business Update,Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction in proteinuria has been observed in one patient to date,2023-04-03 15:00:00.000 +0300,Three patients now dosed in Phase 2 clinical study evaluating ELX-02 for the treatment of Alport syndrome; encouraging initial reduction in proteinuria has been observed in one patient to date,https://www.globenewswire.com/news-release/2023/04/03/2639530/0/en/Eloxx-Pharmaceuticals-Reports-Fourth-Quarter-2022-Financial-and-Operating-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-04-03 10:00:00.000 +0300,pre_market,7,2.509999990463257,2.509999990463257,409.3900146484375,408.8500061035156,0.0,-0.0013190564635183048,0.0013190564635183048
ANAB,AnaptysBio Announces Participation in Upcoming Investor Conferences,"SAN DIEGO, May  30, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below:",2023-05-30 23:15:00.000 +0300,"SAN DIEGO, May  30, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, interim president and chief executive officer of AnaptysBio, and other members of its senior management team are scheduled to participate in both of the upcoming investor conferences below:",https://www.globenewswire.com/news-release/2023/05/30/2678841/0/en/AnaptysBio-Announces-Participation-in-Upcoming-Investor-Conferences.html,,Calendar of Events,biotech,2023-05-30 18:15:00.000 +0300,market_open,15,18.610000610351562,18.549999237060547,422.0299987792969,420.17999267578125,-0.003224146766424106,-0.004383589102354538,0.0011594423359304325
TTOO,T2 Biosystems to Attend Upcoming Investor Conferences,"LEXINGTON, Mass., July  28, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2023:",2023-07-28 15:30:00.000 +0300,"LEXINGTON, Mass., July  28, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced plans to participate in two upcoming investor conferences in August 2023:",https://www.globenewswire.com/news-release/2023/07/28/2713129/32489/en/T2-Biosystems-to-Attend-Upcoming-Investor-Conferences.html,,Calendar of Events,biotech,2023-07-28 10:30:00.000 +0300,pre_market,7,0.11699999868869781,0.11800000071525574,452.489990234375,455.8800048828125,0.008547025963809027,0.0074919108081961845,0.0010551151556128426
FBIO,Urica Therapeutics Announces Topline Data from the Phase 1 Clinical Trial Evaluating Dotinurad in Healthy Volunteers in the United States,"Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects",2023-06-29 15:00:00.000 +0300,"Data from Phase 1 clinical trial in healthy volunteers show comparable pharmacokinetic, pharmacodynamic and safety profile between U.S. and Japanese healthy subjects",https://www.globenewswire.com/news-release/2023/06/29/2696949/28889/en/Urica-Therapeutics-Announces-Topline-Data-from-the-Phase-1-Clinical-Trial-Evaluating-Dotinurad-in-Healthy-Volunteers-in-the-United-States.html,,Clinical Study,biotech,2023-06-29 10:00:00.000 +0300,pre_market,7,7.949999809265137,7.949999809265137,436.3900146484375,435.9599914550781,0.0,-0.0009854102498331,0.0009854102498331
FBIO,Urica Therapeutics Expands Exclusive License Agreement with Fuji Yakuhin Co. Ltd. to Develop Dotinurad in Additional Territories Including Turkey and the Middle East and North Africa,"MIAMI, Dec.  14, 2022  (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, today announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. (“Fuji”) for the development of dotinurad to include the Middle East and North Africa (“MENA”) and Turkey territories. The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.",2022-12-14 15:00:00.000 +0200,"MIAMI, Dec.  14, 2022  (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. (“Urica” or the “Company”) (formerly known as UR-1 Therapeutics, Inc.), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) subsidiary company focused on the development and commercialization of pharmaceutical products to treat gout and other conditions associated with hyperuricemia, today announced that the Company has expanded its exclusive license agreement with Fuji Yakuhin Co. Ltd. (“Fuji”) for the development of dotinurad to include the Middle East and North Africa (“MENA”) and Turkey territories. The agreement builds upon the exclusive license agreement between Urica and Fuji previously announced in May of 2021 to develop dotinurad in the United States (“US”), United Kingdom, European Union and Canada.",https://www.globenewswire.com/news-release/2022/12/14/2573643/28889/en/Urica-Therapeutics-Expands-Exclusive-License-Agreement-with-Fuji-Yakuhin-Co-Ltd-to-Develop-Dotinurad-in-Additional-Territories-Including-Turkey-and-the-Middle-East-and-North-Africa.html,,Partnerships,biotech,2022-12-14 10:00:00.000 +0200,pre_market,8,9.899999618530273,9.899999618530273,401.9700012207031,401.6099853515625,0.0,-0.0008956286987768,0.0008956286987768
SCPH,scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event,"BURLINGTON, Mass., Dec.  14, 2022  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in the 12th Annual LifeSci Partners Corporate Access Event, on Monday, January 9 and Tuesday, January 10, 2023, in San Francisco. Learn more about the event and schedule an in-person meeting with the scPharmaceuticals management here.",2022-12-14 15:00:00.000 +0200,"BURLINGTON, Mass., Dec.  14, 2022  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in the 12th Annual LifeSci Partners Corporate Access Event, on Monday, January 9 and Tuesday, January 10, 2023, in San Francisco. Learn more about the event and schedule an in-person meeting with the scPharmaceuticals management here.",https://www.globenewswire.com/news-release/2022/12/14/2573598/0/en/scPharmaceuticals-to-Participate-in-the-12th-Annual-LifeSci-Partners-Corporate-Access-Event.html,,Calendar of Events,biotech,2022-12-14 10:00:00.000 +0200,pre_market,8,6.429999828338623,6.429999828338623,401.9700012207031,401.6099853515625,0.0,-0.0008956286987768,0.0008956286987768
SCPH,scPharmaceuticals Inc. Reports First Quarter 2023 Financial Results and Provides Business Update,Announced launch and commercial availability of FUROSCIX® on February 20th,2023-05-10 23:01:00.000 +0300,Announced launch and commercial availability of FUROSCIX® on February 20th,https://www.globenewswire.com/news-release/2023/05/10/2665991/0/en/scPharmaceuticals-Inc-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-05-10 18:01:00.000 +0300,market_open,15,11.380000114440918,11.359999656677246,413.8800048828125,412.8500061035156,-0.0017575094518928716,-0.002488641072642571,0.0007311316207497
FBIO,Fortress Biotech to Present at ROTH MKM 2023 Healthcare Opportunities Conference,"Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.",2023-10-05 15:30:00.000 +0300,"Fortress Biotech will present at the ROTH MKM 2023 Healthcare Opportunities Conference in New York City on Thursday, October 12, 2023, at 11:00 a.m. ET.",https://www.globenewswire.com/news-release/2023/10/05/2755404/28889/en/Fortress-Biotech-to-Present-at-ROTH-MKM-2023-Healthcare-Opportunities-Conference.html,,Calendar of Events,biotech,2023-10-05 10:30:00.000 +0300,pre_market,7,4.650000095367432,4.650000095367432,424.6600036621094,424.3599853515625,0.0,-0.0007064906229916,0.0007064906229916
SCPH,scPharmaceuticals to Present at the Jefferies Healthcare Conference,"BURLINGTON, Mass., May  31, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference, which is being held June 7-9 in New York.",2023-05-31 15:00:00.000 +0300,"BURLINGTON, Mass., May  31, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present at the Jefferies Healthcare Conference, which is being held June 7-9 in New York.",https://www.globenewswire.com/news-release/2023/05/31/2679300/0/en/scPharmaceuticals-to-Present-at-the-Jefferies-Healthcare-Conference.html,,Health,biotech,2023-05-31 10:00:00.000 +0300,pre_market,7,10.210000038146973,10.170000076293945,420.17999267578125,418.2799987792969,-0.0039177239670497585,-0.004521857131713661,0.0006041331646639
VIR,"Vir Biotechnology Appoints Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer","SAN FRANCISCO, May  15, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company’s business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and joins Vir’s executive management team.",2023-05-15 15:00:00.000 +0300,"SAN FRANCISCO, May  15, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Jeff Calcagno, M.D., as Executive Vice President and Chief Business Officer. Dr. Calcagno will be responsible for leading the Company’s business development efforts, optimizing existing alliances and establishing new strategic industry and public-private partnerships. He reports to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and joins Vir’s executive management team.",https://www.globenewswire.com/news-release/2023/05/15/2668713/0/en/Vir-Biotechnology-Appoints-Jeff-Calcagno-M-D-as-Executive-Vice-President-and-Chief-Business-Officer.html,,Directors and Officers,biotech,2023-05-15 10:00:00.000 +0300,pre_market,7,24.690000534057617,24.739999771118164,411.5899963378906,412.2200012207031,0.00202508043657502,0.001530661309599235,0.0004944191269758
SCPH,scPharmaceuticals to Participate in the SVB Securities Global Biopharma Conference,"BURLINGTON, Mass., Jan.  31, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present virtually at the SVB Securities Global Biopharma Conference, on Thursday, February 16 at 11:20 am ET. Mr. Tucker will also be meeting virtually with investors on that day.",2023-01-31 15:00:00.000 +0200,"BURLINGTON, Mass., Jan.  31, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to present virtually at the SVB Securities Global Biopharma Conference, on Thursday, February 16 at 11:20 am ET. Mr. Tucker will also be meeting virtually with investors on that day.",https://www.globenewswire.com/news-release/2023/01/31/2598379/0/en/scPharmaceuticals-to-Participate-in-the-SVB-Securities-Global-Biopharma-Conference.html,,Conference Calls/ Webcasts,biotech,2023-01-31 10:00:00.000 +0200,pre_market,8,5.590000152587891,5.599999904632568,400.5899963378906,401.1300048828125,0.0017888643598781208,0.0013480330259330472,0.0004408313339451
MDWD,MediWound Reports Second Quarter 2023 Financial Results and Provides Company Update,EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders,2023-08-15 23:03:00.000 +0300,EscharEx® Phase III study protocol: FDA/EMA-aligned; patient enrollment commencing early 2024; two key research collaborations with wound industry leaders,https://www.globenewswire.com/news-release/2023/08/15/2725894/30505/en/MediWound-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Company-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-15 18:03:00.000 +0300,market_open,15,9.12600040435791,9.0600004196167,446.2699890136719,442.8900146484375,-0.007232082162706696,-0.0075738329899903405,0.0003417508272836
MDWD,MediWound Announces Collaboration with MIMEDX on EscharEx® Phase III Study,MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers,2023-08-15 23:01:00.000 +0300,MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers MediWound to join forces with leading chronic wound allograft company in pivotal study for patients with venous leg ulcers,https://www.globenewswire.com/news-release/2023/08/15/2725886/30505/en/MediWound-Announces-Collaboration-with-MIMEDX-on-EscharEx-Phase-III-Study.html,,Partnerships,biotech,2023-08-15 18:01:00.000 +0300,market_open,15,9.12600040435791,9.0600004196167,446.2699890136719,442.8900146484375,-0.007232082162706696,-0.0075738329899903405,0.0003417508272836
MDWD,MediWound Announces Collaboration with Mölnlycke on EscharEx® Phase III Study,MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers,2023-08-15 23:02:00.000 +0300,MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers MediWound joins forces with one of the largest global chronic wound companies in pivotal study for patients with venous leg ulcers,https://www.globenewswire.com/news-release/2023/08/15/2725890/30505/en/MediWound-Announces-Collaboration-with-M%C3%B6lnlycke-on-EscharEx-Phase-III-Study.html,,Partnerships,biotech,2023-08-15 18:02:00.000 +0300,market_open,15,9.12600040435791,9.0600004196167,446.2699890136719,442.8900146484375,-0.007232082162706696,-0.0075738329899903405,0.0003417508272836
MDWD,MediWound Expands its Global Leadership Team to Help Drive Company’s Future Growth,"Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development",2023-03-06 14:00:00.000 +0200,"Appoints Barry Wolfenson, as Executive Vice President of Strategy and Corporate Development",https://www.globenewswire.com/news-release/2023/03/06/2620914/30505/en/MediWound-Expands-its-Global-Leadership-Team-to-Help-Drive-Company-s-Future-Growth.html,,Directors and Officers,biotech,2023-03-06 09:00:00.000 +0200,pre_market,7,12.199999809265137,12.229999542236328,404.19000244140625,405.04998779296875,0.0024589945442792947,0.0021276759602364696,0.0003313185840428
ELOX,Eloxx Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"WATERTOWN, Mass., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will become exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The offering is expected to close on or about September 20, 2023, subject to the satisfaction of customary closing conditions.",2023-09-19 15:00:00.000 +0300,"WATERTOWN, Mass., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 380,590 of its shares of common stock (or common stock equivalents in lieu thereof) at a purchase price of $5.255 per share (or common stock equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Eloxx has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 380,590 of its shares of common stock. The warrants will have an exercise price $5.13 per share, will become exercisable immediately upon issuance and have a term of five and one-half years from the date of issuance. The offering is expected to close on or about September 20, 2023, subject to the satisfaction of customary closing conditions.",https://www.globenewswire.com/news-release/2023/09/19/2745534/0/en/Eloxx-Pharmaceuticals-Announces-2-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,,Prospectus/Announcement of Prospectus,biotech,2023-09-19 10:00:00.000 +0300,pre_market,7,5.460000038146973,5.449999809265137,443.6300048828125,442.67999267578125,-0.0018315437384556939,-0.0021414516524467307,0.000309907913991
FBIO,Fortress Biotech to Participate in Two March 2023 Investor Conferences,"MIAMI, March  07, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in March 2023.",2023-03-07 15:00:00.000 +0200,"MIAMI, March  07, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in two investor conferences in March 2023.",https://www.globenewswire.com/news-release/2023/03/07/2622003/28889/en/Fortress-Biotech-to-Participate-in-Two-March-2023-Investor-Conferences.html,,Conference Calls/ Webcasts,biotech,2023-03-07 10:00:00.000 +0200,pre_market,8,12.149999618530273,12.149999618530273,404.4700012207031,404.4200134277344,0.0,-0.0001235883818772,0.0001235883818772
ELOX,Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinical Benefit of Reduction or Stabilization of Proteinuria,ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH,2023-10-09 15:00:00.000 +0300,ELX-02 treatment improved podocyte foot process effacement in all three patients by an average of 60% based on a blinded kidney biopsy analysis by NIPOKA GmbH,https://www.globenewswire.com/news-release/2023/10/09/2756643/0/en/Eloxx-Pharmaceuticals-Reports-Additional-Confirmation-that-All-Nonsense-Mutation-Alport-Syndrome-Patients-Treated-with-ELX-02-in-Phase-2-Study-had-Improvement-in-Kidney-Morphology-.html,,Health,biotech,2023-10-09 10:00:00.000 +0300,pre_market,7,4.320000171661377,4.300000190734863,429.5400085449219,427.5799865722656,-0.0046296250305059876,-0.004563071969234895,-0.0000665530612711
OCUP,Abstract on ZETA-1 Study of APX3330 Receives Award at Women in Ophthalmology (WIO) Summer Symposium,ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction,2023-08-28 15:00:00.000 +0300,ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction ZETA-1 abstract rated as one of top three scoring abstracts out of nearly 600 submissions at WIO and received an award distinction,https://www.globenewswire.com/news-release/2023/08/28/2732556/0/en/Abstract-on-ZETA-1-Study-of-APX3330-Receives-Award-at-Women-in-Ophthalmology-WIO-Summer-Symposium.html,,Clinical Study,biotech,2023-08-28 10:00:00.000 +0300,pre_market,7,3.930000066757202,3.950000047683716,439.9700012207031,442.239990234375,0.005089053584423077,0.00515941770432929,-0.0000703641199062
IMNN,IMUNON’s CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention,"Dr. Corinne Le Goff highlights clinical progress across the Company’s pipeline, provides context on the promise of DNA as a therapeutic and a vaccine",2023-06-08 15:30:00.000 +0300,"Dr. Corinne Le Goff highlights clinical progress across the Company’s pipeline, provides context on the promise of DNA as a therapeutic and a vaccine",https://www.globenewswire.com/news-release/2023/06/08/2684743/0/en/IMUNON-s-CEO-Presents-Business-Overview-to-Investors-and-Senior-Biopharmaceutical-Professionals-at-the-BIO-2023-International-Convention.html,,Press releases,biotech,2023-06-08 10:30:00.000 +0300,pre_market,7,1.2699999809265137,1.2699999809265137,426.54998779296875,426.6199951171875,0.0,0.0001641245486396,-0.0001641245486396
ARQT,"Arcutis Biotherapeutics Publishes Annual Environmental, Social, and Governance (ESG) Report","WESTLAKE VILLAGE, Calif., Aug.  31, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of its annual Environmental, Social, and Governance (ESG) report. The second annual report details the Company’s advancement toward improving patient care, access and affordability, social capital management, drug safety, sustainable operations, and ethical business practices.",2023-08-31 15:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., Aug.  31, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT), an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, today announced the publication of its annual Environmental, Social, and Governance (ESG) report. The second annual report details the Company’s advancement toward improving patient care, access and affordability, social capital management, drug safety, sustainable operations, and ethical business practices.",https://www.globenewswire.com/news-release/2023/08/31/2735212/0/en/Arcutis-Biotherapeutics-Publishes-Annual-Environmental-Social-and-Governance-ESG-Report.html,,"Environmental, Social, and Governance Criteria",biotech,2023-08-31 10:00:00.000 +0300,pre_market,7,8.930000305175781,8.9399995803833,451.010009765625,451.6499938964844,0.0011197396266295762,0.0014190020553910847,-0.0002992624287615
ONCT,"Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of Dual-Action AR Inhibitor, ONCT-534, in Patients with Metastatic Castration-Resistant Prostate Cancer","SAN DIEGO, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.",2023-10-05 23:01:00.000 +0300,"SAN DIEGO, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-534, the company’s dual-action androgen receptor inhibitor.",https://www.globenewswire.com/news-release/2023/10/05/2755756/0/en/Oncternal-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Study-of-Dual-Action-AR-Inhibitor-ONCT-534-in-Patients-with-Metastatic-Castration-Resistant-Prostate-Cancer.html,,Clinical Study,biotech,2023-10-05 18:01:00.000 +0300,market_open,15,0.30000001192092896,0.30000001192092896,424.3599853515625,424.5,0.0,0.0003299430984792,-0.0003299430984792
ECOR,electroCore Expands Intellectual Patent Portfolio for nVNS Technology,"ROCKAWAY, N.J., July  18, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent related to non-invasive nerve stimulation with mobile devices.",2023-07-18 15:00:00.000 +0300,"ROCKAWAY, N.J., July  18, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office (USPTO) has issued a patent related to non-invasive nerve stimulation with mobile devices.",https://www.globenewswire.com/news-release/2023/07/18/2706335/0/en/electroCore-Expands-Intellectual-Patent-Portfolio-for-nVNS-Technology.html,,Patents,biotech,2023-07-18 10:00:00.000 +0300,pre_market,7,4.565000057220459,4.559999942779541,450.8399963378906,450.5,-0.0010953153073917905,-0.0007541396962389,-0.0003411756111528
DBVT,"Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023",Monthly information regarding the total number of voting rights and ,2023-07-19 23:30:00.000 +0300,Monthly information regarding the total number of voting rights and ,https://www.globenewswire.com/news-release/2023/07/19/2707774/0/en/Monthly-information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-Company-as-of-June-30-2023.html,,European Regulatory News,biotech,2023-07-19 18:30:00.000 +0300,market_open,15,1.7000000476837158,1.7000000476837158,455.010009765625,455.20001220703125,0.0,0.0004175785967964,-0.0004175785967964
DBVT,Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 30 juin 2023,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Information mensuelle relative au nombre total des droits de vote etd’actions composant le capital social au 30 juin 2023,2023-07-19 23:30:00.000 +0300,                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        Information mensuelle relative au nombre total des droits de vote etd’actions composant le capital social au 30 juin 2023,https://www.globenewswire.com/news-release/2023/07/19/2707774/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-juin-2023.html,,European Regulatory News,biotech,2023-07-19 18:30:00.000 +0300,market_open,15,1.7000000476837158,1.7000000476837158,455.010009765625,455.20001220703125,0.0,0.0004175785967964,-0.0004175785967964
BIOR,Biora Therapeutics Announces New Patents Covering its BioJet™ Systemic Oral Delivery Platform,Intellectual property relates to key features of the company’s liquid jet injection technology Intellectual property relates to key features of the company’s liquid jet injection technology,2023-08-03 15:00:00.000 +0300,Intellectual property relates to key features of the company’s liquid jet injection technology Intellectual property relates to key features of the company’s liquid jet injection technology,https://www.globenewswire.com/news-release/2023/08/03/2717952/0/en/Biora-Therapeutics-Announces-New-Patents-Covering-its-BioJet-Systemic-Oral-Delivery-Platform.html,,Patents,biotech,2023-08-03 10:00:00.000 +0300,pre_market,7,3.8499999046325684,3.8299999237060547,450.1300048828125,448.0400085449219,-0.005194800369332063,-0.004643094917511081,-0.000551705451821
ANAB,AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP),"SAN DIEGO, May  02, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) IgG4 antibody for the treatment of generalized pustular psoriasis (GPP), in the British Journal of Dermatology. Patients with GPP who received a single dose of imsidolimab demonstrated a rapid and sustained improvement of symptoms and pustular eruptions of GPP flare within days after initiating treatment.",2023-05-02 16:15:00.000 +0300,"SAN DIEGO, May  02, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the publication of data from the open-label, single-arm Phase 2 GALLOP study evaluating the efficacy, tolerability and safety of imsidolimab, its investigational anti-interleukin-36 receptor (IL-36R) IgG4 antibody for the treatment of generalized pustular psoriasis (GPP), in the British Journal of Dermatology. Patients with GPP who received a single dose of imsidolimab demonstrated a rapid and sustained improvement of symptoms and pustular eruptions of GPP flare within days after initiating treatment.",https://www.globenewswire.com/news-release/2023/05/02/2659323/0/en/AnaptysBio-Announces-British-Journal-of-Dermatology-Publication-of-Imsidolimab-IL-36R-Previously-Reported-Phase-2-GALLOP-Data-in-Generalized-Pustular-Psoriasis-GPP.html,,Clinical Study,biotech,2023-05-02 11:15:00.000 +0300,pre_market,8,21.170000076293945,21.1200008392334,415.510009765625,414.7699890136719,-0.002361796735019182,-0.0017809938017390855,-0.0005808029332801
EYEN,"Eyenovia to Report First Quarter 2023 Results on Thursday, May 11",Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT,2023-05-04 15:00:00.000 +0300,Company to host an investor conference call and webcast at 4:30pm EDT Company to host an investor conference call and webcast at 4:30pm EDT,https://www.globenewswire.com/news-release/2023/05/04/2661428/0/en/Eyenovia-to-Report-First-Quarter-2023-Results-on-Thursday-May-11.html,,Conference Calls/ Webcasts,biotech,2023-05-04 10:00:00.000 +0300,pre_market,7,5.75,5.730000019073486,408.0199890136719,406.92999267578125,-0.0034782575524371605,-0.002671428771236258,-0.0008068287812009
QGEN,"QIAGEN reports progress toward achieving Environmental, Social and Governance goals in 2022 Sustainability Report","Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with ISS-ESG rating // Environment: Net-zero target validated by Science Based Targets initiative (SBTi), achieved 20% decrease in Scope 1 and 2 emissions, reduced plastic usage by 16.5% in 2022 // Social: Increasing workforce diversity with 35% women in leadership, delivered 16 million QuantiFERON-TB tuberculosis tests globally in 2022 // Governance: Enforcement of ethical supplier policy, secures 95% supplier compliance Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with ISS-ESG rating // Environment: Net-zero target validated by Science Based Targets initiative (SBTi), achieved 20% decrease in Scope 1 and 2 emissions, reduced plastic usage by 16.5% in 2022 // Social: Increasing workforce diversity with 35% women in leadership, delivered 16 million QuantiFERON-TB tuberculosis tests globally in 2022 // Governance: Enforcement of ethical supplier policy, secures 95% supplier compliance",2023-09-27 23:05:00.000 +0300,"Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with ISS-ESG rating // Environment: Net-zero target validated by Science Based Targets initiative (SBTi), achieved 20% decrease in Scope 1 and 2 emissions, reduced plastic usage by 16.5% in 2022 // Social: Increasing workforce diversity with 35% women in leadership, delivered 16 million QuantiFERON-TB tuberculosis tests globally in 2022 // Governance: Enforcement of ethical supplier policy, secures 95% supplier compliance Progress on Environment, Social and Governance (ESG) goals reflected in QIAGEN securing a „Prime“ rating and among the industry leaders with ISS-ESG rating // Environment: Net-zero target validated by Science Based Targets initiative (SBTi), achieved 20% decrease in Scope 1 and 2 emissions, reduced plastic usage by 16.5% in 2022 // Social: Increasing workforce diversity with 35% women in leadership, delivered 16 million QuantiFERON-TB tuberculosis tests globally in 2022 // Governance: Enforcement of ethical supplier policy, secures 95% supplier compliance",https://www.globenewswire.com/news-release/2023/09/27/2750741/8690/en/QIAGEN-reports-progress-toward-achieving-Environmental-Social-and-Governance-goals-in-2022-Sustainability-Report.html,,Company Announcement,biotech,2023-09-27 18:05:00.000 +0300,market_open,15,39.599998474121094,39.470001220703125,427.0899963378906,426.04998779296875,-0.0032827590511884225,-0.0024351039683427195,-0.0008476550828457
QGEN,QIAGEN meldet in Nachhaltigkeitsbericht 2022 Fortschritte bei ESG-Zielen,"Fortschritte bei Umwelt-, Sozial- und Governance-Zielen (ESG) spiegeln sich im „Prime“-Rating von ISS-ESG wider, das QIAGEN als einen Branchenführer einstuft // Umwelt: Netto-Null-Ziel von der Science Based Targets Initiative (SBTi) validiert; Scope-1- und Scope-2-Emissionen 2022 um 20% und Plastikverbrauch um 16,5% reduziert // Soziales: Anteil von Frauen in Führungspositionen nun bei 35%; weltweit 16 Mio. QuantiFERON-Tuberkulosetests im Jahr 2022 bereitgestellt // Governance: ethische Lieferantenrichtlinie durchgesetzt, bisher von 95% der Lieferanten unterzeichnet",2023-09-27 23:05:00.000 +0300,"Fortschritte bei Umwelt-, Sozial- und Governance-Zielen (ESG) spiegeln sich im „Prime“-Rating von ISS-ESG wider, das QIAGEN als einen Branchenführer einstuft // Umwelt: Netto-Null-Ziel von der Science Based Targets Initiative (SBTi) validiert; Scope-1- und Scope-2-Emissionen 2022 um 20% und Plastikverbrauch um 16,5% reduziert // Soziales: Anteil von Frauen in Führungspositionen nun bei 35%; weltweit 16 Mio. QuantiFERON-Tuberkulosetests im Jahr 2022 bereitgestellt // Governance: ethische Lieferantenrichtlinie durchgesetzt, bisher von 95% der Lieferanten unterzeichnet",https://www.globenewswire.com/news-release/2023/09/27/2750740/0/de/QIAGEN-meldet-in-Nachhaltigkeitsbericht-2022-Fortschritte-bei-ESG-Zielen.html,,"Environmental, Social, and Governance Criteria",biotech,2023-09-27 18:05:00.000 +0300,market_open,15,39.599998474121094,39.470001220703125,427.0899963378906,426.04998779296875,-0.0032827590511884225,-0.0024351039683427195,-0.0008476550828457
ANAB,AnaptysBio to Participate in Upcoming November Investor Conferences,"SAN DIEGO, Nov.  09, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.",2022-11-09 21:10:00.000 +0200,"SAN DIEGO, Nov.  09, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Guggenheim 4th Annual Immunology and Neurology Conference on Monday November 14th, 2022, at 1:00 p.m. ET / 10:00 a.m. PT; members of its senior management team will also be hosting investor meetings at the Jefferies London Healthcare Conference on November 16th, 2022.",https://www.globenewswire.com/news-release/2022/11/09/2552375/0/en/AnaptysBio-to-Participate-in-Upcoming-November-Investor-Conferences.html,,Calendar of Events,biotech,2022-11-09 16:10:00.000 +0200,market_open,14,29.770000457763672,29.290000915527344,379.92999267578125,374.1300048828125,-0.0161235987522852,-0.015265938211722741,-0.0008576605405625
VIR,Vir Biotechnology to Host a Virtual-Only 2023 Annual Meeting of Stockholders,"SAN FRANCISCO, May  17, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.",2023-05-17 23:05:00.000 +0300,"SAN FRANCISCO, May  17, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today reminds stockholders that it will hold its 2023 Annual General Meeting of Stockholders on Friday, May 19, 2023, at 11:30 a.m. PT. The Annual Meeting will be held in virtual format only via live audio webcast.",https://www.globenewswire.com/news-release/2023/05/17/2671486/0/en/Vir-Biotechnology-to-Host-a-Virtual-Only-2023-Annual-Meeting-of-Stockholders.html,,Conference Calls/ Webcasts,biotech,2023-05-17 18:05:00.000 +0300,market_open,15,24.8700008392334,25.010000228881836,412.3500061035156,415.2300109863281,0.005629247483883595,0.006984369686390907,-0.0013551222025073115
SPRY,ARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray),"SAN DIEGO, Oct.  06, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the United States (U.S.) Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.",2023-10-06 16:03:00.000 +0300,"SAN DIEGO, Oct.  06, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect patients from severe allergic reactions that could lead to anaphylaxis, today announced that the United States (U.S.) Food and Drug Administration (FDA) has scheduled a Type A meeting to discuss the contents of a Complete Response Letter (CRL) previously issued regarding its new drug application (NDA) for neffy® (epinephrine nasal spray) for the treatment of allergic reactions (Type I), including anaphylaxis.",https://www.globenewswire.com/news-release/2023/10/06/2756120/0/en/ARS-Pharmaceuticals-Announces-Scheduling-of-a-Type-A-Meeting-with-the-U-S-FDA-for-neffy-epinephrine-nasal-spray.html,,Clinical Study,biotech,2023-10-06 11:03:00.000 +0300,pre_market,8,3.990000009536743,3.9600000381469727,424.5,421.9700012207031,-0.007518789804026501,-0.005959950010122203,-0.0015588397939042984
ONCT,"Oncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate Cancer","SAN DIEGO, Aug.  03, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), for a Phase 1/2 dose escalation study of ONCT-534, a novel dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor signaling inhibitors (ARSIs). The letter was received prior to the 30-day review date.",2023-08-03 23:05:00.000 +0300,"SAN DIEGO, Aug.  03, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the receipt of a Study May Proceed letter from the U.S. Food and Drug Administration (FDA), for a Phase 1/2 dose escalation study of ONCT-534, a novel dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer (mCRPC) who have relapsed or are refractory to approved androgen receptor signaling inhibitors (ARSIs). The letter was received prior to the 30-day review date.",https://www.globenewswire.com/news-release/2023/08/03/2718561/0/en/Oncternal-Therapeutics-Receives-FDA-Study-May-Proceed-Letter-for-ONCT-534-its-Novel-Dual-action-Androgen-Receptor-Inhibitor-for-the-Treatment-of-Patients-with-Advanced-Prostate-Can.html,,Regulatory information,biotech,2023-08-03 18:05:00.000 +0300,market_open,15,0.3799999952316284,0.3799999952316284,448.0400085449219,448.8399963378906,0.0,0.0017855275817149278,-0.0017855275817149278
ONCT,Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results,"SAN DIEGO, Aug.  03, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2023 financial results after the U.S. financial markets close on Thursday, August 10, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s second quarter financial results.",2023-08-03 23:30:00.000 +0300,"SAN DIEGO, Aug.  03, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report second quarter 2023 financial results after the U.S. financial markets close on Thursday, August 10, 2023. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a business update and discuss the Company’s second quarter financial results.",https://www.globenewswire.com/news-release/2023/08/03/2718622/0/en/Oncternal-Therapeutics-to-Provide-Business-Update-and-Report-Second-Quarter-2023-Financial-Results.html,,Conference Calls/ Webcasts,biotech,2023-08-03 18:30:00.000 +0300,market_open,15,0.3799999952316284,0.3799999952316284,448.0400085449219,448.8399963378906,0.0,0.0017855275817149278,-0.0017855275817149278
DBVT,"Monthly information regarding the total number of voting rights and  total number of shares of the Company as of May 31, 2023", ,2023-06-16 23:30:00.000 +0300, ,https://www.globenewswire.com/news-release/2023/06/16/2689932/0/en/Monthly-information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-Company-as-of-May-31-2023.html,,European Regulatory News,biotech,2023-06-16 18:30:00.000 +0300,market_open,15,1.9900000095367432,1.9700000286102295,443.0199890136719,439.4599914550781,-0.010050241623450803,-0.008035749281922099,-0.0020144923415287043
DBVT,Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 31 mai 2023,Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 mai 2023,2023-06-16 23:30:00.000 +0300,Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 mai 2023,https://www.globenewswire.com/news-release/2023/06/16/2689932/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-31-mai-2023.html,,European Regulatory News,biotech,2023-06-16 18:30:00.000 +0300,market_open,15,1.9900000095367432,1.9700000286102295,443.0199890136719,439.4599914550781,-0.010050241623450803,-0.008035749281922099,-0.0020144923415287043
SCLX,Scilex Holding Company Provides Notice to All Record Holders and Beneficial Owners of Restricted Shares of Scilex Holding Company,"PALO ALTO, Calif., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.",2023-10-03 16:00:00.000 +0300,"PALO ALTO, Calif., Oct.  03, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, provides notice to all record holders and beneficial owners of restricted shares of Scilex common stock that were part of the previously announced dividend of Scilex common stock then-held by Sorrento Therapeutics, Inc. (OTC: SRNEQ, “Sorrento”) to Sorrento equity holders of record as of January 9, 2023.",https://www.globenewswire.com/news-release/2023/10/03/2753697/0/en/Scilex-Holding-Company-Provides-Notice-to-All-Record-Holders-and-Beneficial-Owners-of-Restricted-Shares-of-Scilex-Holding-Company.html,,Changes in share capital and votes,biotech,2023-10-03 11:00:00.000 +0300,pre_market,8,1.3300000429153442,1.3200000524520874,427.30999755859375,425.05999755859375,-0.007518789579387513,-0.0052654981462058464,-0.002253291433181667
VIR,Vir Biotechnology Appoints Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer,"SAN FRANCISCO, June  29, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company’s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir’s corporate social responsibility and environmental, social and governance efforts. She will report to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company’s Executive Management Team.",2023-06-29 16:00:00.000 +0300,"SAN FRANCISCO, June  29, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Sasha Damouni Ellis as Executive Vice President and Chief Corporate Affairs Officer, effective July 10, 2023. Ms. Damouni Ellis will be responsible for the Company’s strategic approach to corporate communications, government affairs, investor relations and patient advocacy, as well as for establishing Vir’s corporate social responsibility and environmental, social and governance efforts. She will report to Vir’s Chief Executive Officer Marianne De Backer, M.Sc., Ph.D., MBA, and will join the Company’s Executive Management Team.",https://www.globenewswire.com/news-release/2023/06/29/2697070/0/en/Vir-Biotechnology-Appoints-Sasha-Damouni-Ellis-as-Executive-Vice-President-and-Chief-Corporate-Affairs-Officer.html,,Management Changes,biotech,2023-06-29 11:00:00.000 +0300,pre_market,8,24.8799991607666,24.790000915527344,436.3900146484375,435.9599914550781,-0.003617292937098507,-0.0009854102498331,-0.0026318826872654346
ONCT,"Oncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphoma","SAN DIEGO, June  06, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-808, the company’s ROR1 targeting autologous CAR T cell therapy.",2023-06-06 23:01:00.000 +0300,"SAN DIEGO, June  06, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that the first patient has been dosed in the Phase 1/2 dose escalation/dose expansion study of ONCT-808, the company’s ROR1 targeting autologous CAR T cell therapy.",https://www.globenewswire.com/news-release/2023/06/06/2683302/0/en/Oncternal-Therapeutics-Announces-First-Patient-Dosed-in-Phase-1-2-Study-of-ROR1-targeting-autologous-CAR-T-ONCT-808-in-patients-with-relapsed-or-refractory-aggressive-B-cell-lympho.html,,Product / Services Announcement,biotech,2023-06-06 18:01:00.000 +0300,market_open,15,0.30000001192092896,0.30000001192092896,426.6700134277344,428.0299987792969,0.0,0.00318744066553166,-0.00318744066553166
IMNN,"IMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023","LAWRENCEVILLE, N.J., Aug.  03, 2023  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, August 10, 2023 to discuss financial results for the second quarter and six-months ended June 30, 2023 and provide an update on its clinical development of IMNN-001 (formerly GEN-1), a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic non-viral and synthetic DNA technology for the expression of pathogen antigens, being evaluated in preclinical studies for the development of next-generation vaccines.",2023-08-03 15:30:00.000 +0300,"LAWRENCEVILLE, N.J., Aug.  03, 2023  (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m. ET on Thursday, August 10, 2023 to discuss financial results for the second quarter and six-months ended June 30, 2023 and provide an update on its clinical development of IMNN-001 (formerly GEN-1), a DNA-based interleukin-12 (IL-12) immunotherapy in Phase 2 clinical development for the treatment of advanced-stage ovarian cancer, and on its PlaCCine modality, a proprietary mono- or multi-cistronic non-viral and synthetic DNA technology for the expression of pathogen antigens, being evaluated in preclinical studies for the development of next-generation vaccines.",https://www.globenewswire.com/news-release/2023/08/03/2718025/0/en/IMUNON-to-Hold-Second-Quarter-2023-Financial-Results-and-Business-Update-Conference-Call-on-Thursday-August-10-2023.html,,Press releases,biotech,2023-08-03 10:30:00.000 +0300,pre_market,7,1.2699999809265137,1.2599999904632568,450.1300048828125,448.0400085449219,-0.00787400835704065,-0.004643094917511081,-0.003230913439529569
ICCC,ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders,"PORTLAND, Maine, May  16, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2023 Annual Meeting of Stockholders will be conducted virtually.",2023-05-16 16:00:00.000 +0300,"PORTLAND, Maine, May  16, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2023 Annual Meeting of Stockholders will be conducted virtually.",https://www.globenewswire.com/news-release/2023/05/16/2669999/0/en/ImmuCell-to-Hold-Virtual-Only-Annual-Meeting-of-Stockholders.html,,Conference Calls/ Webcasts,biotech,2023-05-16 11:00:00.000 +0300,pre_market,8,4.96999979019165,4.940000057220459,413.010009765625,411.8599853515625,-0.006036163830508849,-0.002784495258880326,-0.003251668571628523
QGEN,QIAGEN extends AI capabilities of its NGS interpretation software QCI Interpret to enable clinical exome completeness,"AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence for diagnostic labs AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence for diagnostic labs",2023-09-28 23:05:00.000 +0300,"AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence for diagnostic labs AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage of the clinical exome // Enhanced AI-trained phenotype driven ranking of pathogenic variants improves accuracy and efficiency of prioritizing candidate variants // New features reduce time needed for prioritization, assessment and interpretation of clinically relevant variants and facilitate access to trusted evidence for diagnostic labs",https://www.globenewswire.com/news-release/2023/09/28/2751629/8690/en/QIAGEN-extends-AI-capabilities-of-its-NGS-interpretation-software-QCI-Interpret-to-enable-clinical-exome-completeness.html,,Company Announcement,biotech,2023-09-28 18:05:00.000 +0300,market_open,15,39.540000915527344,39.689998626708984,425.4800109863281,428.5199890136719,0.0037935687331442773,0.007144819847815208,-0.0033512511146709307
QGEN,QIAGEN erweitert KI-Funktionen seiner NGS‑Interpretationssoftware QCI Interpret zur vollständigen Abdeckung des klinischen Exoms,"QIAGENs proprietäre, human-zertifizierte Inhalte durch KI-gesteuerte Literaturextraktion für tausende Gene seltener Krankheiten erweitert; vollständige bibliografische Abdeckung des klinischen Exoms gewährleistet // Genauigkeit und Effizienz bei der Priorisierung von Kandidaten-Varianten durch verbessertes KI-trainiertes phänotypgesteuertes Ranking von pathogenen Varianten erhöht // Zeitaufwand für die Priorisierung, Bewertung und Auswertung klinisch relevanter Varianten verringert und Zugang zu verlässlicher Evidenz für diagnostische Labore erleichtert",2023-09-28 23:05:00.000 +0300,"QIAGENs proprietäre, human-zertifizierte Inhalte durch KI-gesteuerte Literaturextraktion für tausende Gene seltener Krankheiten erweitert; vollständige bibliografische Abdeckung des klinischen Exoms gewährleistet // Genauigkeit und Effizienz bei der Priorisierung von Kandidaten-Varianten durch verbessertes KI-trainiertes phänotypgesteuertes Ranking von pathogenen Varianten erhöht // Zeitaufwand für die Priorisierung, Bewertung und Auswertung klinisch relevanter Varianten verringert und Zugang zu verlässlicher Evidenz für diagnostische Labore erleichtert",https://www.globenewswire.com/news-release/2023/09/28/2751627/0/de/QIAGEN-erweitert-KI-Funktionen-seiner-NGS-Interpretationssoftware-QCI-Interpret-zur-vollst%C3%A4ndigen-Abdeckung-des-klinischen-Exoms.html,,Product / Services Announcement,biotech,2023-09-28 18:05:00.000 +0300,market_open,15,39.540000915527344,39.689998626708984,425.4800109863281,428.5199890136719,0.0037935687331442773,0.007144819847815208,-0.0033512511146709307
IMCR,Immunocore to present four posters at AACR Annual Meeting 2023,Immunocore to present four posters at AACR Annual Meeting 2023,2023-03-14 22:30:00.000 +0200,Immunocore to present four posters at AACR Annual Meeting 2023,https://www.globenewswire.com/news-release/2023/03/14/2627205/0/en/Immunocore-to-present-four-posters-at-AACR-Annual-Meeting-2023.html,,Press releases,biotech,2023-03-14 17:30:00.000 +0200,market_open,15,52.81999969482422,52.79999923706055,390.5,391.7300109863281,-0.0003786531215302,0.0031498360725432137,-0.0035284891940734605
TALS,Talaris Therapeutics Presents Data on Mechanisms of FCR001 Activity to Induce Immune Tolerance,"BOSTON and LOUISVILLE, Ky., Nov.  07, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting.",2022-11-07 14:00:00.000 +0200,"BOSTON and LOUISVILLE, Ky., Nov.  07, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented new data characterizing the mechanisms of FCR001-induced immune tolerance in two oral presentations at the 2022 American Society of Nephrology (ASN) Annual Meeting.",https://www.globenewswire.com/news-release/2022/11/07/2549491/0/en/Talaris-Therapeutics-Presents-Data-on-Mechanisms-of-FCR001-Activity-to-Induce-Immune-Tolerance.html,,Health,biotech,2022-11-07 09:00:00.000 +0200,pre_market,7,1.649999976158142,1.649999976158142,376.3500061035156,377.7099914550781,0.0,0.003613618518683999,-0.003613618518683999
VIR,Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results,– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 –,2023-08-03 23:05:00.000 +0300,– Phase 2 data readouts from ongoing chronic hepatitis B and chronic hepatitis delta programs on track for Q4 2023 –,https://www.globenewswire.com/news-release/2023/08/03/2718588/0/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Second-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-08-03 18:05:00.000 +0300,market_open,15,14.0,13.970000267028809,448.0400085449219,448.8399963378906,-0.002142838069370815,0.0017855275817149278,-0.003928365651085742
SCPH,scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"BURLINGTON, Mass., Oct.  05, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on October 2, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 52,500 shares of its common stock to 14 new employees comprised of sales representatives.",2023-10-05 15:00:00.000 +0300,"BURLINGTON, Mass., Oct.  05, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on October 2, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 52,500 shares of its common stock to 14 new employees comprised of sales representatives.",https://www.globenewswire.com/news-release/2023/10/05/2755310/0/en/scPharmaceuticals-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Health,biotech,2023-10-05 10:00:00.000 +0300,pre_market,7,6.329999923706055,6.300000190734863,424.6600036621094,424.3599853515625,-0.0047392943653666465,-0.0007064906229916,-0.004032803742375008
VIR,Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention,"– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector –",2023-05-02 16:00:00.000 +0300,"– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV T cell vaccine based on a novel vector –",https://www.globenewswire.com/news-release/2023/05/02/2659283/0/en/Vir-Biotechnology-Receives-Expanded-Support-to-Develop-Its-Novel-T-Cell-Vaccine-Platform-with-New-10-Million-Grant-for-HIV-Prevention.html,,Health,biotech,2023-05-02 11:00:00.000 +0300,pre_market,8,25.15999984741211,25.010000228881836,415.510009765625,414.7699890136719,-0.005961829071541191,-0.0017809938017390855,-0.004180835269802105
ORIC,ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),"SOUTH SAN FRANCISCO and SAN DIEGO, June  02, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2023 (the “Grant Date”), ORIC granted a total of 3,380 non-qualified stock options and 560 restricted stock units to one new non-executive employee who began their employment with ORIC in May 2023.",2023-06-02 23:15:00.000 +0300,"SOUTH SAN FRANCISCO and SAN DIEGO, June  02, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on June 1, 2023 (the “Grant Date”), ORIC granted a total of 3,380 non-qualified stock options and 560 restricted stock units to one new non-executive employee who began their employment with ORIC in May 2023.",https://www.globenewswire.com/news-release/2023/06/02/2681448/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,,Product / Services Announcement,biotech,2023-06-02 18:15:00.000 +0300,market_open,15,5.300000190734863,5.320000171661377,424.5,427.9200134277344,0.003773581171086827,0.008056568734356596,-0.00428298756326977
ARQT,Arcutis and Huadong Announce Strategic Collaboration and Licensing Agreement for  Topical Roflumilast in Greater China and Southeast Asia,"WESTLAKE VILLAGE, Calif. and HANGZHOU, China, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam). Huadong will receive an exclusive license for both the cream and foam formulations of topical roflumilast, a next generation phosphodiesterase type 4 (PDE4) inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, and potentially additional dermatological conditions in the future.",2023-08-10 15:16:00.000 +0300,"WESTLAKE VILLAGE, Calif. and HANGZHOU, China, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, and Hangzhou Zhongmei Huadong Pharmaceutical Co, a wholly owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), today announced that the companies have entered into a strategic collaboration and licensing agreement for the development, manufacture, and commercialization of topical roflumilast in Greater China (mainland China, Hong Kong, Macau, and Taiwan) and Southeast Asia (Indonesia, Singapore, The Philippines, Thailand, Myanmar, Brunei, Cambodia, Laos, Malaysia, and Vietnam). Huadong will receive an exclusive license for both the cream and foam formulations of topical roflumilast, a next generation phosphodiesterase type 4 (PDE4) inhibitor, for multiple dermatological conditions including plaque psoriasis, seborrheic dermatitis, and atopic dermatitis, and potentially additional dermatological conditions in the future.",https://www.globenewswire.com/news-release/2023/08/10/2722655/0/en/Arcutis-and-Huadong-Announce-Strategic-Collaboration-and-Licensing-Agreement-for-Topical-Roflumilast-in-Greater-China-and-Southeast-Asia.html,,Licensing Agreements,biotech,2023-08-10 10:16:00.000 +0300,pre_market,7,9.390000343322754,9.399999618530273,445.75,448.19000244140625,0.001064885499672003,0.005473925836020752,-0.004409040336348749
PYPD,PolyPid to Present at the Barclays Global Healthcare Conference,"PETACH TIKVA, Israel, March  07, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023.",2023-03-07 15:00:00.000 +0200,"PETACH TIKVA, Israel, March  07, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will present at the Barclays Global Healthcare Conference, which is being held in Miami, Florida, on March 14-16, 2023.",https://www.globenewswire.com/news-release/2023/03/07/2622027/0/en/PolyPid-to-Present-at-the-Barclays-Global-Healthcare-Conference.html,,Calendar of Events,biotech,2023-03-07 10:00:00.000 +0200,pre_market,8,19.649999618530273,19.559999465942383,404.4700012207031,404.4200134277344,-0.004580160525958433,-0.0001235883818772,-0.004456572144081198
BIOR,Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update,"SAN DIEGO, May  08, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial markets. The company’s management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate update.",2023-05-08 16:00:00.000 +0300,"SAN DIEGO, May  08, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will report first quarter ended March 31, 2023 financial results on Monday, May 15, 2023 after the close of financial markets. The company’s management will host a webcast and conference call at 4:30 PM Eastern time / 1:30 PM Pacific time that day to discuss the financial results and provide a corporate update.",https://www.globenewswire.com/news-release/2023/05/08/2663346/0/en/Biora-Therapeutics-to-Report-First-Quarter-2023-Financial-Results-and-Provide-Corporate-Update.html,,Conference Calls/ Webcasts,biotech,2023-05-08 11:00:00.000 +0300,pre_market,8,2.569999933242798,2.559999942779541,412.6300048828125,412.9700012207031,-0.003891046973934726,0.0008239738600376,-0.004715020833972326
RAD.AX,Dr Ken Herrmann Appointed to RAD Scientific Advisory Board,"SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Ken Herrmann to the Company’s Scientific Advisory Board (SAB).",2023-03-03 14:30:00.000 +0200,"SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce the appointment of Dr Ken Herrmann to the Company’s Scientific Advisory Board (SAB).",https://www.globenewswire.com/news-release/2023/03/03/2620158/0/en/Dr-Ken-Herrmann-Appointed-to-RAD-Scientific-Advisory-Board.html,,Directors and Officers,biotech,2023-03-03 09:30:00.000 +0200,pre_market,7,0.12999999523162842,0.12999999523162842,397.80999755859375,399.7099914550781,0.0,0.0047761341045847484,-0.0047761341045847484
RAD.AX,Radiopharm Theranostics Partners With Next Generation Preclinical Platform for Therapeutic Radiopharmaceuticals,"SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15), a private US-based venture which is developing next-generation therapeutic radiopharmaceuticals for Prostate Cancer. Pharma15 was founded by leading radiopharmaceutical scientist Professor David Ulmert and CEO Suzanne Dance.",2023-03-03 15:41:00.000 +0200,"SYDNEY, Australia, March  03, 2023  (GLOBE NEWSWIRE) -- Radiopharm Theranostics (ASX:RAD, “Radiopharm” or the “Company”), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to announce that through its wholly owned subsidiary, Radiopharm Theranostics (USA) Inc., it has entered into a binding agreement to acquire Pharma15 Corporation (Pharma15), a private US-based venture which is developing next-generation therapeutic radiopharmaceuticals for Prostate Cancer. Pharma15 was founded by leading radiopharmaceutical scientist Professor David Ulmert and CEO Suzanne Dance.",https://www.globenewswire.com/news-release/2023/03/03/2620252/0/en/Radiopharm-Theranostics-Partners-With-Next-Generation-Preclinical-Platform-for-Therapeutic-Radiopharmaceuticals.html,,Mergers and Acquisitions,biotech,2023-03-03 10:41:00.000 +0200,pre_market,8,0.12999999523162842,0.12999999523162842,397.80999755859375,399.7099914550781,0.0,0.0047761341045847484,-0.0047761341045847484
SCPH,"scPharmaceuticals to Announce Second Quarter 2023 Financial Results on Thursday, August 10, 2023",Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET,2023-08-03 15:00:00.000 +0300,Management to host conference call and webcast at 4:30 p.m. ET Management to host conference call and webcast at 4:30 p.m. ET,https://www.globenewswire.com/news-release/2023/08/03/2717942/0/en/scPharmaceuticals-to-Announce-Second-Quarter-2023-Financial-Results-on-Thursday-August-10-2023.html,,Conference Calls/ Webcasts,biotech,2023-08-03 10:00:00.000 +0300,pre_market,7,8.199999809265137,8.119999885559082,450.1300048828125,448.0400085449219,-0.009756088483765963,-0.004643094917511081,-0.005112993566254881
ORPHA.CO,Resolutions passed at the Annual General Meeting,Company announcement                                                                                        Orphazyme A/SNo. 8/2023 Ole Maaløes Vej 3DK-2200 Copenhagen N                                                                                                                                                 ,2023-05-17 16:29:00.000 +0300,Company announcement                                                                                        Orphazyme A/SNo. 8/2023 Ole Maaløes Vej 3DK-2200 Copenhagen N                                                                                                                                                 ,https://www.globenewswire.com/news-release/2023/05/17/2671121/0/en/Resolutions-passed-at-the-Annual-General-Meeting.html,,European Regulatory News,biotech,2023-05-17 11:29:00.000 +0300,pre_market,8,1.121999979019165,1.121999979019165,410.25,412.3500061035156,0.0,0.005118844859270262,-0.005118844859270262
ONCT,"Oncternal Therapeutics Announces Strategic Reprioritization and Capital Preservation, Extends Cash Runway into 2025","SAN DIEGO, April  03, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced a strategic reprioritization based on the rapidly changing commercial landscape for Bruton’s tyrosine kinase inhibitors (BTK inhibitors). The Phase 3 study and the Phase 1/2 study of zilovertamab in combination with ibrutinib will be closed, and other project and indirect expenses will be reduced, resulting in extending the expected cash runway into 2025. The projected cash runway will support the clinical advancement of our two pipeline assets ONCT-808 and ONCT-534.",2023-04-03 23:01:00.000 +0300,"SAN DIEGO, April  03, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced a strategic reprioritization based on the rapidly changing commercial landscape for Bruton’s tyrosine kinase inhibitors (BTK inhibitors). The Phase 3 study and the Phase 1/2 study of zilovertamab in combination with ibrutinib will be closed, and other project and indirect expenses will be reduced, resulting in extending the expected cash runway into 2025. The projected cash runway will support the clinical advancement of our two pipeline assets ONCT-808 and ONCT-534.",https://www.globenewswire.com/news-release/2023/04/03/2640129/0/en/Oncternal-Therapeutics-Announces-Strategic-Reprioritization-and-Capital-Preservation-Extends-Cash-Runway-into-2025.html,,Product / Services Announcement,biotech,2023-04-03 18:01:00.000 +0300,market_open,15,0.7900000214576721,0.7900000214576721,408.8500061035156,410.95001220703125,0.0,0.005136372929352311,-0.005136372929352311
VIR,"Vir Biotechnology Announces First Patient Dosed in New Phase 2 Chronic Hepatitis B Virus Trial Evaluating Combinations of VIR-2218, VIR-3434, PEG-IFNα and an NRTI",– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ,2023-05-11 15:30:00.000 +0300,– STRIVE is the first Phase 2 sub-protocol trial initiated under Vir’s new PREVAIL platform trial investigating the Company’s novel therapies in two chronic hepatitis B virus patient populations – ,https://www.globenewswire.com/news-release/2023/05/11/2666740/0/en/Vir-Biotechnology-Announces-First-Patient-Dosed-in-New-Phase-2-Chronic-Hepatitis-B-Virus-Trial-Evaluating-Combinations-of-VIR-2218-VIR-3434-PEG-IFN%CE%B1-and-an-NRTI.html,,Product / Services Announcement,biotech,2023-05-11 10:30:00.000 +0300,pre_market,7,24.440000534057617,24.260000228881836,412.8500061035156,411.95001220703125,-0.007364987775877799,-0.002179953695480183,-0.005185034080397616
EYEN,Eyenovia to Participate in Panel Discussion at Cantor Global Healthcare Conference,"NEW YORK, Sept.  21, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Michael Rowe, CEO, will be participating in a panel discussion at the Cantor Global Healthcare Conference, which is taking place September 26-28, 2023, in New York.",2023-09-21 15:00:00.000 +0300,"NEW YORK, Sept.  21, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (Nasdaq: EYEN), an ophthalmic technology company commercializing Mydcombi™ for mydriasis, preparing for regulatory approval of AP13007 for relief of pain and inflammation post ocular surgery, and incorporating its advanced Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced that Michael Rowe, CEO, will be participating in a panel discussion at the Cantor Global Healthcare Conference, which is taking place September 26-28, 2023, in New York.",https://www.globenewswire.com/news-release/2023/09/21/2747224/0/en/Eyenovia-to-Participate-in-Panel-Discussion-at-Cantor-Global-Healthcare-Conference.html,,Calendar of Events,biotech,2023-09-21 10:00:00.000 +0300,pre_market,7,1.659999966621399,1.6399999856948853,438.6400146484375,435.70001220703125,-0.01204818152329224,-0.006702540450539178,-0.005345641072753061
ECOR,"electroCore to Announce Second Quarter Financial Results on Wednesday, August 9","ROCKAWAY, N.J., Aug.  01, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday, August 9, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.",2023-08-01 15:00:00.000 +0300,"ROCKAWAY, N.J., Aug.  01, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday, August 9, 2023. Management will host a conference call and webcast at 4:30 PM EDT to discuss the financial results and answer questions.",https://www.globenewswire.com/news-release/2023/08/01/2715804/0/en/electroCore-to-Announce-Second-Quarter-Financial-Results-on-Wednesday-August-9.html,,Conference Calls/ Webcasts,biotech,2023-08-01 10:00:00.000 +0300,pre_market,7,4.5,4.460000038146973,457.7900085449219,456.2699890136719,-0.008888880411783854,-0.0033203423029728356,-0.005568538108811018
EYEN,Eyenovia Announces Poster Presentation at ARVO 2023,"NEW YORK, April  24, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting, which is being held April 23-27 in New Orleans.",2023-04-24 15:00:00.000 +0300,"NEW YORK, April  24, 2023  (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in connection with its own drug-device therapeutic programs for mydriasis, presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced a poster presentation at the Association for Research in Vision and Ophthalmology (ARVO) 2023 annual meeting, which is being held April 23-27 in New Orleans.",https://www.globenewswire.com/news-release/2023/04/24/2652646/0/en/Eyenovia-Announces-Poster-Presentation-at-ARVO-2023.html,,Product / Services Announcement,biotech,2023-04-24 10:00:00.000 +0300,pre_market,7,4.900000095367432,4.869999885559082,412.20001220703125,411.989990234375,-0.0061224916784618985,-0.0005095147172164,-0.005612976961245528
VIR,"Vir Biotechnology Announces First Participant Dosed in New Phase 1 Trial Evaluating VIR-1388, an Investigational T Cell Vaccine for the Prevention of HIV","– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine –",2023-09-20 15:00:00.000 +0300,"– Based on a novel human cytomegalovirus vector platform, VIR-1388 was designed with the goal of creating a novel HIV vaccine –",https://www.globenewswire.com/news-release/2023/09/20/2746429/0/en/Vir-Biotechnology-Announces-First-Participant-Dosed-in-New-Phase-1-Trial-Evaluating-VIR-1388-an-Investigational-T-Cell-Vaccine-for-the-Prevention-of-HIV.html,,Clinical Study,biotech,2023-09-20 10:00:00.000 +0300,pre_market,7,9.850000381469727,9.819999694824219,442.7099914550781,444.010009765625,-0.003045754871435993,0.002936500950145798,-0.005982255821581791
OCUP,Ocuphire Pharma to Present at the Canaccord 43rd Annual Growth Conference and the H.C. Wainwright Ophthalmology Conference in August,"FARMINGTON HILLS, Mich., Aug.  08, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that Ronil Patel, MS, SVP of Operations and Business Development and Charlie Hoffmann, MBA, SVP of Corporate Development, will participate in a Fireside Chat at the Canaccord 43rd Annual Growth Conference being held August 7-10, 2023 in Boston, MA and will present a company overview and participate in a panel at the H.C. Wainwright Ophthalmology Conference being held virtually on August 16, 2023.",2023-08-08 15:00:00.000 +0300,"FARMINGTON HILLS, Mich., Aug.  08, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that Ronil Patel, MS, SVP of Operations and Business Development and Charlie Hoffmann, MBA, SVP of Corporate Development, will participate in a Fireside Chat at the Canaccord 43rd Annual Growth Conference being held August 7-10, 2023 in Boston, MA and will present a company overview and participate in a panel at the H.C. Wainwright Ophthalmology Conference being held virtually on August 16, 2023.",https://www.globenewswire.com/news-release/2023/08/08/2720577/0/en/Ocuphire-Pharma-to-Present-at-the-Canaccord-43rd-Annual-Growth-Conference-and-the-H-C-Wainwright-Ophthalmology-Conference-in-August.html,,Calendar of Events,biotech,2023-08-08 10:00:00.000 +0300,pre_market,7,4.199999809265137,4.150000095367432,450.7099914550781,448.0799865722656,-0.011904694325796505,-0.005835248680247263,-0.006069445645549241
OCUP,Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences,"FARMINGTON HILLS, Mich., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that company management will be participating in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City on September 11-13, 2023. Additionally, Ronil Patel, MS, Ocuphire’s SVP of Operations & Business Development, will be participating in panel presentations at both the Cantor Annual Global Healthcare Conference being held in New York City on September 26-28, 2023 and the Inaugural Jones Trading 2023 Healthcare Summit being held in Miami Beach on October 9-11, 2023.",2023-09-11 16:41:00.000 +0300,"FARMINGTON HILLS, Mich., Sept.  11, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that company management will be participating in one-on-one meetings at the H.C. Wainwright 25th Annual Global Investment Conference being held in New York City on September 11-13, 2023. Additionally, Ronil Patel, MS, Ocuphire’s SVP of Operations & Business Development, will be participating in panel presentations at both the Cantor Annual Global Healthcare Conference being held in New York City on September 26-28, 2023 and the Inaugural Jones Trading 2023 Healthcare Summit being held in Miami Beach on October 9-11, 2023.",https://www.globenewswire.com/news-release/2023/09/11/2740925/0/en/Ocuphire-Pharma-to-Participate-in-Three-Upcoming-Investment-Bank-Conferences.html,,Calendar of Events,biotech,2023-09-11 11:41:00.000 +0300,pre_market,8,4.010000228881836,4.010000228881836,445.5199890136719,448.239990234375,0.0,0.006105228245145371,-0.006105228245145371
VIR,Vir Biotechnology to Participate in the 22nd Annual Needham Virtual Healthcare Conference,"SAN FRANCISCO, April  11, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, at 12:00 p.m. PT / 3:00 p.m. ET.",2023-04-11 23:05:00.000 +0300,"SAN FRANCISCO, April  11, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Phil Pang, M.D., Ph.D., Executive Vice President, Chief Medical Officer and Interim Head of Research, is scheduled to participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, at 12:00 p.m. PT / 3:00 p.m. ET.",https://www.globenewswire.com/news-release/2023/04/11/2644920/0/en/Vir-Biotechnology-to-Participate-in-the-22nd-Annual-Needham-Virtual-Healthcare-Conference.html,,Conference Calls/ Webcasts,biotech,2023-04-11 18:05:00.000 +0300,market_open,15,23.690000534057617,23.510000228881836,410.260009765625,409.7200012207031,-0.007598155386995715,-0.001316259279646518,-0.006281896107349197
SCPH,scPharmaceuticals to Participate in the Cowen 43rd Annual Health Care Conference,"BURLINGTON, Mass., Feb.  23, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, on Wednesday, March 8 at 10:30 am ET in Boston. Mr. Tucker will also be meeting with investors March 6 – 8.",2023-02-23 15:00:00.000 +0200,"BURLINGTON, Mass., Feb.  23, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs, today announced that John Tucker, President & Chief Executive Officer, is scheduled to participate in a fireside chat at the Cowen 43rd Annual Health Care Conference, on Wednesday, March 8 at 10:30 am ET in Boston. Mr. Tucker will also be meeting with investors March 6 – 8.",https://www.globenewswire.com/news-release/2023/02/23/2614259/0/en/scPharmaceuticals-to-Participate-in-the-Cowen-43rd-Annual-Health-Care-Conference.html,,Conference Calls/ Webcasts,biotech,2023-02-23 10:00:00.000 +0200,pre_market,8,8.100000381469727,8.109999656677246,398.5400085449219,401.55999755859375,0.0012344783625436305,0.007577630724448267,-0.006343152361904637
QGEN,"QIAGEN erweitert QIAwave-Portfolio um neue, umweltfreundlichere Nukleinsäure-Extraktionskits","Im Vergleich zu Standardkits von QIAGEN bis zu 62% weniger Kunststoff und bis zu 58% weniger Pappe eingesetzt // Zwei Neuzugänge im wachsenden QIAwave-Portfolio: QIAwave RNeasy Plus Mini Kit und QIAwave DNA/RNA Mini Kit // QIAGEN hat sich zum Ziel gesetzt, Einsatz von Kunststoff zu reduzieren und bis 2050 Netto-Null-Treibhausgasemissionen zu erreichen Im Vergleich zu Standardkits von QIAGEN bis zu 62% weniger Kunststoff und bis zu 58% weniger Pappe eingesetzt // Zwei Neuzugänge im wachsenden QIAwave-Portfolio: QIAwave RNeasy Plus Mini Kit und QIAwave DNA/RNA Mini Kit // QIAGEN hat sich zum Ziel gesetzt, Einsatz von Kunststoff zu reduzieren und bis 2050 Netto-Null-Treibhausgasemissionen zu erreichen",2023-09-25 23:05:00.000 +0300,"Im Vergleich zu Standardkits von QIAGEN bis zu 62% weniger Kunststoff und bis zu 58% weniger Pappe eingesetzt // Zwei Neuzugänge im wachsenden QIAwave-Portfolio: QIAwave RNeasy Plus Mini Kit und QIAwave DNA/RNA Mini Kit // QIAGEN hat sich zum Ziel gesetzt, Einsatz von Kunststoff zu reduzieren und bis 2050 Netto-Null-Treibhausgasemissionen zu erreichen Im Vergleich zu Standardkits von QIAGEN bis zu 62% weniger Kunststoff und bis zu 58% weniger Pappe eingesetzt // Zwei Neuzugänge im wachsenden QIAwave-Portfolio: QIAwave RNeasy Plus Mini Kit und QIAwave DNA/RNA Mini Kit // QIAGEN hat sich zum Ziel gesetzt, Einsatz von Kunststoff zu reduzieren und bis 2050 Netto-Null-Treibhausgasemissionen zu erreichen",https://www.globenewswire.com/news-release/2023/09/25/2748978/0/de/QIAGEN-erweitert-QIAwave-Portfolio-um-neue-umweltfreundlichere-Nukleins%C3%A4ure-Extraktionskits.html,,Product / Services Announcement,biotech,2023-09-25 18:05:00.000 +0300,market_open,15,39.099998474121094,39.130001068115234,429.1700134277344,432.2300109863281,0.0007673297996162,0.007130035796662216,-0.006362705997046027
QGEN,QIAGEN enhances QIAwave portfolio with new eco-friendlier nucleic acid extraction kits,New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit // Goal of reducing plastic usage and hitting net-zero greenhouse gas emissions by 2050 New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit // Goal of reducing plastic usage and hitting net-zero greenhouse gas emissions by 2050,2023-09-25 23:05:00.000 +0300,New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit // Goal of reducing plastic usage and hitting net-zero greenhouse gas emissions by 2050 New kits reduce use of plastics by up to 62% and cardboard by up to 58% compared to QIAGEN standard kits // Two additions to growing QIAwave portfolio: QIAwave RNeasy Plus Mini Kit and QIAwave DNA/RNA Mini Kit // Goal of reducing plastic usage and hitting net-zero greenhouse gas emissions by 2050,https://www.globenewswire.com/news-release/2023/09/25/2748977/8690/en/QIAGEN-enhances-QIAwave-portfolio-with-new-eco-friendlier-nucleic-acid-extraction-kits.html,,Company Announcement,biotech,2023-09-25 18:05:00.000 +0300,market_open,15,39.099998474121094,39.130001068115234,429.1700134277344,432.2300109863281,0.0007673297996162,0.007130035796662216,-0.006362705997046027
IMCR,Immunocore to present at the 41st Annual  J.P. Morgan Healthcare Conference,Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference,2023-01-04 14:00:00.000 +0200,Immunocore to present at the 41st Annual J.P. Morgan Healthcare Conference,https://www.globenewswire.com/news-release/2023/01/04/2582742/0/en/Immunocore-to-present-at-the-41st-Annual-J-P-Morgan-Healthcare-Conference.html,,Conference Calls/ Webcasts,biotech,2023-01-04 09:00:00.000 +0200,pre_market,7,55.41999816894531,55.40999984741211,380.82000732421875,383.17999267578125,-0.000180409993929,0.0061971149261422056,-0.006377524920071179
SCPH,"scPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22",Management to host conference call and webcast at 4:30 p.m. ET,2023-03-15 14:00:00.000 +0200,Management to host conference call and webcast at 4:30 p.m. ET,https://www.globenewswire.com/news-release/2023/03/15/2627575/0/en/scPharmaceuticals-to-Announce-Fourth-Quarter-and-Full-Year-2022-Financial-Results-on-Wednesday-March-22.html,,Earnings Releases and Operating Results,biotech,2023-03-15 09:00:00.000 +0200,pre_market,7,7.039999961853027,6.889999866485596,391.7300109863281,385.8900146484375,-0.021306831843781644,-0.014908217839083174,-0.006398614004698469
SCPH,scPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"BURLINGTON, Mass., July  19, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on July 3, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 26,250 shares of its common stock to seven new employees.",2023-07-19 15:00:00.000 +0300,"BURLINGTON, Mass., July  19, 2023  (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH) (“scPharmaceuticals” or the “Company”), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize therapies, advance patient care, and reduce healthcare costs, today announced that on July 3, 2023, the Compensation Committee of scPharmaceuticals’ board of directors granted inducement equity grants consisting of stock options to purchase an aggregate of 26,250 shares of its common stock to seven new employees.",https://www.globenewswire.com/news-release/2023/07/19/2707252/0/en/scPharmaceuticals-Inc-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Major shareholder announcements,biotech,2023-07-19 10:00:00.000 +0300,pre_market,7,8.609999656677246,8.569999694824219,454.19000244140625,455.010009765625,-0.004645756498028021,0.0018054279482396507,-0.006451184446267672
IMNN,IMUNON Reports 2022 Financial Results and Provides Business Update,Conference Call Begins Today at 11:00 a.m. Eastern Time,2023-03-30 15:00:00.000 +0300,Conference Call Begins Today at 11:00 a.m. Eastern Time,https://www.globenewswire.com/news-release/2023/03/30/2637567/0/en/IMUNON-Reports-2022-Financial-Results-and-Provides-Business-Update.html,,Press releases,biotech,2023-03-30 10:00:00.000 +0300,pre_market,7,1.2999999523162842,1.2999999523162842,401.3500061035156,404.0899963378906,0.0,0.0068269345775674554,-0.0068269345775674554
ANAB,"AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors","SAN DIEGO, April  06, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the company’s Board of Directors.",2023-04-06 23:15:00.000 +0300,"SAN DIEGO, April  06, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced the appointment of Rita Jain, M.D., to the company’s Board of Directors, effective immediately. Additionally, Laura J. Hamill has decided to resign from the company’s Board of Directors.",https://www.globenewswire.com/news-release/2023/04/06/2642996/0/en/AnaptysBio-Announces-Appointment-of-Rita-Jain-M-D-to-Board-of-Directors.html,,Directors and Officers,biotech,2023-04-06 18:15:00.000 +0300,market_open,15,21.43000030517578,21.40999984741211,406.7699890136719,409.19000244140625,-0.000933292462849,0.005949341134045748,-0.006882633596894727
IMCR,Immunocore to present at upcoming investor conferences,Immunocore to present at upcoming investor conferences,2023-06-01 23:30:00.000 +0300,Immunocore to present at upcoming investor conferences,https://www.globenewswire.com/news-release/2023/06/01/2680861/0/en/Immunocore-to-present-at-upcoming-investor-conferences.html,,Press releases,biotech,2023-06-01 18:30:00.000 +0300,market_open,15,54.939998626708984,55.04999923706055,418.0899963378906,421.82000732421875,0.0020021953604142592,0.008921550429332964,-0.006919355068918704
ELOX,Eloxx Pharmaceuticals Key Opinion Leader Event Highlights Significant Unmet Need in Treatment of Alport Syndrome Patients with Nonsense Mutations and Additional Positive Results from Phase 2 Clinical Study Evaluating ELX-02,"Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available",2023-06-28 16:00:00.000 +0300,"Alport syndrome is a rare progressive hereditary glomerular kidney disease caused by variants in COL4A and patients have significant unmet medical needs, with no disease modifying treatments currently available",https://www.globenewswire.com/news-release/2023/06/28/2696256/0/en/Eloxx-Pharmaceuticals-Key-Opinion-Leader-Event-Highlights-Significant-Unmet-Need-in-Treatment-of-Alport-Syndrome-Patients-with-Nonsense-Mutations-and-Additional-Positive-Results-fr.html,,Clinical Study,biotech,2023-06-28 11:00:00.000 +0300,pre_market,8,4.059999942779541,4.019999980926514,436.1700134277344,435.04998779296875,-0.009852207491816546,-0.0025678648240021512,-0.007284342667814395
DYAI,Dyadic to Present at Industry and Investor Events in October,Dyadic to Present at Industry and Investor Events in October,2023-09-29 15:30:00.000 +0300,Dyadic to Present at Industry and Investor Events in October,https://www.globenewswire.com/news-release/2023/09/29/2751979/0/en/Dyadic-to-Present-at-Industry-and-Investor-Events-in-October.html,,Product / Services Announcement,biotech,2023-09-29 10:30:00.000 +0300,pre_market,7,1.8799999952316284,1.8799999952316284,428.5199890136719,431.6700134277344,0.0,0.007350939267297514,-0.007350939267297514
IMCR,"Immunocore to report second quarter 2023 financial results and host call on August 10, 2023","Immunocore to report second quarter 2023 financial results and host call on August 10, 2023",2023-08-03 15:00:00.000 +0300,"Immunocore to report second quarter 2023 financial results and host call on August 10, 2023",https://www.globenewswire.com/news-release/2023/08/03/2717932/0/en/Immunocore-to-report-second-quarter-2023-financial-results-and-host-call-on-August-10-2023.html,,Earnings Releases and Operating Results,biotech,2023-08-03 10:00:00.000 +0300,pre_market,7,65.66999816894531,64.875,450.1300048828125,448.0400085449219,-0.012105956922673697,-0.004643094917511081,-0.007462862005162616
EYEN,Eyenovia Announces Presentation at the OCTANE Ophthalmology Tech Forum 2023,Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device,2023-06-01 15:00:00.000 +0300,Presentation to highlight recent FDA approval of Mydcombi™ for mydriasis which leverages Eyenovia’s novel Optejet dispensing device,https://www.globenewswire.com/news-release/2023/06/01/2680264/0/en/Eyenovia-Announces-Presentation-at-the-OCTANE-Ophthalmology-Tech-Forum-2023.html,,Calendar of Events,biotech,2023-06-01 10:00:00.000 +0300,pre_market,7,2.8399999141693115,2.819999933242798,417.8500061035156,418.0899963378906,-0.007042247017941755,0.0005743454131135,-0.007616592431055249
SPRY,ARS Pharmaceuticals Highlights Progress and Reports Fourth Quarter and Full Year 2022 Financial Results,New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA and EMA; FDA PDUFA Target Action Date Anticipated in Mid-2023,2023-03-23 22:01:00.000 +0200,New Drug Application and Marketing Authorization Application for neffy® Currently Under Review with the FDA and EMA; FDA PDUFA Target Action Date Anticipated in Mid-2023,https://www.globenewswire.com/news-release/2023/03/23/2633627/0/en/ARS-Pharmaceuticals-Highlights-Progress-and-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-03-23 17:01:00.000 +0200,market_open,15,8.010000228881836,7.909999847412109,395.0899963378906,393.1700134277344,-0.012484441774315182,-0.004859609020609658,-0.007624832753705524
OCUP,Ocuphire Provides Corporate Update and Reiterates Previous Guidance on Clinical Programs,"PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval",2023-04-25 15:00:00.000 +0300,"PDUFA Date of September 28, 2023 Set for Nyxol® in its First Indication, Reversal of Pharmacologically-induced Mydriasis (RM); $10 Million Milestone Linked to Approval",https://www.globenewswire.com/news-release/2023/04/25/2653839/0/en/Ocuphire-Provides-Corporate-Update-and-Reiterates-Previous-Guidance-on-Clinical-Programs.html,,Health,biotech,2023-04-25 10:00:00.000 +0300,pre_market,7,5.349999904632568,5.28000020980835,412.6300048828125,410.5799865722656,-0.013084055340562898,-0.004968175572033553,-0.008115879768529344
JSPR,Jasper Therapeutics Announces Research Collaboration with AVROBIO to Evaluate JSP191 as Conditioning Agent in Clinical Studies of Ex Vivo Lentiviral Gene Therapy,"REDWOOD CITY, Calif. and CAMBRIDGE, Mass. , Nov.  09, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1 who are being treated with one of AVROBIO’s investigational ex vivo lentiviral gene therapies.",2021-11-09 15:00:00.000 +0200,"REDWOOD CITY, Calif. and CAMBRIDGE, Mass. , Nov.  09, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR), a biotechnology company focused on hematopoietic stem cell therapeutics, today announced that it has entered into a non-exclusive research collaboration with AVROBIO, Inc. to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted conditioning agent option for patients with Fabry disease and/or Gaucher disease type 1 who are being treated with one of AVROBIO’s investigational ex vivo lentiviral gene therapies.",https://www.globenewswire.com/news-release/2021/11/09/2330363/0/en/Jasper-Therapeutics-Announces-Research-Collaboration-with-AVROBIO-to-Evaluate-JSP191-as-Conditioning-Agent-in-Clinical-Studies-of-Ex-Vivo-Lentiviral-Gene-Therapy.html,,Product / Services Announcement,biotech,2021-11-09 10:00:00.000 +0200,pre_market,8,9.220000267028809,9.149999618530273,468.92999267578125,469.32000732421875,-0.007592261005551274,0.0008317118856314,-0.00842397289118269
ORIC,ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4),"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct.  06, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 2, 2023 (the “Grant Date”), ORIC granted a total of 72,120 non-qualified stock options and 12,040 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2023.",2023-10-06 23:30:00.000 +0300,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct.  06, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on October 2, 2023 (the “Grant Date”), ORIC granted a total of 72,120 non-qualified stock options and 12,040 restricted stock units to four new non-executive employees who began their employment with ORIC in September 2023.",https://www.globenewswire.com/news-release/2023/10/06/2756315/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,,Changes in company's own shares,biotech,2023-10-06 18:30:00.000 +0300,market_open,15,6.389999866485596,6.449999809265137,421.9700012207031,429.5400085449219,0.009389662603004103,0.017939681262458766,-0.008550018659454662
SCPH,scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update,Generated net FUROSCIX® revenue of $1.6 million,2023-08-10 23:01:00.000 +0300,Generated net FUROSCIX® revenue of $1.6 million,https://www.globenewswire.com/news-release/2023/08/10/2723110/0/en/scPharmaceuticals-Inc-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-10 18:01:00.000 +0300,market_open,15,7.860000133514404,7.75,448.19000244140625,445.9100036621094,-0.013994927690315503,-0.005087125475528537,-0.008907802214786965
TALS,Talaris Therapeutics Announces Third Quarter Financial Results and Corporate Update,Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients,2022-11-10 14:00:00.000 +0200,Enrollment and dosing continue in the Phase 3 FREEDOM-1 trial of FCR001 in living donor kidney transplant (LDKT) patients,https://www.globenewswire.com/news-release/2022/11/10/2552990/0/en/Talaris-Therapeutics-Announces-Third-Quarter-Financial-Results-and-Corporate-Update.html,,Earnings Releases and Operating Results,biotech,2022-11-10 09:00:00.000 +0200,pre_market,7,1.4299999475479126,1.4700000286102295,374.1300048828125,388.04998779296875,0.02797208568497285,0.03720627249481463,-0.009234186809841782
ICCC,"ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023","PORTLAND, Maine, April  05, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2023, which ended March 31, 2023.",2023-04-05 23:05:00.000 +0300,"PORTLAND, Maine, April  05, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2023, which ended March 31, 2023.",https://www.globenewswire.com/news-release/2023/04/05/2642158/0/en/ImmuCell-Announces-Preliminary-Unaudited-Sales-Results-for-Q1-2023.html,,Earnings Releases and Operating Results,biotech,2023-04-05 18:05:00.000 +0300,market_open,15,5.0,4.949999809265137,407.9100036621094,407.6000061035156,-0.010000038146972656,-0.0007599655703726,-0.00924007257660009
IMNN,IMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET,Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development,2023-09-13 15:30:00.000 +0300,Program will feature executive management plus key opinion leaders in immuno-oncology and vaccine development,https://www.globenewswire.com/news-release/2023/09/13/2742458/0/en/IMUNON-Reminds-Investors-of-its-Virtual-R-D-Day-Tomorrow-at-4-00-p-m-ET.html,,Press releases,biotech,2023-09-13 10:30:00.000 +0300,pre_market,7,1.1399999856948853,1.1299999952316284,445.989990234375,446.2200012207031,-0.008771921569070334,0.0005157312750612,-0.009287652844131576
SCLX,"Scilex Holding Company announces the State of Indiana Medicaid will add Elyxyb as a preferred agent to its preferred drug list (PDL) effective October 1, 2023","PALO ALTO, Calif., Sept.  25, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (“PDL”) effective October 1, 2023.",2023-09-25 16:00:00.000 +0300,"PALO ALTO, Calif., Sept.  25, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced the State of Indiana Medicaid will add Elyxyb as a preferred agent to its Preferred Drug List (“PDL”) effective October 1, 2023.",https://www.globenewswire.com/news-release/2023/09/25/2748673/0/en/Scilex-Holding-Company-announces-the-State-of-Indiana-Medicaid-will-add-Elyxyb-as-a-preferred-agent-to-its-preferred-drug-list-PDL-effective-October-1-2023.html,,Product / Services Announcement,biotech,2023-09-25 11:00:00.000 +0300,pre_market,8,1.5800000429153442,1.559999942779541,430.4200134277344,429.1700134277344,-0.01265829088137235,-0.002904140051586773,-0.009754150829785577
VIR,Vir Biotechnology to Participate in the 44th Annual Goldman Sachs Global Healthcare Conference,"SAN FRANCISCO, June  05, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET.",2023-06-05 23:05:00.000 +0300,"SAN FRANCISCO, June  05, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, is scheduled to participate in a fireside chat at the 44th Annual Goldman Sachs Global Healthcare Conference on Monday, June 12, at 10:40 a.m. PT / 1:40 p.m. ET.",https://www.globenewswire.com/news-release/2023/06/05/2682362/0/en/Vir-Biotechnology-to-Participate-in-the-44th-Annual-Goldman-Sachs-Global-Healthcare-Conference.html,,Trade Show,biotech,2023-06-05 18:05:00.000 +0300,market_open,15,27.020000457763672,26.68000030517578,428.2799987792969,427.1000061035156,-0.012583277084667784,-0.002755189780387874,-0.00982808730427991
OCUP,Ocuphire Announces APX3330 and Nyxol® Data Presentations at ARVO 2023 Annual Meeting,Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients,2023-03-23 14:00:00.000 +0200,Oral Presentation to Feature Results from ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy Patients,https://www.globenewswire.com/news-release/2023/03/23/2633095/0/en/Ocuphire-Announces-APX3330-and-Nyxol-Data-Presentations-at-ARVO-2023-Annual-Meeting.html,,Clinical Study,biotech,2023-03-23 09:00:00.000 +0200,pre_market,7,3.5899999141693115,3.5799999237060547,392.1099853515625,395.0899963378906,-0.0027855127304566327,0.007599936491431791,-0.010385449221888424
SPRY,ARS Reports Second Quarter 2023 Financial Results and Provides Business Updates,"ARS continues engagement with U.S. FDA on final labeling and post-marketing commitments for the neffy® new drug application; PDUFA target action date set for September 19, 2023",2023-08-10 23:00:00.000 +0300,"ARS continues engagement with U.S. FDA on final labeling and post-marketing commitments for the neffy® new drug application; PDUFA target action date set for September 19, 2023",https://www.globenewswire.com/news-release/2023/08/10/2723095/0/en/ARS-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Updates.html,,Earnings Releases and Operating Results,biotech,2023-08-10 18:00:00.000 +0300,market_open,15,6.960000038146973,6.849999904632568,448.19000244140625,445.9100036621094,-0.015804616797630174,-0.005087125475528537,-0.010717491322101636
ANAB,AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference,"SAN DIEGO, Nov.  21, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT.",2022-11-21 20:56:00.000 +0200,"SAN DIEGO, Nov.  21, 2022  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Dan Faga, interim chief executive officer of AnaptysBio, will represent the company in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on Tuesday November 29th, 2022, at 8:10 a.m. ET / 5:10 a.m. PT.",https://www.globenewswire.com/news-release/2022/11/21/2560251/0/en/AnaptysBio-to-Participate-at-the-Piper-Sandler-34th-Annual-Healthcare-Conference.html,,Calendar of Events,biotech,2022-11-21 15:56:00.000 +0200,market_open,13,27.34000015258789,27.040000915527344,394.6400146484375,394.5899963378906,-0.01097290546401662,-0.0001267441432452,-0.010846161320771456
JSPR,Jasper Therapeutics Reports First Quarter 2022 Financial Results and Provides a Corporate Update,"REDWOOD CITY, Calif., May  12, 2022  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on hematopoietic stem cell therapies, today announced first quarter 2022 financial results and provided a corporate update.",2022-05-12 23:05:00.000 +0300,"REDWOOD CITY, Calif., May  12, 2022  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a biotechnology company focused on hematopoietic stem cell therapies, today announced first quarter 2022 financial results and provided a corporate update.",https://www.globenewswire.com/news-release/2022/05/12/2442458/0/en/Jasper-Therapeutics-Reports-First-Quarter-2022-Financial-Results-and-Provides-a-Corporate-Update.html,,Earnings Releases and Operating Results,biotech,2022-05-12 18:05:00.000 +0300,market_open,15,2.940000057220459,2.930000066757202,389.3699951171875,392.3399963378906,-0.00340135723422776,0.007627709525509927,-0.011029066759737687
ELOX,Eloxx Pharmaceuticals Announces FDA Clearance to Begin Single Ascending Dose Study of ZKN-013,ZKN-013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa (RDEB and JEB) and Familial Adenomatous Polyposis (FAP),2023-05-02 15:00:00.000 +0300,ZKN-013 is in development for potential treatment of recessive dystrophic and junctional epidermolysis bullosa (RDEB and JEB) and Familial Adenomatous Polyposis (FAP),https://www.globenewswire.com/news-release/2023/05/02/2659091/0/en/Eloxx-Pharmaceuticals-Announces-FDA-Clearance-to-Begin-Single-Ascending-Dose-Study-of-ZKN-013.html,,Clinical Study,biotech,2023-05-02 10:00:00.000 +0300,pre_market,7,6.960000038146973,6.869999885559082,415.510009765625,414.7699890136719,-0.012931056335432468,-0.0017809938017390855,-0.011150062533693383
CHRS,Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights,"– Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA® autoinjector launched in late May, and YUSIMRY™ launched in July –– Planned merger with Surface Oncology expected to significantly advancenext-generation immuno-oncology pipeline –– Conference call today at 5:00 p.m. Eastern Daylight Time –",2023-08-02 23:01:00.000 +0300,"– Net revenue rose 81% from prior quarter to $58.7 million –– CIMERLI® net sales quadrupled to $26.7 million compared to prior quarter –– UDENYCA® autoinjector launched in late May, and YUSIMRY™ launched in July –– Planned merger with Surface Oncology expected to significantly advancenext-generation immuno-oncology pipeline –– Conference call today at 5:00 p.m. Eastern Daylight Time –",https://www.globenewswire.com/news-release/2023/08/02/2717332/33333/en/Coherus-BioSciences-Reports-Second-Quarter-2023-Financial-Results-and-Business-Highlights.html,,Earnings Releases and Operating Results,biotech,2023-08-02 18:01:00.000 +0300,market_open,15,4.420000076293945,4.340000152587891,453.25,450.1300048828125,-0.0180995299378213,-0.006883607539299503,-0.011215922398521795
BIOR,Biora Therapeutics Appoints Dr. Ariella Kelman as Chief Medical Officer,"SAN DIEGO, May  01, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies.",2023-05-01 16:00:00.000 +0300,"SAN DIEGO, May  01, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced the appointment of Ariella Kelman, MD, as Chief Medical Officer. Dr. Kelman has a proven track record of leading global biopharmaceutical development, clinical trials, and regulatory strategies.",https://www.globenewswire.com/news-release/2023/05/01/2658330/0/en/Biora-Therapeutics-Appoints-Dr-Ariella-Kelman-as-Chief-Medical-Officer.html,,Management Changes,biotech,2023-05-01 11:00:00.000 +0300,pre_market,8,2.430000066757202,2.4000000953674316,415.92999267578125,415.4700012207031,-0.012345666899427295,-0.001105934804361872,-0.011239732095065423
ECOR,"electroCore to Announce Third Quarter Financial Results on Wednesday, November 8","ROCKAWAY, N.J., Oct.  09, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.",2023-10-09 15:00:00.000 +0300,"ROCKAWAY, N.J., Oct.  09, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the third quarter ended September 30, 2023, after the close of the market on Wednesday, November 8, 2023. Management will host a conference call and webcast at 4:30 PM EST to discuss the financial results and answer questions.",https://www.globenewswire.com/news-release/2023/10/09/2756628/0/en/electroCore-to-Announce-Third-Quarter-Financial-Results-on-Wednesday-November-8.html,,Conference Calls/ Webcasts,biotech,2023-10-09 10:00:00.000 +0300,pre_market,7,5.590000152587891,5.5,429.5400085449219,427.5799865722656,-0.016100205747977495,-0.004563071969234895,-0.0115371337787426
QGEN,QIAGEN erweitert Angebot an digitalen PCR-Kits und -Dienstleistungen für Biopharma-Branche,"Neue Partnerschaft mit Niba Labs ermöglicht Biopharma-Kunden Zugang zu Dienstleistungen für maßgeschneidertes digitales PCR-Testdesign // Neues CGT Viral Vector Lysis Kit bietet standardisierten Workflow von Zelllysaten bis zur absoluten und präzisen Quantifizierung von Virustitern // Biopharma-Unternehmen setzen vermehrt auf digitale PCR-Technologie, um Sicherheit von Medikamenten und Effizienz im Entwicklungsprozess zu erhöhen",2023-07-18 23:05:00.000 +0300,"Neue Partnerschaft mit Niba Labs ermöglicht Biopharma-Kunden Zugang zu Dienstleistungen für maßgeschneidertes digitales PCR-Testdesign // Neues CGT Viral Vector Lysis Kit bietet standardisierten Workflow von Zelllysaten bis zur absoluten und präzisen Quantifizierung von Virustitern // Biopharma-Unternehmen setzen vermehrt auf digitale PCR-Technologie, um Sicherheit von Medikamenten und Effizienz im Entwicklungsprozess zu erhöhen",https://www.globenewswire.com/news-release/2023/07/18/2706827/0/de/QIAGEN-erweitert-Angebot-an-digitalen-PCR-Kits-und-Dienstleistungen-f%C3%BCr-Biopharma-Branche.html,,Clinical Study,biotech,2023-07-18 18:05:00.000 +0300,market_open,15,45.81999969482422,45.65999984741211,450.5,454.19000244140625,-0.003491921616712337,0.008190904420435628,-0.011682826037147966
QGEN,QIAGEN expands range of digital PCR kits and services for the biopharma industry,New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers // Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysates to absolute and precise quantification of viral titers // Biopharmaceutical companies increasingly adopting dPCR technology for enhanced drug safety and efficacy in drug development process New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers // Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysates to absolute and precise quantification of viral titers // Biopharmaceutical companies increasingly adopting dPCR technology for enhanced drug safety and efficacy in drug development process,2023-07-18 23:05:00.000 +0300,New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers // Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysates to absolute and precise quantification of viral titers // Biopharmaceutical companies increasingly adopting dPCR technology for enhanced drug safety and efficacy in drug development process New partnership with Niba Labs to offer customized digital PCR (dPCR) assay design services to biopharma customers // Launch of CGT Viral Vector Lysis Kit enabling standardized workflow from cell lysates to absolute and precise quantification of viral titers // Biopharmaceutical companies increasingly adopting dPCR technology for enhanced drug safety and efficacy in drug development process,https://www.globenewswire.com/news-release/2023/07/18/2706829/8690/en/QIAGEN-expands-range-of-digital-PCR-kits-and-services-for-the-biopharma-industry.html,,Company Announcement,biotech,2023-07-18 18:05:00.000 +0300,market_open,15,45.81999969482422,45.65999984741211,450.5,454.19000244140625,-0.003491921616712337,0.008190904420435628,-0.011682826037147966
QGEN,QIAGEN delivers ahead of outlook for Q2 2023 with 9% CER sales growth in non-COVID products and updates 2023 full-year outlook,"Q2 2023: Net sales of $495 million (-4% at actual rates, -4% at constant exchange rates, CER); diluted EPS of $0.35 and adjusted diluted EPS of $0.51 // Net sales at CER of $497 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.50 CER // 9% CER sales growth in non-COVID product portfolio to $457 million, 10% CER sales growth in recurring consumables and related revenues // Full-year 2023: Outlook revised to net sales of at least $1.97 billion CER due to significant drop in COVID-19 demand and volatility in large-scale customer bulk orders in the OEM  business; adj. diluted EPS revised to at least $2.07 CER Q2 2023: Net sales of $495 million (-4% at actual rates, -4% at constant exchange rates, CER); diluted EPS of $0.35 and adjusted diluted EPS of $0.51 // Net sales at CER of $497 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.50 CER // 9% CER sales growth in non-COVID product portfolio to $457 million, 10% CER sales growth in recurring consumables and related revenues // Full-year 2023: Outlook revised to net sales of at least $1.97 billion CER due to significant drop in COVID-19 demand and volatility in large-scale customer bulk orders in the OEM  business; adj. diluted EPS revised to at least $2.07 CER",2023-08-08 23:05:00.000 +0300,"Q2 2023: Net sales of $495 million (-4% at actual rates, -4% at constant exchange rates, CER); diluted EPS of $0.35 and adjusted diluted EPS of $0.51 // Net sales at CER of $497 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.50 CER // 9% CER sales growth in non-COVID product portfolio to $457 million, 10% CER sales growth in recurring consumables and related revenues // Full-year 2023: Outlook revised to net sales of at least $1.97 billion CER due to significant drop in COVID-19 demand and volatility in large-scale customer bulk orders in the OEM  business; adj. diluted EPS revised to at least $2.07 CER Q2 2023: Net sales of $495 million (-4% at actual rates, -4% at constant exchange rates, CER); diluted EPS of $0.35 and adjusted diluted EPS of $0.51 // Net sales at CER of $497 million ahead of outlook for at least $490 million CER and adjusted diluted EPS of $0.52 CER ahead of outlook for at least $0.50 CER // 9% CER sales growth in non-COVID product portfolio to $457 million, 10% CER sales growth in recurring consumables and related revenues // Full-year 2023: Outlook revised to net sales of at least $1.97 billion CER due to significant drop in COVID-19 demand and volatility in large-scale customer bulk orders in the OEM  business; adj. diluted EPS revised to at least $2.07 CER",https://www.globenewswire.com/news-release/2023/08/08/2721128/8690/en/QIAGEN-delivers-ahead-of-outlook-for-Q2-2023-with-9-CER-sales-growth-in-non-COVID-products-and-updates-2023-full-year-outlook.html,,Company Announcement,biotech,2023-08-08 18:05:00.000 +0300,market_open,15,45.060001373291016,44.599998474121094,448.0799865722656,448.75,-0.010208674770316034,0.0014952987140975918,-0.011703973484413627
QGEN,QIAGEN übertrifft Prognose für zweites Quartal 2023 mit Umsatzwachstum von 9% (CER) bei Nicht-COVID-Produkten und passt Jahresprognose an,"Q2 2023: Konzernumsatz von $495 Mio. (-4% bei tatsächlichen Kursen; -4% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,35; bereinigter verwässerter Gewinn je Aktie von $0,51 // Konzernumsatz bei konstanten Wechselkursen (CER) von $497 Mio. gegenüber Prognose von mind. $490 Millionen (CER) und bereinigter verwässerter Gewinn je Aktie von $0,52 (CER) gegenüber Prognose von mind. $0,50 CER // Umsatzwachstum von 9% (CER) beim Nicht-COVID-Produktportfolio auf $457 Mio., Umsatzwachstum von 10% (CER) bei Verbrauchsmaterialien und damit verbundenen Umsätzen // Gesamtjahr 2023: Prognose angepasst auf mindestens $1,97 Mrd. (CER), aufgrund des deutlichen Abfalls der COVID-19-Nachfrage und Volatilität bei Großkundenaufträgen im OEM-Geschäft; Prognose für bereinigten verwässerten Gewinn je Aktie angepasst auf mindestens $2,07 (CER)",2023-08-08 23:05:00.000 +0300,"Q2 2023: Konzernumsatz von $495 Mio. (-4% bei tatsächlichen Kursen; -4% bei konstanten Wechselkursen, CER); verwässerter Gewinn je Aktie von $0,35; bereinigter verwässerter Gewinn je Aktie von $0,51 // Konzernumsatz bei konstanten Wechselkursen (CER) von $497 Mio. gegenüber Prognose von mind. $490 Millionen (CER) und bereinigter verwässerter Gewinn je Aktie von $0,52 (CER) gegenüber Prognose von mind. $0,50 CER // Umsatzwachstum von 9% (CER) beim Nicht-COVID-Produktportfolio auf $457 Mio., Umsatzwachstum von 10% (CER) bei Verbrauchsmaterialien und damit verbundenen Umsätzen // Gesamtjahr 2023: Prognose angepasst auf mindestens $1,97 Mrd. (CER), aufgrund des deutlichen Abfalls der COVID-19-Nachfrage und Volatilität bei Großkundenaufträgen im OEM-Geschäft; Prognose für bereinigten verwässerten Gewinn je Aktie angepasst auf mindestens $2,07 (CER)",https://www.globenewswire.com/news-release/2023/08/08/2721133/0/de/QIAGEN-%C3%BCbertrifft-Prognose-f%C3%BCr-zweites-Quartal-2023-mit-Umsatzwachstum-von-9-CER-bei-Nicht-COVID-Produkten-und-passt-Jahresprognose-an.html,,Earnings Releases and Operating Results,biotech,2023-08-08 18:05:00.000 +0300,market_open,15,45.060001373291016,44.599998474121094,448.0799865722656,448.75,-0.010208674770316034,0.0014952987140975918,-0.011703973484413627
ECOR,TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project,"ROCKAWAY, N.J., June  27, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air Force Research Laboratories (AFRL) Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments (A2PEX) Grant Program. A2PEX is a five-year project led by the Florida Institute for Human and Machine Cognition (IHMC) that includes internationally-recognized leaders in wearable technologies from industry and academia.",2023-06-27 15:00:00.000 +0300,"ROCKAWAY, N.J., June  27, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air Force Research Laboratories (AFRL) Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments (A2PEX) Grant Program. A2PEX is a five-year project led by the Florida Institute for Human and Machine Cognition (IHMC) that includes internationally-recognized leaders in wearable technologies from industry and academia.",https://www.globenewswire.com/news-release/2023/06/27/2695227/0/en/TAC-STIM-Non-Invasive-Vagal-Nerve-Stimulation-Selected-for-Inclusion-in-the-Air-Force-Research-Laboratories-Real-Time-Assessing-and-Augmenting-Cognitive-Performance-in-Extreme-Envi.html,,Product / Services Announcement,biotech,2023-06-27 10:00:00.000 +0300,pre_market,7,3.869999885559082,3.8289999961853027,431.44000244140625,432.3500061035156,-0.010594286973178093,0.002109224126089148,-0.012703511099267241
DYAI,Dyadic to Participate at Two Industry Events in May,"JUPITER, Fla., May  10, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that they will be participating in the following events during the month of May.",2023-05-10 15:30:00.000 +0300,"JUPITER, Fla., May  10, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, today announced that they will be participating in the following events during the month of May.",https://www.globenewswire.com/news-release/2023/05/10/2665543/0/en/Dyadic-to-Participate-at-Two-Industry-Events-in-May.html,,Product / Services Announcement,biotech,2023-05-10 10:30:00.000 +0300,pre_market,7,1.7999999523162842,1.7899999618530273,410.92999267578125,413.8800048828125,-0.005555550404536735,0.007178868078774609,-0.012734418483311343
SPRY,ARS Pharmaceuticals Announces Availability of Briefing Documents for FDA Advisory Committee Meeting on neffy® for the Treatment of Type I Allergic Reactions Including Anaphylaxis,"SAN DIEGO, May  09, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the Pulmonology, Allergy-Drugs Advisory Committee (PADAC) meeting to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.",2023-05-09 16:10:00.000 +0300,"SAN DIEGO, May  09, 2023  (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (NASDAQ: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced that the U.S. Food and Drug Administration (FDA) posted briefing documents for the Pulmonology, Allergy-Drugs Advisory Committee (PADAC) meeting to review the new drug application (NDA) for neffy®. neffy has the potential to be the first, non-injectable epinephrine nasal spray medicine for the treatment of patients with allergic reactions (type 1), including anaphylaxis.",https://www.globenewswire.com/news-release/2023/05/09/2664565/0/en/ARS-Pharmaceuticals-Announces-Availability-of-Briefing-Documents-for-FDA-Advisory-Committee-Meeting-on-neffy-for-the-Treatment-of-Type-I-Allergic-Reactions-Including-Anaphylaxis.html,,Product / Services Announcement,biotech,2023-05-09 11:10:00.000 +0300,pre_market,8,6.010000228881836,5.909999847412109,412.739990234375,411.1300048828125,-0.016638997946982058,-0.0039007253710702165,-0.012738272575911841
IMNN,IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update,Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet,2023-08-10 15:00:00.000 +0300,Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet,https://www.globenewswire.com/news-release/2023/08/10/2722608/0/en/IMUNON-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,,Press releases,biotech,2023-08-10 10:00:00.000 +0300,pre_market,7,1.25,1.2400000095367432,445.75,448.19000244140625,-0.007999992370605469,0.005473925836020752,-0.013473918206626221
ICCC,"ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2023","PORTLAND, Maine, Oct.  05, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023.",2023-10-05 23:05:00.000 +0300,"PORTLAND, Maine, Oct.  05, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2023, which ended September 30, 2023.",https://www.globenewswire.com/news-release/2023/10/05/2755774/0/en/ImmuCell-Announces-Preliminary-Unaudited-Sales-Results-for-Q3-2023.html,,Conference Calls/ Webcasts,biotech,2023-10-05 18:05:00.000 +0300,market_open,15,5.309999942779541,5.239999771118164,424.3599853515625,424.5,-0.013182706669622877,0.0003299430984792,-0.013512649768102118
FBIO,"Aevitas Therapeutics, a Fortress Biotech Subsidiary, Announces Asset Purchase Agreement with 4D Molecular Therapeutics for World-Wide Rights to Aevitas’ Short-Form Human Complement Factor H","Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT",2023-04-24 15:00:00.000 +0300,"Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT Company is eligible to receive up to ~$140 million in potential late-stage development, regulatory and sales milestone payments plus royalties from 4DMT",https://www.globenewswire.com/news-release/2023/04/24/2652668/28889/en/Aevitas-Therapeutics-a-Fortress-Biotech-Subsidiary-Announces-Asset-Purchase-Agreement-with-4D-Molecular-Therapeutics-for-World-Wide-Rights-to-Aevitas-Short-Form-Human-Complement-Fa.html,,Health,biotech,2023-04-24 10:00:00.000 +0300,pre_market,7,10.649999618530273,10.5,412.20001220703125,411.989990234375,-0.014084471727988077,-0.0005095147172164,-0.013574957010771707
DYAI,Dyadic to Participate at Upcoming Events in June,"JUPITER, Fla., June  01, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating in the following events during the month of June.",2023-06-01 15:30:00.000 +0300,"JUPITER, Fla., June  01, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that its management will be participating in the following events during the month of June.",https://www.globenewswire.com/news-release/2023/06/01/2680321/0/en/Dyadic-to-Participate-at-Upcoming-Events-in-June.html,,Calendar of Events,biotech,2023-06-01 10:30:00.000 +0300,pre_market,7,2.2799999713897705,2.25,417.8500061035156,418.0899963378906,-0.0131578823536055,0.0005743454131135,-0.013732227766718995
FBIO,"Fortress Biotech to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference","MIAMI, Dec.  06, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Fortress will participate in one-on-one meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.",2022-12-06 15:30:00.000 +0200,"MIAMI, Dec.  06, 2022  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Fortress will participate in one-on-one meetings at the Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference, which is being held on Thursday, December 8, 2022 in Miami, FL.",https://www.globenewswire.com/news-release/2022/12/06/2568308/28889/en/Fortress-Biotech-to-Participate-in-Cantor-Medical-Aesthetic-Dermatology-Ophthalmology-MedTech-Diagnostic-Conference.html,,Trade Show,biotech,2022-12-06 10:30:00.000 +0200,pre_market,8,10.5,10.350000381469727,399.5899963378906,399.4200134277344,-0.014285677955264137,-0.0004253933074253,-0.01386028464783881
ECOR,electroCore to Participate in the LD Micro Main Event XVI Conference,"ROCKAWAY, N.J., Sept.  25, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the LD Micro Main Event XVI Conference in Los Angeles, California from October 3 – 5, 2023.",2023-09-25 15:00:00.000 +0300,"ROCKAWAY, N.J., Sept.  25, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the LD Micro Main Event XVI Conference in Los Angeles, California from October 3 – 5, 2023.",https://www.globenewswire.com/news-release/2023/09/25/2748582/0/en/electroCore-to-Participate-in-the-LD-Micro-Main-Event-XVI-Conference.html,,Conference Calls/ Webcasts,biotech,2023-09-25 10:00:00.000 +0300,pre_market,7,5.320000171661377,5.230000019073486,430.4200134277344,429.1700134277344,-0.016917321369142847,-0.002904140051586773,-0.014013181317556075
DYAI,Dyadic to Present at BioProcess International,"JUPITER, Fla., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.",2023-09-12 23:30:00.000 +0300,"JUPITER, Fla., Sept.  12, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.",https://www.globenewswire.com/news-release/2023/09/12/2742080/0/en/Dyadic-to-Present-at-BioProcess-International.html,,Conference Calls/ Webcasts,biotech,2023-09-12 18:30:00.000 +0300,market_open,15,1.850000023841858,1.8200000524520874,446.95001220703125,445.989990234375,-0.016216200542241165,-0.002147940365670153,-0.014068260176571012
DYAI,Dyadic Announces Development and License Agreement to Commercialize Animal-Free Alternative Proteins Using Dapibus™,"JUPITER, Fla., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.",2023-09-19 15:00:00.000 +0300,"JUPITER, Fla., Sept.  19, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced that it entered into a development and exclusive license agreement to commercialize certain non-animal dairy enzymes used in the production of food products using Dapibus™.",https://www.globenewswire.com/news-release/2023/09/19/2745544/0/en/Dyadic-Announces-Development-and-License-Agreement-to-Commercialize-Animal-Free-Alternative-Proteins-Using-Dapibus.html,,Licensing Agreements,biotech,2023-09-19 10:00:00.000 +0300,pre_market,7,1.840000033378601,1.809999942779541,443.6300048828125,442.67999267578125,-0.016304396768935924,-0.0021414516524467307,-0.014162945116489193
JSPR,Jasper Therapeutics to Present at the Credit Suisse 30th Annual Virtual Healthcare Conference,"REDWOOD CITY, Calif., Nov.  08, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman, and Chief Executive Officer, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Wednesday, November 10, 2021, at 11:40 a.m. Pacific Time.",2021-11-08 15:00:00.000 +0200,"REDWOOD CITY, Calif., Nov.  08, 2021  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on hematopoietic cell transplant therapies, today announced that Bill Lis, Executive Chairman, and Chief Executive Officer, will present at the Credit Suisse 30th Annual Virtual Healthcare Conference on Wednesday, November 10, 2021, at 11:40 a.m. Pacific Time.",https://www.globenewswire.com/news-release/2021/11/08/2329239/0/en/Jasper-Therapeutics-to-Present-at-the-Credit-Suisse-30th-Annual-Virtual-Healthcare-Conference.html,,Calendar of Events,biotech,2021-11-08 10:00:00.000 +0200,pre_market,8,9.270000457763672,9.15999984741211,468.5299987792969,469.70001220703125,-0.011866300422826456,0.0024972006718517823,-0.014363501094678238
ALVO,Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update,"REYKJAVIK, Iceland, Aug.  30, 2023  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.",2023-08-30 23:15:00.000 +0300,"REYKJAVIK, Iceland, Aug.  30, 2023  (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.",https://www.globenewswire.com/news-release/2023/08/30/2734797/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-30 18:15:00.000 +0300,market_open,15,9.84000015258789,9.729999542236328,449.510009765625,451.010009765625,-0.011178923642865256,0.0033369668470388495,-0.014515890489904105
ALVO,Alvotech birtir uppgjör fyrir fyrri helming ársins 2023 og kynnir helstu áfanga á liðnum ársfjórðung,Alvotech (NASDAQ: ALVO) birtir í dag óendurskoðað fjárhagsuppgjör fyrir fyrstu sex mánuði ársins 2023 og kynnir helstu áfanga í rekstri á síðasta ársfjórðungi.,2023-08-30 23:15:00.000 +0300,Alvotech (NASDAQ: ALVO) birtir í dag óendurskoðað fjárhagsuppgjör fyrir fyrstu sex mánuði ársins 2023 og kynnir helstu áfanga í rekstri á síðasta ársfjórðungi.,https://www.globenewswire.com/news-release/2023/08/30/2734798/0/is/Alvotech-birtir-uppgj%C3%B6r-fyrir-fyrri-helming-%C3%A1rsins-2023-og-kynnir-helstu-%C3%A1fanga-%C3%A1-li%C3%B0num-%C3%A1rsfj%C3%B3r%C3%B0ung.html,,European Regulatory News,biotech,2023-08-30 18:15:00.000 +0300,market_open,15,9.84000015258789,9.729999542236328,449.510009765625,451.010009765625,-0.011178923642865256,0.0033369668470388495,-0.014515890489904105
ALVO,Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update,"Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.",2023-08-30 23:15:00.000 +0300,"Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported unaudited financial results for the first six months of 2023 and provided a summary of recent corporate highlights.",https://www.globenewswire.com/news-release/2023/08/30/2734798/0/en/Alvotech-Reports-Financial-Results-for-First-Six-Months-of-2023-and-Provides-Business-Update.html,,European Regulatory News,biotech,2023-08-30 18:15:00.000 +0300,market_open,15,9.84000015258789,9.729999542236328,449.510009765625,451.010009765625,-0.011178923642865256,0.0033369668470388495,-0.014515890489904105
DBVT,Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF,"AMF Regulated InformationMontrouge, France, July 10, 2023",2023-07-10 23:30:00.000 +0300,"AMF Regulated InformationMontrouge, France, July 10, 2023",https://www.globenewswire.com/news-release/2023/07/10/2702197/0/en/Half-Year-Report-on-the-DBV-Technologies-Liquidity-Contract-with-ODDO-BHF.html,,European Regulatory News,biotech,2023-07-10 18:30:00.000 +0300,market_open,15,1.7899999618530273,1.7699999809265137,438.17999267578125,439.6600036621094,-0.01117317394007622,0.003377632505058753,-0.014550806445134973
DBVT,Bilan semestriel du contrat de liquidité DBV Technologies avec ODDO BHF,"Informations RéglementéesMontrouge, France, le 10 juillet (22 :30 CET) 2023",2023-07-10 23:30:00.000 +0300,"Informations RéglementéesMontrouge, France, le 10 juillet (22 :30 CET) 2023",https://www.globenewswire.com/news-release/2023/07/10/2702197/0/fr/Bilan-semestriel-du-contrat-de-liquidit%C3%A9-DBV-Technologies-avec-ODDO-BHF.html,,European Regulatory News,biotech,2023-07-10 18:30:00.000 +0300,market_open,15,1.7899999618530273,1.7699999809265137,438.17999267578125,439.6600036621094,-0.01117317394007622,0.003377632505058753,-0.014550806445134973
ARQT,Arcutis Appoints L. Todd Edwards as Chief Commercial Officer,"WESTLAKE VILLAGE, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie.",2023-09-27 15:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the appointment of Todd Edwards as Chief Commercial Officer (CCO), effective immediately. Mr. Edwards brings to Arcutis over 25 years of sales, market access, marketing, and general management experience from leading companies in dermatology and immunology, including Incyte, UCB, and AbbVie.",https://www.globenewswire.com/news-release/2023/09/27/2750305/0/en/Arcutis-Appoints-L-Todd-Edwards-as-Chief-Commercial-Officer.html,,Directors and Officers,biotech,2023-09-27 10:00:00.000 +0300,pre_market,7,5.829999923706055,5.760000228881836,425.8800048828125,427.0899963378906,-0.012006808874831144,0.0028411558213705594,-0.014847964696201704
JSPR,Jasper Therapeutics Announces Fiscal 2021 Financial Results and Provides Business Update,"REDWOOD CITY, Calif., March  18, 2022  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update.",2022-03-18 22:05:00.000 +0200,"REDWOOD CITY, Calif., March  18, 2022  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (NASDAQ: JSPR), a biotechnology company focused on transforming the field of hematopoietic stem cell therapies, today announced results for the fiscal year ended December 31, 2021, and provided a business update.",https://www.globenewswire.com/news-release/2022/03/18/2406265/0/en/Jasper-Therapeutics-Announces-Fiscal-2021-Financial-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2022-03-18 17:05:00.000 +0200,market_open,15,3.5,3.5,438.0,444.5199890136719,0.0,0.014885819665917522,-0.014885819665917522
QGEN,Therapie von gastrointestinalen Stromatumoren: QIAGEN erhält FDA-Zulassung für Begleitdiagnostikum zu AYVAKIT® (avapritinib) von Blueprint Medicines,"therascreen® PDGFRA RGQ PCR-Kit von QIAGEN in USA zugelassen, um Patienten mit inoperablen oder metastasierenden gastrointestinalen Stromatumoren und PDGFRA-D842V-Mutation zu ermitteln, die für eine Behandlung mit AYVAKIT® (avapritinib) infrage kommen // Erstes von der FDA zugelassenes Begleitdiagnostikum zum Nachweis von PDGFRA-Genmutationen, die mit primären Resistenzen gegen andere Medikamente assoziiert sind // Zulassung erweitert das Portfolio von QIAGEN in der Präzisionsmedizin, das nun 12 von der FDA zugelassene Begleitdiagnostika umfasst",2023-08-07 23:05:00.000 +0300,"therascreen® PDGFRA RGQ PCR-Kit von QIAGEN in USA zugelassen, um Patienten mit inoperablen oder metastasierenden gastrointestinalen Stromatumoren und PDGFRA-D842V-Mutation zu ermitteln, die für eine Behandlung mit AYVAKIT® (avapritinib) infrage kommen // Erstes von der FDA zugelassenes Begleitdiagnostikum zum Nachweis von PDGFRA-Genmutationen, die mit primären Resistenzen gegen andere Medikamente assoziiert sind // Zulassung erweitert das Portfolio von QIAGEN in der Präzisionsmedizin, das nun 12 von der FDA zugelassene Begleitdiagnostika umfasst",https://www.globenewswire.com/news-release/2023/08/07/2720111/0/de/Therapie-von-gastrointestinalen-Stromatumoren-QIAGEN-erh%C3%A4lt-FDA-Zulassung-f%C3%BCr-Begleitdiagnostikum-zu-AYVAKIT-avapritinib-von-Blueprint-Medicines.html,,Health,biotech,2023-08-07 18:05:00.000 +0300,market_open,15,45.70000076293945,45.220001220703125,448.7099914550781,450.7099914550781,-0.010503272083653556,0.004457221898523797,-0.014960493982177352
QGEN,QIAGEN receives FDA approval for companion diagnostic to Blueprint Medicines’ AYVAKIT® (avapritinib) in gastrointestinal stromal tumors,"QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may be eligible for treatment with AYVAKIT® (avapritinib) // First FDA-approved companion diagnostic to detect mutation in the platelet-derived growth factor receptor alpha gene associated with primary resistance to other drugs // Approval adds to QIAGEN’s leading portfolio in precision medicine, including now 12 FDA approved companion diagnostics QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may be eligible for treatment with AYVAKIT® (avapritinib) // First FDA-approved companion diagnostic to detect mutation in the platelet-derived growth factor receptor alpha gene associated with primary resistance to other drugs // Approval adds to QIAGEN’s leading portfolio in precision medicine, including now 12 FDA approved companion diagnostics",2023-08-07 23:05:00.000 +0300,"QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may be eligible for treatment with AYVAKIT® (avapritinib) // First FDA-approved companion diagnostic to detect mutation in the platelet-derived growth factor receptor alpha gene associated with primary resistance to other drugs // Approval adds to QIAGEN’s leading portfolio in precision medicine, including now 12 FDA approved companion diagnostics QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in U.S. to aid in identifying patients with unresectable or metastatic gastrointestinal stromal tumors positive for the PDGFRA D842V mutation who may be eligible for treatment with AYVAKIT® (avapritinib) // First FDA-approved companion diagnostic to detect mutation in the platelet-derived growth factor receptor alpha gene associated with primary resistance to other drugs // Approval adds to QIAGEN’s leading portfolio in precision medicine, including now 12 FDA approved companion diagnostics",https://www.globenewswire.com/news-release/2023/08/07/2720112/8690/en/QIAGEN-receives-FDA-approval-for-companion-diagnostic-to-Blueprint-Medicines-AYVAKIT-avapritinib-in-gastrointestinal-stromal-tumors.html,,Company Announcement,biotech,2023-08-07 18:05:00.000 +0300,market_open,15,45.70000076293945,45.220001220703125,448.7099914550781,450.7099914550781,-0.010503272083653556,0.004457221898523797,-0.014960493982177352
TTOO,"T2 Biosystems to Report Preliminary Third Quarter 2023 Financial Results and Business Updates on October 12, 2023","LEXINGTON, Mass., Oct.  05, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report preliminary financial results for the third quarter 2023 and business updates after market close on Thursday, October 12, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.",2023-10-05 23:05:00.000 +0300,"LEXINGTON, Mass., Oct.  05, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report preliminary financial results for the third quarter 2023 and business updates after market close on Thursday, October 12, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.",https://www.globenewswire.com/news-release/2023/10/05/2755776/32489/en/T2-Biosystems-to-Report-Preliminary-Third-Quarter-2023-Financial-Results-and-Business-Updates-on-October-12-2023.html,,Conference Calls/ Webcasts,biotech,2023-10-05 18:05:00.000 +0300,market_open,15,0.19699999690055847,0.1940000057220459,424.3599853515625,424.5,-0.015228381856406356,0.0003299430984792,-0.015558324954885598
DYAI,Dyadic Announces Continued Progress Towards Commercialization of Animal-Free Recombinant Serum Albumin,"JUPITER, Fla., Aug.  07, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and manufacture biopharmaceuticals and alternative proteins for food, nutrition, health and wellness at flexible commercial scales affordably, today announced positive results from third party analytical testing of the company’s animal-free recombinant serum albumin.",2023-08-07 15:30:00.000 +0300,"JUPITER, Fla., Aug.  07, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to develop and manufacture biopharmaceuticals and alternative proteins for food, nutrition, health and wellness at flexible commercial scales affordably, today announced positive results from third party analytical testing of the company’s animal-free recombinant serum albumin.",https://www.globenewswire.com/news-release/2023/08/07/2719707/0/en/Dyadic-Announces-Continued-Progress-Towards-Commercialization-of-Animal-Free-Recombinant-Serum-Albumin.html,,Product / Services Announcement,biotech,2023-08-07 10:30:00.000 +0300,pre_market,7,1.7200000286102295,1.7000000476837158,446.80999755859375,448.7099914550781,-0.011627895694091225,0.004252353140856508,-0.015880248834947732
BIOR,Biora Therapeutics Announces Clinical Device Performance Study Results for its NaviCap™ Targeted Oral Delivery Platform,Phase 1-ready device shows 100% success in human functional study of twelve subjects to date Phase 1-ready device shows 100% success in human functional study of twelve subjects to date,2023-07-27 15:00:00.000 +0300,Phase 1-ready device shows 100% success in human functional study of twelve subjects to date Phase 1-ready device shows 100% success in human functional study of twelve subjects to date,https://www.globenewswire.com/news-release/2023/07/27/2712117/0/en/Biora-Therapeutics-Announces-Clinical-Device-Performance-Study-Results-for-its-NaviCap-Targeted-Oral-Delivery-Platform.html,,Clinical Study,biotech,2023-07-27 10:00:00.000 +0300,pre_market,7,3.6600000858306885,3.630000114440918,455.510009765625,459.0199890136719,-0.00819671330225163,0.007705602890818746,-0.015902316193070375
VIR,Vir Biotechnology to Participate in Upcoming Investor Healthcare Conferences,"SAN FRANCISCO, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of September:",2023-08-29 23:30:00.000 +0300,"SAN FRANCISCO, Aug.  29, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that management will be participating in the following upcoming investor conferences during the month of September:",https://www.globenewswire.com/news-release/2023/08/29/2733902/0/en/Vir-Biotechnology-to-Participate-in-Upcoming-Investor-Healthcare-Conferences.html,,Conference Calls/ Webcasts,biotech,2023-08-29 18:30:00.000 +0300,market_open,15,13.0600004196167,13.039999961853027,442.6499938964844,449.1600036621094,-0.0015314285697594849,0.014706901288577436,-0.01623832985833692
MYNZ,Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit,Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit,2023-10-05 15:01:00.000 +0300,Mainz Biomed to Attend the JonesTrading 2023 Healthcare Summit,https://www.globenewswire.com/news-release/2023/10/05/2755334/0/en/Mainz-Biomed-to-Attend-the-JonesTrading-2023-Healthcare-Summit.html,,Calendar of Events,biotech,2023-10-05 10:01:00.000 +0300,pre_market,7,2.950000047683716,2.9000000953674316,424.6600036621094,424.3599853515625,-0.016949136104436064,-0.0007064906229916,-0.016242645481444426
IMCR,Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV,Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV,2023-02-22 14:00:00.000 +0200,Immunocore announces initial Phase 1 safety and pharmacodynamic activity data with first soluble TCR therapy for people living with HIV,https://www.globenewswire.com/news-release/2023/02/22/2613010/0/en/Immunocore-announces-initial-Phase-1-safety-and-pharmacodynamic-activity-data-with-first-soluble-TCR-therapy-for-people-living-with-HIV.html,,Health,biotech,2023-02-22 09:00:00.000 +0200,pre_market,7,58.599998474121094,57.709999084472656,399.0899963378906,399.5199890136719,-0.015187703290495454,0.0010774328590717056,-0.01626513614956716
MDWD,MediWound to Present Phase 2 EscharEx® Data at the Symposium on Advanced Wound Care (SAWC) Spring 2023,Data to be highlighted in oral and poster presentations,2023-04-26 15:00:00.000 +0300,Data to be highlighted in oral and poster presentations,https://www.globenewswire.com/news-release/2023/04/26/2654972/30505/en/MediWound-to-Present-Phase-2-EscharEx-Data-at-the-Symposium-on-Advanced-Wound-Care-SAWC-Spring-2023.html,,Health,biotech,2023-04-26 10:00:00.000 +0300,pre_market,7,11.850000381469727,11.65999984741211,406.0799865722656,406.7200012207031,-0.016033799826262275,0.0015760802541388075,-0.017609880080401083
ADTX,"Aditxt, Inc. to Present at 8th Annual Dawson James Conference","Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023",2023-10-06 15:00:00.000 +0300,"Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023 Chief Executive Officer, Amro Albanna to Present at 9:00am Eastern Time on Thursday, October 12, 2023",https://www.globenewswire.com/news-release/2023/10/06/2756039/0/en/Aditxt-Inc-to-Present-at-8th-Annual-Dawson-James-Conference.html,,Advisory,biotech,2023-10-06 10:00:00.000 +0300,pre_market,7,11.779999732971191,11.5,424.5,421.9700012207031,-0.023769078040595925,-0.005959950010122203,-0.01780912803047372
ARQT,Arcutis to Report Second Quarter Financial Results,"WESTLAKE VILLAGE, Calif., July  24, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, August 8, 2023, to report its second quarter financial results.",2023-07-24 23:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., July  24, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will host a conference call and webcast at 4:30 p.m. ET on Tuesday, August 8, 2023, to report its second quarter financial results.",https://www.globenewswire.com/news-release/2023/07/24/2709892/0/en/Arcutis-to-Report-Second-Quarter-Financial-Results.html,,Conference Calls/ Webcasts,biotech,2023-07-24 18:00:00.000 +0300,market_open,15,10.470000267028809,10.300000190734863,453.3699951171875,454.20001220703125,-0.016236874112534112,0.0018307719936984503,-0.018067646106232564
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"WESTLAKE VILLAGE, Calif., Oct.  05, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of inducement awards to L. Todd Edwards, its new Chief Commercial Officer. The Compensation Committee of Arcutis’ Board of Directors granted Mr. Edwards 60,000 restricted stock units of Arcutis’ common stock and options to purchase 240,000 shares of Arcutis’ common stock, with a grant date of September 27, 2023. Additionally, the Company also reported the grant of an aggregate of 79,200 restricted stock units of Arcutis’ common stock to nine newly hired employees, with a grant date of October 2, 2023. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",2023-10-05 23:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., Oct.  05, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of inducement awards to L. Todd Edwards, its new Chief Commercial Officer. The Compensation Committee of Arcutis’ Board of Directors granted Mr. Edwards 60,000 restricted stock units of Arcutis’ common stock and options to purchase 240,000 shares of Arcutis’ common stock, with a grant date of September 27, 2023. Additionally, the Company also reported the grant of an aggregate of 79,200 restricted stock units of Arcutis’ common stock to nine newly hired employees, with a grant date of October 2, 2023. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",https://www.globenewswire.com/news-release/2023/10/05/2755752/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Stock Market News,biotech,2023-10-05 18:00:00.000 +0300,market_open,15,4.510000228881836,4.429999828338623,424.3599853515625,424.5,-0.017738447113792584,0.0003299430984792,-0.018068390212271825
ANAB,AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors,"SAN DIEGO, Sept.  18, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.",2023-09-18 23:15:00.000 +0300,"SAN DIEGO, Sept.  18, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced it has appointed John Orwin chairman of the AnaptysBio Board of Directors.",https://www.globenewswire.com/news-release/2023/09/18/2745192/0/en/AnaptysBio-Announces-Appointment-of-John-Orwin-as-Chairman-of-the-Board-of-Directors.html,,Directors and Officers,biotech,2023-09-18 18:15:00.000 +0300,market_open,15,19.600000381469727,19.270000457763672,443.04998779296875,443.6300048828125,-0.016836730473640395,0.0013091459334714712,-0.018145876407111867
ICCC,"ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022","PORTLAND, Maine, Aug.  11, 2022  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2022.",2022-08-11 23:05:00.000 +0300,"PORTLAND, Maine, Aug.  11, 2022  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2022.",https://www.globenewswire.com/news-release/2022/08/11/2497126/0/en/ImmuCell-Announces-Unaudited-Financial-Results-for-the-Quarter-Ended-June-30-2022.html,,Conference Calls/ Webcasts,biotech,2022-08-11 18:05:00.000 +0300,market_open,15,8.979999542236328,8.75,422.989990234375,419.989990234375,-0.025612422490062882,-0.007092366413535523,-0.01852005607652736
FBIO,Fortress Biotech to Present at H.C. Wainwright 25th Annual Global Investment Conference,"MIAMI, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET. The Company will also attend one-on-one meetings during the conference.",2023-09-07 15:30:00.000 +0300,"MIAMI, Sept.  07, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Tuesday, September 12, 2023, at 11:30 a.m. ET. The Company will also attend one-on-one meetings during the conference.",https://www.globenewswire.com/news-release/2023/09/07/2739367/28889/en/Fortress-Biotech-to-Present-at-H-C-Wainwright-25th-Annual-Global-Investment-Conference.html,,Calendar of Events,biotech,2023-09-07 10:30:00.000 +0300,pre_market,7,5.849999904632568,5.699999809265137,446.2200012207031,443.1099853515625,-0.025641042361154186,-0.006969691767811171,-0.018671350593343017
TALS,Talaris Therapeutics Presents Additional Phase 2 Data and Analyses at American Transplant Congress 2022,"BOSTON and LOUISVILLE, Ky., June  07, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).",2022-06-07 23:01:00.000 +0300,"BOSTON and LOUISVILLE, Ky., June  07, 2022  (GLOBE NEWSWIRE) -- Talaris Therapeutics, Inc. (Nasdaq: TALS), a late-clinical stage cell therapy company developing therapies with the potential to transform the standard of care in solid organ transplantation and severe immune and blood disorders, presented additional data and analyses from its Phase 2 trial of FCR001 and other studies of its Facilitated Allo-HSCT Therapy platform at the 2022 American Transplant Congress (ATC).",https://www.globenewswire.com/news-release/2022/06/07/2458199/0/en/Talaris-Therapeutics-Presents-Additional-Phase-2-Data-and-Analyses-at-American-Transplant-Congress-2022.html,,Calendar of Events,biotech,2022-06-07 18:01:00.000 +0300,market_open,15,8.75,8.75,408.1000061035156,415.739990234375,0.0,0.018720862574359957,-0.018720862574359957
SCLX,"Scilex Holding Company Enters Master Distributor Agreement Among CH Trading Group LLC (“CHT” or “Territories Distributor”) and Farouk, Maamoun Tamer & Co. (“Master Distributor”) For the Distribution of ZTlido® in the Kingdom of Saudi Arabia","PALO ALTO, Calif., May  31, 2023  (GLOBE NEWSWIRE) --  Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a master distributor agreement with Farouk, Maamoun Tamer & Co. for the distribution of ZTlido® in Kingdom of Saudi Arabia.",2023-05-31 22:16:00.000 +0300,"PALO ALTO, Calif., May  31, 2023  (GLOBE NEWSWIRE) --  Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announced a master distributor agreement with Farouk, Maamoun Tamer & Co. for the distribution of ZTlido® in Kingdom of Saudi Arabia.",https://www.globenewswire.com/news-release/2023/05/31/2679753/0/en/Scilex-Holding-Company-Enters-Master-Distributor-Agreement-Among-CH-Trading-Group-LLC-CHT-or-Territories-Distributor-and-Farouk-Maamoun-Tamer-Co-Master-Distributor-For-the-Distribu.html,,Product / Services Announcement,biotech,2023-05-31 17:16:00.000 +0300,market_open,14,6.070000171661377,5.949999809265137,418.2799987792969,417.8500061035156,-0.01976941663963673,-0.001028002001138317,-0.018741414638498412
EYEN,Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update,"Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the Optejet®",2023-08-10 23:05:00.000 +0300,"Announced FDA approval of and first commercial sale of Mydcombi™, the only fixed dose combination of tropicamide and phenylephrine for mydriasis and the first FDA approved product to utilize the Optejet®",https://www.globenewswire.com/news-release/2023/08/10/2723131/0/en/Eyenovia-Reports-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,,Company Announcement,biotech,2023-08-10 18:05:00.000 +0300,market_open,15,2.0799999237060547,2.0299999713897705,448.19000244140625,445.9100036621094,-0.024038439495322868,-0.005087125475528537,-0.01895131401979433
QGEN,QIAGEN N.V. to release results for Q3 2023 and hold webcast,"Venlo, the Netherlands, Oct.  09, 2023  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. ",2023-10-09 18:14:00.000 +0300,"Venlo, the Netherlands, Oct.  09, 2023  (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced its plans to release results for the third quarter 2023. ",https://www.globenewswire.com/news-release/2023/10/09/2756849/8690/en/QIAGEN-N-V-to-release-results-for-Q3-2023-and-hold-webcast.html,,Company Announcement,biotech,2023-10-09 13:14:00.000 +0300,market_open,10,40.18000030517578,39.86000061035156,427.5799865722656,432.2900085449219,-0.007964153618560278,0.011015534217152153,-0.018979687835712432
ECOR,Data Highlighting Non-Invasive Vagus Nerve Stimulation (nVNS) for Treatment of Acute Neurological Injury Presented at 2023 World Stroke Congress,“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH),2023-10-10 15:00:00.000 +0300,“VANQUISH” Clinical Trial (n=40) suggests safety and efficacy of nVNS for the Treatment of Headache Associated with Subarachnoid Hemorrhage (SAH),https://www.globenewswire.com/news-release/2023/10/10/2757401/0/en/Data-Highlighting-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-for-Treatment-of-Acute-Neurological-Injury-Presented-at-2023-World-Stroke-Congress.html,,Clinical Study,biotech,2023-10-10 10:00:00.000 +0300,pre_market,7,5.679999828338623,5.579999923706055,432.2900085449219,432.94000244140625,-0.017605617544854384,0.001503606106169882,-0.019109223651024267
CHRS,FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections,"– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL –",2023-09-25 15:30:00.000 +0300,"– No issues with clinical efficacy or safety, trial design, labeling, drug substance manufacturing, or device design or manufacturing were identified in the UDENYCA® ONBODY™ CRL –",https://www.globenewswire.com/news-release/2023/09/25/2748635/33333/en/FDA-Issues-Complete-Response-Letter-CRL-for-UDENYCA-ONBODY-Biologics-License-Application-Solely-Due-to-an-Ongoing-Review-of-Inspection-Findings-at-a-Third-Party-Filler-Coherus-Also.html,,Product / Services Announcement,biotech,2023-09-25 10:30:00.000 +0300,pre_market,7,4.460000038146973,4.360000133514404,430.4200134277344,429.1700134277344,-0.02242150308907083,-0.002904140051586773,-0.019517363037484057
DYAI,Dyadic Appoints Doug Pace to Its Executive Leadership Team,"JUPITER, Fla., Oct.  09, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic’s management team is in response to the increased interest in the Company’s microbial platforms, specifically the C1 technology for infectious disease and other recombinant vaccines and antibodies for human and animal pharmaceutical use, and the Dapibus™ platform for non-pharmaceutical applications for large nutritional markets such as dairy proteins and enzymes as well as cell culture markets for recombinant serum albumin.",2023-10-09 15:30:00.000 +0300,"JUPITER, Fla., Oct.  09, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced the appointment of Doug Pace as Executive Vice President of Business Development. The expansion of Dyadic’s management team is in response to the increased interest in the Company’s microbial platforms, specifically the C1 technology for infectious disease and other recombinant vaccines and antibodies for human and animal pharmaceutical use, and the Dapibus™ platform for non-pharmaceutical applications for large nutritional markets such as dairy proteins and enzymes as well as cell culture markets for recombinant serum albumin.",https://www.globenewswire.com/news-release/2023/10/09/2756672/0/en/Dyadic-Appoints-Doug-Pace-to-Its-Executive-Leadership-Team.html,,Health,biotech,2023-10-09 10:30:00.000 +0300,pre_market,7,2.0399999618530273,1.9900000095367432,429.5400085449219,427.5799865722656,-0.024509781005518688,-0.004563071969234895,-0.019946709036283792
ARQT,Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4),"WESTLAKE VILLAGE, Calif., Aug.  04, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 38,500 restricted stock units of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 1, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",2023-08-04 23:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., Aug.  04, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 38,500 restricted stock units of Arcutis’ common stock to five newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of August 1, 2023, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4).",https://www.globenewswire.com/news-release/2023/08/04/2719254/0/en/Arcutis-Biotherapeutics-Reports-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Stock Market News,biotech,2023-08-04 18:00:00.000 +0300,market_open,15,10.119999885559082,9.829999923706055,450.7200012207031,446.80999755859375,-0.028656123036804385,-0.008675016976215288,-0.019981106060589095
ICCC,"ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023","PORTLAND, Maine, July  11, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2023, which ended June 30, 2023.",2023-07-11 23:05:00.000 +0300,"PORTLAND, Maine, July  11, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2023, which ended June 30, 2023.",https://www.globenewswire.com/news-release/2023/07/11/2703133/0/en/ImmuCell-Announces-Preliminary-Unaudited-Sales-Results-for-Q2-2023.html,,Pre-Release Comments,biotech,2023-07-11 18:05:00.000 +0300,market_open,15,5.059999942779541,4.980000019073486,440.45001220703125,442.4599914550781,-0.015810261780775717,0.004563467345534082,-0.0203737291263098
EYEN,Eyenovia Reports Fourth Quarter 2022 Financial Results and Provides Business Update,"Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023",2023-03-30 23:05:00.000 +0300,"Announced FDA acceptance of Mydcombi New Drug Application (NDA) and PDUFA action date of May 8, 2023",https://www.globenewswire.com/news-release/2023/03/30/2638171/0/en/Eyenovia-Reports-Fourth-Quarter-2022-Financial-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-03-30 18:05:00.000 +0300,market_open,15,3.25,3.180000066757202,404.0899963378906,403.70001220703125,-0.021538440997783955,-0.0009650922675484,-0.020573348730235516
ALVO,Alvotech and Islandsbanki enter into Market Making Agreement for Shares Trading on Nasdaq Iceland,"Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price.",2023-10-05 20:21:00.000 +0300,"Alvotech (Nasdaq: ALVO) and Íslandsbanki hf. (“Islandsbanki”) have entered into a market making agreement. According to the market making agreement, Islandsbanki places bids and offers for ALVO shares trading on the Nasdaq Iceland Main Market (the “Exchange”) for a minimum amount with a fixed spread between the bid and offer price.",https://www.globenewswire.com/news-release/2023/10/05/2755706/0/en/Alvotech-and-Islandsbanki-enter-into-Market-Making-Agreement-for-Shares-Trading-on-Nasdaq-Iceland.html,,European Regulatory News,biotech,2023-10-05 15:21:00.000 +0300,market_open,12,9.300000190734863,9.100000381469727,424.3599853515625,424.5,-0.021505355393904912,0.0003299430984792,-0.021835298492384154
ALVO,Alvotech og Íslandsbanki gera samning um viðskiptavakt með hlutabréf í Kauphöllinni,"Alvotech (NASDAQ: ALVO) og Íslandbanki hf. hafa gert samning um viðskiptavakt á hlutabréfum Alvotech á Aðalmarkaði Nasdaq Iceland („Kauphöllinni“).  Samkvæmt samningnum gefur Íslandsbanki út virk kaup og sölutilboð fyrir hlutabréf í Alvotech á Nasdaq Iceland markaðnum („Kauphöllinni“), fyrir ákveðna lágmarksfjárhæð með föstu bili milli kaup og söluverðs.",2023-10-05 20:21:00.000 +0300,"Alvotech (NASDAQ: ALVO) og Íslandbanki hf. hafa gert samning um viðskiptavakt á hlutabréfum Alvotech á Aðalmarkaði Nasdaq Iceland („Kauphöllinni“).  Samkvæmt samningnum gefur Íslandsbanki út virk kaup og sölutilboð fyrir hlutabréf í Alvotech á Nasdaq Iceland markaðnum („Kauphöllinni“), fyrir ákveðna lágmarksfjárhæð með föstu bili milli kaup og söluverðs.",https://www.globenewswire.com/news-release/2023/10/05/2755706/0/is/Alvotech-og-%C3%8Dslandsbanki-gera-samning-um-vi%C3%B0skiptavakt-me%C3%B0-hlutabr%C3%A9f-%C3%AD-Kauph%C3%B6llinni.html,,European Regulatory News,biotech,2023-10-05 15:21:00.000 +0300,market_open,12,9.300000190734863,9.100000381469727,424.3599853515625,424.5,-0.021505355393904912,0.0003299430984792,-0.021835298492384154
ICCC,"ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023","Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET",2023-08-07 19:00:00.000 +0300,"Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET Conference Call Scheduled for Friday, August 11, 2023 at 9:00 AM ET",https://www.globenewswire.com/news-release/2023/08/07/2719984/0/en/ImmuCell-to-Announce-Unaudited-Financial-Results-for-the-Quarter-Ended-June-30-2023.html,,Health,biotech,2023-08-07 14:00:00.000 +0300,market_open,11,5.110000133514404,5.019999980926514,448.7099914550781,450.7099914550781,-0.017612553862301563,0.004457221898523797,-0.02206977576082536
SCLX,Scilex Holding Company Submits a Request to the Securities and Exchange Commission to Withdraw its Registration Statement on Form S-1 (File No. 333-271401),"PALO ALTO, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, submitted a request to the Securities and Exchange Commission (the “SEC”) to withdraw its Registration Statement on Form S-1 (File No. 333-271401) (the “Registration Statement”), as amended, initially filed with the SEC on April 21, 2023. The Company anticipates that, in accordance with SEC rules and regulations, such request will be deemed granted as of the date of such request, unless the SEC notifies the Company within 15 days that such request will not be granted. The Registration Statement had not been declared effective by the SEC, and no securities had been sold pursuant to the Registration Statement.",2023-09-27 16:00:00.000 +0300,"PALO ALTO, Calif., Sept.  27, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, submitted a request to the Securities and Exchange Commission (the “SEC”) to withdraw its Registration Statement on Form S-1 (File No. 333-271401) (the “Registration Statement”), as amended, initially filed with the SEC on April 21, 2023. The Company anticipates that, in accordance with SEC rules and regulations, such request will be deemed granted as of the date of such request, unless the SEC notifies the Company within 15 days that such request will not be granted. The Registration Statement had not been declared effective by the SEC, and no securities had been sold pursuant to the Registration Statement.",https://www.globenewswire.com/news-release/2023/09/27/2750433/0/en/Scilex-Holding-Company-Submits-a-Request-to-the-Securities-and-Exchange-Commission-to-Withdraw-its-Registration-Statement-on-Form-S-1-File-No-333-271401.html,,Regulatory information,biotech,2023-09-27 11:00:00.000 +0300,pre_market,8,1.559999942779541,1.5299999713897705,425.8800048828125,427.0899963378906,-0.019230751596258297,0.0028411558213705594,-0.022071907417628857
ORIC,ORIC Pharmaceuticals Reports Inducement Grants  under Nasdaq Listing Rule 5635(c)(4),"SOUTH SAN FRANCISCO and SAN DIEGO, Aug.  04, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2023 (the “Grant Date”), ORIC granted a total of 28,060 non-qualified stock options and 4,680 restricted stock units to three new non-executive employee who began their employment with ORIC in July 2023.",2023-08-04 23:30:00.000 +0300,"SOUTH SAN FRANCISCO and SAN DIEGO, Aug.  04, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq:ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that on August 1, 2023 (the “Grant Date”), ORIC granted a total of 28,060 non-qualified stock options and 4,680 restricted stock units to three new non-executive employee who began their employment with ORIC in July 2023.",https://www.globenewswire.com/news-release/2023/08/04/2719281/0/en/ORIC-Pharmaceuticals-Reports-Inducement-Grants-under-Nasdaq-Listing-Rule-5635-c-4.html,,Product / Services Announcement,biotech,2023-08-04 18:30:00.000 +0300,market_open,15,7.920000076293945,7.670000076293945,450.7200012207031,446.80999755859375,-0.03156565626158227,-0.008675016976215288,-0.022890639285366977
SNCE,Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"RESEARCH TRIANGLE PARK, N.C., July  07, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",2023-07-07 23:52:00.000 +0300,"RESEARCH TRIANGLE PARK, N.C., July  07, 2023  (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",https://www.globenewswire.com/news-release/2023/07/07/2701346/0/en/Science-37-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html,,Management statements,biotech,2023-07-07 18:52:00.000 +0300,market_open,15,0.2150000035762787,0.20999999344348907,438.6300048828125,438.54998779296875,-0.023255860695907783,-0.0001824250255409,-0.023073435670366887
DYAI,Dyadic Reports 2022 Year End Results and Recent Company Progress,"JUPITER, Fla., March  29, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced its financial results for year end 2022 and highlighted recent Company progress.",2023-03-29 23:00:00.000 +0300,"JUPITER, Fla., March  29, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced its financial results for year end 2022 and highlighted recent Company progress.",https://www.globenewswire.com/news-release/2023/03/29/2637118/0/en/Dyadic-Reports-2022-Year-End-Results-and-Recent-Company-Progress.html,,Conference Calls/ Webcasts,biotech,2023-03-29 18:00:00.000 +0300,market_open,15,1.5199999809265137,1.4900000095367432,399.92999267578125,401.3500061035156,-0.019736823530408253,0.003550654998975193,-0.023287478529383447
ECOR,electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering,"ROCKAWAY, N.J., Aug.  23, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore.",2023-08-23 15:00:00.000 +0300,"ROCKAWAY, N.J., Aug.  23, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey. The litigation has concluded without any finding of wrongdoing or liability, nor any payment, by electroCore.",https://www.globenewswire.com/news-release/2023/08/23/2730348/0/en/electroCore-Announces-Dismissal-of-All-Litigation-Related-to-Its-2018-Initial-Public-Offering.html,,Initial Public Offerings,biotech,2023-08-23 10:00:00.000 +0300,pre_market,7,4.789999961853027,4.690000057220459,438.1499938964844,439.25,-0.020876806978905083,0.002510569710918467,-0.02338737668982355
SCLX,"Scilex Holding Company provides certain preliminary unaudited financial results for gross and net Sales for the one month ended May 2023, and year-to-date May 2023, based on currently available information","PALO ALTO, Calif., June  01, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, is providing certain preliminary unaudited financial results for the month ended May 31, 2023, and year-to-date as of May 31, 2023, based on currently available information.",2023-06-01 19:28:00.000 +0300,"PALO ALTO, Calif., June  01, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, is providing certain preliminary unaudited financial results for the month ended May 31, 2023, and year-to-date as of May 31, 2023, based on currently available information.",https://www.globenewswire.com/news-release/2023/06/01/2680682/0/en/Scilex-Holding-Company-provides-certain-preliminary-unaudited-financial-results-for-gross-and-net-Sales-for-the-one-month-ended-May-2023-and-year-to-date-May-2023-based-on-currentl.html,,Pre-Release Comments,biotech,2023-06-01 14:28:00.000 +0300,market_open,11,5.989999771118164,5.900000095367432,418.0899963378906,421.82000732421875,-0.015024988178577513,0.008921550429332964,-0.023946538607910475
DBVT,"Monthly information regarding the total number of voting rights and  total number of shares of the Company as of September 30, 2023","                  Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023",2023-10-05 23:30:00.000 +0300,"                  Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023",https://www.globenewswire.com/news-release/2023/10/05/2755807/0/en/Monthly-information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-Company-as-of-September-30-2023.html,,European Regulatory News,biotech,2023-10-05 18:30:00.000 +0300,market_open,15,1.2699999809265137,1.2400000095367432,424.3599853515625,424.5,-0.023622025071121953,0.0003299430984792,-0.023951968169601195
DBVT,Information mensuelle relative au nombre total des droits de vote et  d’actions composant le capital social au 30 septembre 2023,          Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2023,2023-10-05 23:30:00.000 +0300,          Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 30 septembre 2023,https://www.globenewswire.com/news-release/2023/10/05/2755807/0/fr/Information-mensuelle-relative-au-nombre-total-des-droits-de-vote-et-d-actions-composant-le-capital-social-au-30-septembre-2023.html,,European Regulatory News,biotech,2023-10-05 18:30:00.000 +0300,market_open,15,1.2699999809265137,1.2400000095367432,424.3599853515625,424.5,-0.023622025071121953,0.0003299430984792,-0.023951968169601195
BIOR,Biora Therapeutics to Participate in Crohn’s & Colitis Foundation’s IBD Innovate Conference,"SAN DIEGO, April  20, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’s & Colitis, an event hosted by the Crohn’s & Colitis Foundation to showcase innovative product development programs in inflammatory bowel disease (IBD), which will take place in New York City on April 26, 2023.",2023-04-20 23:46:00.000 +0300,"SAN DIEGO, April  20, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will participate in IBD Innovate: Product Development for Crohn’s & Colitis, an event hosted by the Crohn’s & Colitis Foundation to showcase innovative product development programs in inflammatory bowel disease (IBD), which will take place in New York City on April 26, 2023.",https://www.globenewswire.com/news-release/2023/04/20/2651613/0/en/Biora-Therapeutics-to-Participate-in-Crohn-s-Colitis-Foundation-s-IBD-Innovate-Conference.html,,Calendar of Events,biotech,2023-04-20 18:46:00.000 +0300,market_open,15,2.680000066757202,2.619999885559082,411.2099914550781,411.8800048828125,-0.022388126755056498,0.001629370495992847,-0.024017497251049343
ANAB,AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update,"SAN DIEGO, Aug.  07, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.",2023-08-07 23:15:00.000 +0300,"SAN DIEGO, Aug.  07, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the second quarter ended June 30, 2023 and provided a business update.",https://www.globenewswire.com/news-release/2023/08/07/2720158/0/en/AnaptysBio-Announces-Second-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-07 18:15:00.000 +0300,market_open,15,18.829999923706055,18.459999084472656,448.7099914550781,450.7099914550781,-0.019649540134494922,0.004457221898523797,-0.02410676203301872
MDAI,"Spectral AI CEO, Wensheng Fan, to Participate in AI Healthcare Panel at Accelerate Health Conference","DALLAS, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the participation of Wensheng Fan, CEO of Spectral AI, as a panelist in the upcoming Accelerate Health: Pioneering Solutions for a Healthier Society Conference. The conference, presented by Worth Media and KPMG, will take place on October 11, 2023, at 8:00 am, at KPMG's Boston office, located at Two Financial Center, 60 South St, Boston, MA 02111.",2023-10-05 15:00:00.000 +0300,"DALLAS, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the participation of Wensheng Fan, CEO of Spectral AI, as a panelist in the upcoming Accelerate Health: Pioneering Solutions for a Healthier Society Conference. The conference, presented by Worth Media and KPMG, will take place on October 11, 2023, at 8:00 am, at KPMG's Boston office, located at Two Financial Center, 60 South St, Boston, MA 02111.",https://www.globenewswire.com/news-release/2023/10/05/2755344/0/en/Spectral-AI-CEO-Wensheng-Fan-to-Participate-in-AI-Healthcare-Panel-at-Accelerate-Health-Conference.html,,Calendar of Events,biotech,2023-10-05 10:00:00.000 +0300,pre_market,7,3.1600000858306885,3.0799999237060547,424.6600036621094,424.3599853515625,-0.025316506313829312,-0.0007064906229916,-0.024610015690837674
ECOR,electroCore to Present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference,"ROCKAWAY, N.J., Sept.  21, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference. Mr. Goldberger will also be available for one-on-one meetings held throughout the conference on September 26 and 27, 2023.",2023-09-21 15:00:00.000 +0300,"ROCKAWAY, N.J., Sept.  21, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at iAccess Alpha’s – Top 10 Best Ideas from the Buyside Virtual Conference. Mr. Goldberger will also be available for one-on-one meetings held throughout the conference on September 26 and 27, 2023.",https://www.globenewswire.com/news-release/2023/09/21/2747197/0/en/electroCore-to-Present-at-iAccess-Alpha-s-Top-10-Best-Ideas-from-the-Buyside-Virtual-Conference.html,,Calendar of Events,biotech,2023-09-21 10:00:00.000 +0300,pre_market,7,5.440000057220459,5.260000228881836,438.6400146484375,435.70001220703125,-0.033088203390680304,-0.006702540450539178,-0.026385662940141125
MDAI,Spectral MD Awarded BARDA Project BioShield Contract Valued at $149 Million for AI-Driven DeepView® Burn Wound Imaging Technology,"DALLAS, Sept.  28, 2023  (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been awarded a new contract valued at up to $149 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The contract is for the advanced development of the DeepView® System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI).",2023-09-28 17:01:00.000 +0300,"DALLAS, Sept.  28, 2023  (GLOBE NEWSWIRE) -- Spectral MD, Inc. (“SMD”), a subsidiary of Spectral AI, Inc. (Nasdaq: MDAI; MDAIW) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced it has been awarded a new contract valued at up to $149 million by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services. The contract is for the advanced development of the DeepView® System, the Company’s AI-driven burn wound imaging technology, to be used at emergency departments, trauma centers and burn centers, for both routine burn care and as a medical countermeasure for use in burn mass casualty incidents (BMCI).",https://www.globenewswire.com/news-release/2023/09/28/2751374/0/en/Spectral-MD-Awarded-BARDA-Project-BioShield-Contract-Valued-at-149-Million-for-AI-Driven-DeepView-Burn-Wound-Imaging-Technology.html,,Financing Agreements,biotech,2023-09-28 12:01:00.000 +0300,pre_market,9,3.5,3.4000000953674316,426.04998779296875,425.4800109863281,-0.02857140132359096,-0.0013378167420992743,-0.027233584581491686
ORPHA.CO,Major shareholder announcement,Company announcement                                                                                         Orphazyme A/SNo. 06/2023                                                                                                             Ole Maaløes Vej 3                                                                                                                DK-2200 Copenhagen N                                                                                                                                                       www.orphazyme.comCompany Registration No. 32266355,2023-05-12 19:02:00.000 +0300,Company announcement                                                                                         Orphazyme A/SNo. 06/2023                                                                                                             Ole Maaløes Vej 3                                                                                                                DK-2200 Copenhagen N                                                                                                                                                       www.orphazyme.comCompany Registration No. 32266355,https://www.globenewswire.com/news-release/2023/05/12/2668022/0/en/Major-shareholder-announcement.html,,European Regulatory News,biotech,2023-05-12 14:02:00.000 +0300,market_open,11,1.2000000476837158,1.1619999408721924,413.4200134277344,411.5899963378906,-0.03166675441794577,-0.004426532413539375,-0.027240222004406393
ECOR,gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD),"ROCKAWAY, N.J., July  25, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working Memory in Patients with Posttraumatic Stress Disorder (PTSD): A Pilot Study, in the Journal of Affective Disorders. The study was conducted with the support of Emory University, The Georgia Institute of Technology and the Atlanta Veteran’s Affairs Medical Center and was sponsored by a Department of Defense Small Business Technology Transfer grant (DoD STTR).",2023-07-25 15:00:00.000 +0300,"ROCKAWAY, N.J., July  25, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer reviewed manuscript, Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working Memory in Patients with Posttraumatic Stress Disorder (PTSD): A Pilot Study, in the Journal of Affective Disorders. The study was conducted with the support of Emory University, The Georgia Institute of Technology and the Atlanta Veteran’s Affairs Medical Center and was sponsored by a Department of Defense Small Business Technology Transfer grant (DoD STTR).",https://www.globenewswire.com/news-release/2023/07/25/2710362/0/en/gammaCore-Non-Invasive-Vagus-Nerve-Stimulation-nVNS-Improves-Attention-and-Memory-in-Patients-with-Posttraumatic-Stress-Disorder-PTSD.html,,Research Analysis and Reports,biotech,2023-07-25 10:00:00.000 +0300,pre_market,7,4.71999979019165,4.585000038146973,454.20001220703125,453.9200134277344,-0.028601643653716396,-0.0006164658119147,-0.027985177841801694
ANAB,AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update,"SAN DIEGO, May  11, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.",2023-05-11 23:15:00.000 +0300,"SAN DIEGO, May  11, 2023  (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported operating results for the first quarter ended March 31, 2023 and provided pipeline updates.",https://www.globenewswire.com/news-release/2023/05/11/2667352/0/en/AnaptysBio-Announces-First-Quarter-2023-Financial-Results-and-Provides-Pipeline-Update.html,,Earnings Releases and Operating Results,biotech,2023-05-11 18:15:00.000 +0300,market_open,15,21.350000381469727,20.760000228881836,411.95001220703125,412.1300048828125,-0.027634667074758864,0.0004369284390039,-0.02807159551376275
IMNN,IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer,Intent-to-treat population shows 9-month OS improvement over control arm,2023-09-28 15:30:00.000 +0300,Intent-to-treat population shows 9-month OS improvement over control arm,https://www.globenewswire.com/news-release/2023/09/28/2751209/0/en/IMUNON-Reports-Interim-Progression-Free-Survival-and-Overall-Survival-Data-in-Phase-1-2-OVATION-2-Study-in-Advanced-Ovarian-Cancer.html,,Press releases,biotech,2023-09-28 10:30:00.000 +0300,pre_market,7,1.0199999809265137,0.9900000095367432,426.04998779296875,425.4800109863281,-0.029411737206622428,-0.0013378167420992743,-0.028073920464523155
ARQT,Arcutis Appoints Interim Chief Financial Officer (CFO),"Former and First Arcutis CFO, John Smither, Appointed Interim Former and First Arcutis CFO, John Smither, Appointed Interim",2023-08-18 23:30:00.000 +0300,"Former and First Arcutis CFO, John Smither, Appointed Interim Former and First Arcutis CFO, John Smither, Appointed Interim",https://www.globenewswire.com/news-release/2023/08/18/2728258/0/en/Arcutis-Appoints-Interim-Chief-Financial-Officer-CFO.html,,Directors and Officers,biotech,2023-08-18 18:30:00.000 +0300,market_open,15,7.989999771118164,7.820000171661377,433.3699951171875,436.5,-0.021276546223604764,0.007222477139807789,-0.028499023363412552
EVAX,Evaxion expands preclinical bacterial vaccine pipeline in collaboration with leading pharmaceutical company,"COPENHAGEN, Denmark, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an undisclosed leading pharmaceutical company, leveraging unique assets and know-how from both organizations.",2023-09-18 15:23:00.000 +0300,"COPENHAGEN, Denmark, Sept.  18, 2023  (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced the initiation of a novel pipeline program, EVX-B3, an AI-designed vaccine candidate against an undisclosed bacterial pathogen. The new vaccine project will be a collaboration between Evaxion and an undisclosed leading pharmaceutical company, leveraging unique assets and know-how from both organizations.",https://www.globenewswire.com/news-release/2023/09/18/2744760/0/en/Evaxion-expands-preclinical-bacterial-vaccine-pipeline-in-collaboration-with-leading-pharmaceutical-company.html,,Partnerships,biotech,2023-09-18 10:23:00.000 +0300,pre_market,7,0.7519999742507935,0.7300000190734863,443.3699951171875,443.04998779296875,-0.02925526054601978,-0.0007217613454744,-0.0285334992005454
ECOR,"electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC","ROCKAWAY, N.J., July  13, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.",2023-07-13 15:00:00.000 +0300,"ROCKAWAY, N.J., July  13, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that ReletexTM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.",https://www.globenewswire.com/news-release/2023/07/13/2704254/0/en/electroCore-Inc-Announces-Distribution-Agreement-with-Reliefband-Technologies-LLC.html,,Partnerships,biotech,2023-07-13 10:00:00.000 +0300,pre_market,7,4.801000118255615,4.683000087738037,446.0199890136719,447.8999938964844,-0.024578218623425487,0.004215068672078892,-0.02879328729550438
OCUP,"Ocuphire Pharma, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","FARMINGTON HILLS, Mich., May  24, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to a new hire in connection with such new hire’s employment with the Company effective on May 22, 2023. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.",2023-05-24 23:05:00.000 +0300,"FARMINGTON HILLS, Mich., May  24, 2023  (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, approved an equity award under Ocuphire’s Inducement Plan, as a material inducement to a new hire in connection with such new hire’s employment with the Company effective on May 22, 2023. The equity award was approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.",https://www.globenewswire.com/news-release/2023/05/24/2675653/0/en/Ocuphire-Pharma-Inc-Reports-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html,,Major shareholder announcements,biotech,2023-05-24 18:05:00.000 +0300,market_open,15,4.0,3.869999885559082,412.4200134277344,411.0899963378906,-0.03250002861022949,-0.0032249091861222203,-0.029275119424107272
FBIO,Fortress Biotech Reports First Quarter 2023 Financial Results and Recent Corporate Highlights,Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023,2023-05-15 23:01:00.000 +0300,Fortress is advancing several late-stage clinical assets with two NDA submissions anticipated in second half of 2023,https://www.globenewswire.com/news-release/2023/05/15/2669279/28889/en/Fortress-Biotech-Reports-First-Quarter-2023-Financial-Results-and-Recent-Corporate-Highlights.html,,Earnings Releases and Operating Results,biotech,2023-05-15 18:01:00.000 +0300,market_open,15,10.949999809265137,10.649999618530273,412.2200012207031,413.010009765625,-0.027397278169906794,0.0019164731031546998,-0.029313751273061493
ICCC,ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility,"PORTLAND, Maine, June  15, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the approval by Gorham Savings Bank (GSB) and the Finance Authority of Maine (FAME) of the principal terms of a $3 million debt facility with the Company.",2023-06-15 23:05:00.000 +0300,"PORTLAND, Maine, June  15, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the approval by Gorham Savings Bank (GSB) and the Finance Authority of Maine (FAME) of the principal terms of a $3 million debt facility with the Company.",https://www.globenewswire.com/news-release/2023/06/15/2689370/0/en/ImmuCell-Announces-Approval-of-Principal-Terms-of-a-3-Million-Debt-Facility.html,,Stock Market News,biotech,2023-06-15 18:05:00.000 +0300,market_open,15,5.599999904632568,5.510000228881836,436.3299865722656,442.6000061035156,-0.016071370943467462,0.014369902881317441,-0.030441273824784905
ELOX,Eloxx Pharmaceuticals Intends to Advance ELX-02 into Pivotal Trial for the Treatment of Alport Syndrome with Nonsense Mutations Following Achievement of Remission in Patient in Phase 2 Study,"Patient treated in trial achieved a remission after eight weeks of treatment, demonstrating a significant reduction in proteinuria",2023-05-24 15:00:00.000 +0300,"Patient treated in trial achieved a remission after eight weeks of treatment, demonstrating a significant reduction in proteinuria",https://www.globenewswire.com/news-release/2023/05/24/2675190/0/en/Eloxx-Pharmaceuticals-Intends-to-Advance-ELX-02-into-Pivotal-Trial-for-the-Treatment-of-Alport-Syndrome-with-Nonsense-Mutations-Following-Achievement-of-Remission-in-Patient-in-Pha.html,,Clinical Study,biotech,2023-05-24 10:00:00.000 +0300,pre_market,7,8.59000015258789,8.289999961853027,414.0899963378906,412.4200134277344,-0.03492435220091153,-0.004032898463921286,-0.030891453736990242
IMNN,IMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus,"Production of cGMP Clinical Materials Supports R&D Efficiencies and Lowers Costs for Infectious Disease and Cancer Vaccines, and Non-viral DNA-based Immuno-Oncology Therapies",2023-06-27 19:00:00.000 +0300,"Production of cGMP Clinical Materials Supports R&D Efficiencies and Lowers Costs for Infectious Disease and Cancer Vaccines, and Non-viral DNA-based Immuno-Oncology Therapies",https://www.globenewswire.com/news-release/2023/06/27/2695606/0/en/IMUNON-Unveils-New-Manufacturing-Capabilities-at-Huntsville-s-HudsonAlpha-Biotech-Campus.html,,Press releases,biotech,2023-06-27 14:00:00.000 +0300,market_open,11,1.3200000524520874,1.2899999618530273,432.3500061035156,436.1700134277344,-0.022727340459820916,0.008835451070409244,-0.03156279153023016
EVAX,Evaxion Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency,nasdaq,2023-10-05 15:30:00.000 +0300,nasdaq,https://www.globenewswire.com/news-release/2023/10/05/2755383/0/en/Evaxion-Receives-Nasdaq-Notification-Regarding-Minimum-Bid-Price-Deficiency.html,,Major shareholder announcements,biotech,2023-10-05 10:30:00.000 +0300,pre_market,7,0.8799999952316284,0.8500000238418579,424.6600036621094,424.3599853515625,-0.03409087676400963,-0.0007064906229916,-0.03338438614101799
DYAI,Dyadic Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress,"JUPITER, Fla., May  10, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced its financial results for the first quarter of 2023, and highlighted recent company developments.",2023-05-10 23:00:00.000 +0300,"JUPITER, Fla., May  10, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective, affordable and accessible biopharmaceutical products and alternative proteins for human and animal health, today announced its financial results for the first quarter of 2023, and highlighted recent company developments.",https://www.globenewswire.com/news-release/2023/05/10/2665987/0/en/Dyadic-Announces-First-Quarter-2023-Financial-Results-and-Highlights-Recent-Company-Progress.html,,Earnings Releases and Operating Results,biotech,2023-05-10 18:00:00.000 +0300,market_open,15,1.7899999618530273,1.7200000286102295,413.8800048828125,412.8500061035156,-0.03910610879026677,-0.002488641072642571,-0.0366174677176242
ORPHA.CO,Orphazyme reports financial results in Interim Report First Half 2022,Company announcementOrphazyme A/SNo. 36/2022             www.orphazyme.comCompany Registration No. 32266355,2022-09-26 18:25:00.000 +0300,Company announcementOrphazyme A/SNo. 36/2022             www.orphazyme.comCompany Registration No. 32266355,https://www.globenewswire.com/news-release/2022/09/26/2522740/0/en/Orphazyme-reports-financial-results-in-Interim-Report-First-Half-2022.html,,European Regulatory News,biotech,2022-09-26 13:25:00.000 +0300,market_open,10,1.3589999675750732,1.2999999523162842,366.4100036621094,364.30999755859375,-0.04341428746614728,-0.005731301226841443,-0.03768298623930584
MYNZ,Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology,Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology,2023-09-27 15:01:00.000 +0300,Mainz Biomed to Present Detailed Results of ColoFuture Study at International Conference on Gastroenterology,https://www.globenewswire.com/news-release/2023/09/27/2750324/0/en/Mainz-Biomed-to-Present-Detailed-Results-of-ColoFuture-Study-at-International-Conference-on-Gastroenterology.html,,Calendar of Events,biotech,2023-09-27 10:01:00.000 +0300,pre_market,7,3.1500000953674316,3.0399999618530273,425.8800048828125,427.0899963378906,-0.03492067624892352,0.0028411558213705594,-0.03776183207029408
IMCR,Immunocore Reports 2022 Financial Results and Provides Business Update,Immunocore Reports 2022 Financial Results and Provides Business Update,2023-03-01 14:00:00.000 +0200,Immunocore Reports 2022 Financial Results and Provides Business Update,https://www.globenewswire.com/news-release/2023/03/01/2618009/0/en/Immunocore-Reports-2022-Financial-Results-and-Provides-Business-Update.html,,Press releases,biotech,2023-03-01 09:00:00.000 +0200,pre_market,7,54.849998474121094,52.560001373291016,396.260009765625,395.4100036621094,-0.04175017619937632,-0.0021450716261234037,-0.03960510457325292
SCLX,"Scilex Holding Company to Participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq on May 2, 2023","PALO ALTO, Calif., April  28, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq:",2023-04-28 16:00:00.000 +0300,"PALO ALTO, Calif., April  28, 2023  (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Henry Ji, Ph.D., Executive Chairman of Scilex, and Jaisim Shah, Chief Executive Officer and President of Scilex will participate in the H.C. Wainwright BioConnect Investor Conference at Nasdaq:",https://www.globenewswire.com/news-release/2023/04/28/2657449/0/en/Scilex-Holding-Company-to-Participate-in-the-H-C-Wainwright-BioConnect-Investor-Conference-at-Nasdaq-on-May-2-2023.html,,Calendar of Events,biotech,2023-04-28 11:00:00.000 +0300,pre_market,8,7.739999771118164,7.400000095367432,412.4100036621094,411.489990234375,-0.043927607985137465,-0.0022308222874441934,-0.04169678569769327
ICCC,"ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023","PORTLAND, Maine, Aug.  10, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023.",2023-08-10 23:05:00.000 +0300,"PORTLAND, Maine, Aug.  10, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2023.",https://www.globenewswire.com/news-release/2023/08/10/2723136/0/en/ImmuCell-Announces-Unaudited-Financial-Results-for-the-Quarter-Ended-June-30-2023.html,,Earnings Releases and Operating Results,biotech,2023-08-10 18:05:00.000 +0300,market_open,15,5.269999980926514,5.019999980926514,448.19000244140625,445.9100036621094,-0.04743833034246951,-0.005087125475528537,-0.042351204866940974
ORIC,ORIC Pharmaceuticals to Participate in the 2023 Cantor Global Healthcare Conference,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.  20, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 8:00 a.m. ET.",2023-09-20 23:30:00.000 +0300,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Sept.  20, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the 2023 Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 8:00 a.m. ET.",https://www.globenewswire.com/news-release/2023/09/20/2746872/0/en/ORIC-Pharmaceuticals-to-Participate-in-the-2023-Cantor-Global-Healthcare-Conference.html,,Conference Calls/ Webcasts,biotech,2023-09-20 18:30:00.000 +0300,market_open,15,8.470000267028809,8.0,444.010009765625,438.6400146484375,-0.05548999435789628,-0.012094310936868528,-0.04339568342102776
PYPD,PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market,"PETACH TIKVA, Israel, June  05, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s (""Nasdaq"") minimum bid price rule and approval from Nasdaq to transfer the listing of the ordinary shares of the Company (the “Ordinary Shares”) from The Nasdaq Global Market to The Nasdaq Capital Market. The transfer will become effective at the opening of business on June 6, 2023.",2023-06-05 23:02:00.000 +0300,"PETACH TIKVA, Israel, June  05, 2023  (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC’s (""Nasdaq"") minimum bid price rule and approval from Nasdaq to transfer the listing of the ordinary shares of the Company (the “Ordinary Shares”) from The Nasdaq Global Market to The Nasdaq Capital Market. The transfer will become effective at the opening of business on June 6, 2023.",https://www.globenewswire.com/news-release/2023/06/05/2682356/0/en/PolyPid-Announces-180-Day-Extension-to-Regain-Compliance-with-Nasdaq-Minimum-Bid-Requirement-and-Transfer-of-its-Listing-to-the-Nasdaq-Capital-Market.html,,Stock Market News,biotech,2023-06-05 18:02:00.000 +0300,market_open,15,12.899999618530273,12.300000190734863,428.2799987792969,427.1000061035156,-0.04651158492543967,-0.002755189780387874,-0.043756395145051794
CHRS,Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors, – Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple product launches –,2023-07-20 23:04:00.000 +0300, – Recognized biopharma commercialization and market access leader to support Coherus’ strategic vision and multiple product launches –,https://www.globenewswire.com/news-release/2023/07/20/2708579/33333/en/Coherus-BioSciences-Appoints-Dr-Michael-Ryan-to-its-Board-of-Directors.html,,Health,biotech,2023-07-20 18:04:00.000 +0300,market_open,15,4.389999866485596,4.170000076293945,454.1700134277344,452.17999267578125,-0.050113848948193866,-0.004381664779966299,-0.045732184168227566
EVAX,Evaxion Announces Business Update and Second Quarter 2023 Financial Results,*Subject to additional funding in the range of $5-10 million secured before initiation,2023-08-18 18:57:00.000 +0300,*Subject to additional funding in the range of $5-10 million secured before initiation,https://www.globenewswire.com/news-release/2023/08/18/2728141/0/en/Evaxion-Announces-Business-Update-and-Second-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-08-18 13:57:00.000 +0300,market_open,10,0.9599999785423279,0.9200000166893005,433.3699951171875,436.5,-0.041666627861558524,0.007222477139807789,-0.04888910500136631
DYAI,"Dyadic to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023","JUPITER, Fla., July  26, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.",2023-07-26 23:30:00.000 +0300,"JUPITER, Fla., July  26, 2023  (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical products for human and animal health, and alternative proteins for food, nutrition and wellness, today announced that it will report its financial results for the second quarter 2023 and host a corporate update conference call on Wednesday, August 9, 2023.",https://www.globenewswire.com/news-release/2023/07/26/2711707/0/en/Dyadic-to-Report-Second-Quarter-2023-Financial-Results-on-Wednesday-August-9-2023.html,,Conference Calls/ Webcasts,biotech,2023-07-26 18:30:00.000 +0300,market_open,15,1.9299999475479126,1.840000033378601,454.4700012207031,455.510009765625,-0.04663208114780389,0.002288398666861222,-0.048920479814665116
FBIO,Fortress Biotech Reports Record 2022 Financial Results and Recent Corporate Highlights,Fortress expects to file a total of three new drug applications in 2023,2023-03-30 23:10:00.000 +0300,Fortress expects to file a total of three new drug applications in 2023,https://www.globenewswire.com/news-release/2023/03/30/2638208/28889/en/Fortress-Biotech-Reports-Record-2022-Financial-Results-and-Recent-Corporate-Highlights.html,,Earnings Releases and Operating Results,biotech,2023-03-30 18:10:00.000 +0300,market_open,15,11.699999809265137,11.100000381469727,404.0899963378906,403.70001220703125,-0.05128200321168171,-0.0009650922675484,-0.05031691094413328
MDAI,Artificial Intelligence-Driven Predictive Medical Diagnostics Company Spectral MD Announces Closing of Business Combination,"Company Renamed “Spectral AI, Ltd.” and Will Commence Trading on Nasdaq Global Market Under the Symbol “MDAI” Effective September 12, 2023",2023-09-11 20:29:00.000 +0300,"Company Renamed “Spectral AI, Ltd.” and Will Commence Trading on Nasdaq Global Market Under the Symbol “MDAI” Effective September 12, 2023",https://www.globenewswire.com/news-release/2023/09/11/2741116/0/en/Artificial-Intelligence-Driven-Predictive-Medical-Diagnostics-Company-Spectral-MD-Announces-Closing-of-Business-Combination.html,,Stock Market News,biotech,2023-09-11 15:29:00.000 +0300,market_open,12,12.1899995803833,11.569999694824219,448.239990234375,448.45001220703125,-0.05086135413464771,0.0004685480484381,-0.051329902183085856
ECOR,"electroCore, Inc. Announces Departure of JP Errico from the Board of Directors","ROCKAWAY, N.J., May  26, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and former CEO, JP Errico from the Board of Directors. Mr. Errico will continue as a consultant and strategic advisor to the Company, focused on supporting the growth and direction of the wellness and human performance brands, Truvaga™ and TAC-STIM™.",2023-05-26 23:01:00.000 +0300,"ROCKAWAY, N.J., May  26, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the resignation of its Founder and former CEO, JP Errico from the Board of Directors. Mr. Errico will continue as a consultant and strategic advisor to the Company, focused on supporting the growth and direction of the wellness and human performance brands, Truvaga™ and TAC-STIM™.",https://www.globenewswire.com/news-release/2023/05/26/2677367/0/en/electroCore-Inc-Announces-Departure-of-JP-Errico-from-the-Board-of-Directors.html,,Directors and Officers,biotech,2023-05-26 18:01:00.000 +0300,market_open,15,5.260000228881836,5.034999847412109,415.3299865722656,420.0199890136719,-0.04277573606067254,0.011292231702586709,-0.05406796776325925
ORIC,ORIC Pharmaceuticals to Participate in the H.C. Wainwright BioConnect Investor Conference,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April  25, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.",2023-04-25 23:30:00.000 +0300,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April  25, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 2, 2023, at 2:00 p.m. ET.",https://www.globenewswire.com/news-release/2023/04/25/2654503/0/en/ORIC-Pharmaceuticals-to-Participate-in-the-H-C-Wainwright-BioConnect-Investor-Conference.html,,Calendar of Events,biotech,2023-04-25 18:30:00.000 +0300,market_open,15,5.360000133514404,5.010000228881836,410.5799865722656,406.0799865722656,-0.06529848804370889,-0.01096010557545274,-0.05433838246825615
ONCT,Oncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial Results,"SAN DIEGO, May  04, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2023 financial results.",2023-05-04 23:01:00.000 +0300,"SAN DIEGO, May  04, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported first quarter 2023 financial results.",https://www.globenewswire.com/news-release/2023/05/04/2661987/0/en/Oncternal-Therapeutics-Provides-Business-Update-and-Announces-First-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-05-04 18:01:00.000 +0300,market_open,15,0.3400000035762787,0.3199999928474426,406.92999267578125,405.1300048828125,-0.05882356034843122,-0.004423335279694849,-0.05440022506873637
ICCC,ImmuCell Announces Change in Timing of Anticipated FDA Submission,"PORTLAND, Maine, June  28, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a change to its anticipated FDA submission schedule.",2023-06-28 23:05:00.000 +0300,"PORTLAND, Maine, June  28, 2023  (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced a change to its anticipated FDA submission schedule.",https://www.globenewswire.com/news-release/2023/06/28/2696602/0/en/ImmuCell-Announces-Change-in-Timing-of-Anticipated-FDA-Submission.html,,Calendar of Events,biotech,2023-06-28 18:05:00.000 +0300,market_open,15,5.400000095367432,5.110000133514404,435.04998779296875,436.3900146484375,-0.053703695691008115,0.003080167551013565,-0.05678386324202168
KA,"Kineta, Inc. Announces Closing of $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","SEATTLE, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has closed its previously announced registered direct offering for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also issued unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which are immediately exercisable for a period of five and one-half years following issuance.",2023-10-05 23:09:00.000 +0300,"SEATTLE, Oct.  05, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has closed its previously announced registered direct offering for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company also issued unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which are immediately exercisable for a period of five and one-half years following issuance.",https://www.globenewswire.com/news-release/2023/10/05/2755780/0/en/Kineta-Inc-Announces-Closing-of-3-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html,,Financing Agreements,biotech,2023-10-05 18:09:00.000 +0300,market_open,15,3.5,3.299999952316284,424.3599853515625,424.5,-0.05714287076677595,0.0003299430984792,-0.057472813865255185
EYEN,Eyenovia Reports First Quarter 2023 Financial Results and Provides Business Update,"Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet®",2023-05-11 23:05:00.000 +0300,"Announced FDA approval of Mydcombi™, a fixed dose combination of tropicamide and phenylephrine for mydriasis, the first FDA approved product to utilize the Optejet®",https://www.globenewswire.com/news-release/2023/05/11/2667294/0/en/Eyenovia-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-05-11 18:05:00.000 +0300,market_open,15,4.329999923706055,4.079999923706055,411.95001220703125,412.1300048828125,-0.05773672157158482,0.0004369284390039,-0.058173650010588704
TTOO,T2 Biosystems Announces Exploration of Strategic Alternatives and the Implementation of a Restructuring Program,"LEXINGTON, Mass., May  23, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced it has initiated a process to explore a range of strategic alternatives focused on maximizing value. To support the strategic process, the Company has initiated a restructuring plan which includes a reduction in force.",2023-05-23 15:01:00.000 +0300,"LEXINGTON, Mass., May  23, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced it has initiated a process to explore a range of strategic alternatives focused on maximizing value. To support the strategic process, the Company has initiated a restructuring plan which includes a reduction in force.",https://www.globenewswire.com/news-release/2023/05/23/2674262/32489/en/T2-Biosystems-Announces-Exploration-of-Strategic-Alternatives-and-the-Implementation-of-a-Restructuring-Program.html,,Company Announcement,biotech,2023-05-23 10:01:00.000 +0300,pre_market,7,0.28299999237060547,0.26499998569488525,418.7900085449219,417.0799865722656,-0.06360426558650972,-0.0040832444369857095,-0.05952102114952401
TTOO,T2 Biosystems Announces First Quarter 2023 Financial Results,"Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternatives Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternatives",2023-05-23 15:05:00.000 +0300,"Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternatives Filed FDA submission for T2Biothreat Panel, implemented a restructuring program and announced exploration of strategic alternatives",https://www.globenewswire.com/news-release/2023/05/23/2674269/32489/en/T2-Biosystems-Announces-First-Quarter-2023-Financial-Results.html,,Conference Calls/ Webcasts,biotech,2023-05-23 10:05:00.000 +0300,pre_market,7,0.28299999237060547,0.26499998569488525,418.7900085449219,417.0799865722656,-0.06360426558650972,-0.0040832444369857095,-0.05952102114952401
TALS,Talaris Therapeutics Announces First Quarter Financial Results and Corporate Update,"Multiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients",2022-05-12 23:01:00.000 +0300,"Multiple presentations pending at upcoming American Transplant Congress (ATC), as well as concurrent update on ongoing Phase 3 (FREEDOM-1) clinical trial in living donor kidney transplant (LDKT) patients",https://www.globenewswire.com/news-release/2022/05/12/2442416/0/en/Talaris-Therapeutics-Announces-First-Quarter-Financial-Results-and-Corporate-Update.html,,Earnings Releases and Operating Results,biotech,2022-05-12 18:01:00.000 +0300,market_open,15,6.300000190734863,5.960000038146973,389.3699951171875,392.3399963378906,-0.05396827655464425,0.007627709525509927,-0.06159598608015418
DBVT,DBV Technologies a reçu les commentaires de la FDA sur les éléments de conception des études de sécurité de Viaskin Peanut et publie ses résultats financiers du deuxième trimestre et du premier semestre 2023.,"Montrouge, France, le 31 juillet 2023",2023-07-31 23:25:00.000 +0300,"Montrouge, France, le 31 juillet 2023",https://www.globenewswire.com/news-release/2023/07/31/2715321/0/fr/DBV-Technologies-a-re%C3%A7u-les-commentaires-de-la-FDA-sur-les-%C3%A9l%C3%A9ments-de-conception-des-%C3%A9tudes-de-s%C3%A9curit%C3%A9-de-Viaskin-Peanut-et-publie-ses-r%C3%A9sultats-financiers-du-deuxi%C3%A8me-trimestre-.html,,European Regulatory News,biotech,2023-07-31 18:25:00.000 +0300,market_open,15,1.5800000429153442,1.4800000190734863,457.4100036621094,457.7900085449219,-0.06329115261120019,0.0008307751902453,-0.0641219278014455
DBVT,DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results,"Montrouge, France, July 31, 2023",2023-07-31 23:25:00.000 +0300,"Montrouge, France, July 31, 2023",https://www.globenewswire.com/news-release/2023/07/31/2715321/0/en/DBV-Technologies-Receives-Feedback-from-FDA-on-Design-Elements-for-Viaskin-Peanut-Safety-Studies-and-Reports-Second-Quarter-and-Half-Year-2023-Financial-Results.html,,European Regulatory News,biotech,2023-07-31 18:25:00.000 +0300,market_open,15,1.5800000429153442,1.4800000190734863,457.4100036621094,457.7900085449219,-0.06329115261120019,0.0008307751902453,-0.0641219278014455
JSPR,Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update,"REDWOOD CITY, Calif., Aug.  11, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended June 30, 2023, and provided a business update.",2023-08-11 23:05:00.000 +0300,"REDWOOD CITY, Calif., Aug.  11, 2023  (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended June 30, 2023, and provided a business update.",https://www.globenewswire.com/news-release/2023/08/11/2723853/0/en/Jasper-Therapeutics-Reports-Second-Quarter-2023-Financial-Results-and-Provides-a-Business-Update.html,,Earnings Releases and Operating Results,biotech,2023-08-11 18:05:00.000 +0300,market_open,15,1.4800000190734863,1.3899999856948853,443.9700012207031,445.6499938964844,-0.0608108325802206,0.0037840229546187384,-0.06459485553483935
ORIC,ORIC Pharmaceuticals Presents Promising Preclinical Data on Two Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April  18, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented two preclinical poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.",2023-04-18 23:15:00.000 +0300,"SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, April  18, 2023  (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented two preclinical poster presentations at the 2023 American Association for Cancer Research (AACR) Annual Meeting.",https://www.globenewswire.com/news-release/2023/04/18/2649571/0/en/ORIC-Pharmaceuticals-Presents-Promising-Preclinical-Data-on-Two-Programs-at-the-2023-American-Association-for-Cancer-Research-AACR-Annual-Meeting.html,,Clinical Study,biotech,2023-04-18 18:15:00.000 +0300,market_open,15,6.190000057220459,5.75,415.5799865722656,414.2099914550781,-0.07108239954007939,-0.0032965858834717253,-0.06778581365660766
TTOO,"T2 Biosystems to Report Second Quarter 2023 Financial Results on August 7, 2023","LEXINGTON, Mass., July  24, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2023 after market close Monday, August 7, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.",2023-07-24 23:05:00.000 +0300,"LEXINGTON, Mass., July  24, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that it will report financial results for the second quarter 2023 after market close Monday, August 7, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.",https://www.globenewswire.com/news-release/2023/07/24/2709912/32489/en/T2-Biosystems-to-Report-Second-Quarter-2023-Financial-Results-on-August-7-2023.html,,Calendar of Events,biotech,2023-07-24 18:05:00.000 +0300,market_open,15,0.10100000351667404,0.09399999678134918,453.3699951171875,454.20001220703125,-0.06930699496628465,0.0018307719936984503,-0.0711377669599831
ARQT,Arcutis to Present at Upcoming Investor Conference,"WESTLAKE VILLAGE, Calif., Sept.  05, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.",2023-09-05 23:00:00.000 +0300,"WESTLAKE VILLAGE, Calif., Sept.  05, 2023  (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in immuno-dermatology, today announced that Arcutis management will participate in an upcoming investor conference.",https://www.globenewswire.com/news-release/2023/09/05/2737850/0/en/Arcutis-to-Present-at-Upcoming-Investor-Conference.html,,Conference Calls/ Webcasts,biotech,2023-09-05 18:00:00.000 +0300,market_open,15,8.979999542236328,8.279999732971191,450.7300109863281,449.239990234375,-0.07795098496083139,-0.0033057944126962547,-0.07464519054813513
BIOR,Biora Therapeutics Announces Closing of $8 Million Registered Direct Offering of Common Stock and Warrants Priced At-the-Market Under Nasdaq Rules,"SAN DIEGO, June  14, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced the closing of its previously announced registered direct offering of an aggregate of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock and concurrent private placement of warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, are exercisable upon issuance, and will expire three years following the date of issuance.",2023-06-14 23:05:00.000 +0300,"SAN DIEGO, June  14, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced the closing of its previously announced registered direct offering of an aggregate of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock and concurrent private placement of warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, are exercisable upon issuance, and will expire three years following the date of issuance.",https://www.globenewswire.com/news-release/2023/06/14/2688455/0/en/Biora-Therapeutics-Announces-Closing-of-8-Million-Registered-Direct-Offering-of-Common-Stock-and-Warrants-Priced-At-the-Market-Under-Nasdaq-Rules.html,,Stock Market News,biotech,2023-06-14 18:05:00.000 +0300,market_open,15,5.079999923706055,4.695000171661377,437.010009765625,437.17999267578125,-0.0757873539029122,0.0003889680015508,-0.07617632190446305
TTOO,T2 Biosystems Reports Granting of Inducement Award,"LEXINGTON, Mass., July  21, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to fourteen new employees.",2023-07-21 23:05:00.000 +0300,"LEXINGTON, Mass., July  21, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the rapid detection of sepsis-causing pathogens, announced today that it issued inducement awards to fourteen new employees.",https://www.globenewswire.com/news-release/2023/07/21/2709117/32489/en/T2-Biosystems-Reports-Granting-of-Inducement-Award.html,,Changes in company's own shares,biotech,2023-07-21 18:05:00.000 +0300,market_open,15,0.10999999940395355,0.10100000351667404,453.9599914550781,452.17999267578125,-0.08181814487315386,-0.0039210476975987335,-0.07789709717555512
OCUP,Ocuphire Appoints Rick Rodgers as Interim Chief Executive Officer,Seasoned operating executive with successful track record at late-stage biopharmaceutical companies Seasoned operating executive with successful track record at late-stage biopharmaceutical companies,2023-04-21 15:00:00.000 +0300,Seasoned operating executive with successful track record at late-stage biopharmaceutical companies Seasoned operating executive with successful track record at late-stage biopharmaceutical companies,https://www.globenewswire.com/news-release/2023/04/21/2651886/0/en/Ocuphire-Appoints-Rick-Rodgers-as-Interim-Chief-Executive-Officer.html,,Directors and Officers,biotech,2023-04-21 10:00:00.000 +0300,pre_market,7,6.159999847412109,5.650000095367432,411.8800048828125,412.19000244140625,-0.0827921695905455,0.0007526404654723,-0.08354481005601784
IMNN,IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET,Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development,2023-09-07 23:30:00.000 +0300,Program will feature members of IMUNON executive management along with key opinion leaders in immuno-oncology and vaccine development,https://www.globenewswire.com/news-release/2023/09/07/2739792/0/en/IMUNON-to-Host-Virtual-R-D-Day-on-September-14th-Beginning-at-4-00-p-m-ET.html,,Press releases,biotech,2023-09-07 18:30:00.000 +0300,market_open,15,1.25,1.149999976158142,443.1099853515625,444.8500061035156,-0.08000001907348633,0.0039268371498615545,-0.08392685622334789
TTOO,T2 Biosystems Regains Compliance with Nasdaq’s Market Value of Listed Securities Requirement,"LEXINGTON, Mass., Aug.  09, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the NASDAQ Capital Market.",2023-08-09 15:30:00.000 +0300,"LEXINGTON, Mass., Aug.  09, 2023  (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it received written notice from the NASDAQ Stock Market LLC (“NASDAQ”) on August 8, 2023 informing the Company that it has regained compliance with the market value of listed securities (“MVLS”) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (the “Rule”) for continued listing on the NASDAQ Capital Market.",https://www.globenewswire.com/news-release/2023/08/09/2721642/32489/en/T2-Biosystems-Regains-Compliance-with-Nasdaq-s-Market-Value-of-Listed-Securities-Requirement.html,,Major shareholder announcements,biotech,2023-08-09 10:30:00.000 +0300,pre_market,7,0.3100000023841858,0.2840000092983246,448.75,449.0299987792969,-0.08387094479321706,0.0006239527115251,-0.08449489750474214
BIOR,Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results,NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device,2023-08-14 23:01:00.000 +0300,NaviCap™ targeted oral delivery platform on track for September IND filing; achieved successful device function study results in humans with phase 1-ready device,https://www.globenewswire.com/news-release/2023/08/14/2724944/0/en/Biora-Therapeutics-Provides-Corporate-Update-and-Reports-Second-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-08-14 18:01:00.000 +0300,market_open,15,3.440000057220459,3.1700000762939453,444.70001220703125,448.1099853515625,-0.0784883652428411,0.007668030247194434,-0.08615639549003554
BIOR,Biora Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results,Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023,2023-05-15 23:05:00.000 +0300,Completed execution of toxicology study for NaviCap™ BT-600 program with no adverse events indicated in preliminary data; on track to file IND in Q3 2023,https://www.globenewswire.com/news-release/2023/05/15/2669298/0/en/Biora-Therapeutics-Provides-Corporate-Update-and-Reports-First-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-05-15 18:05:00.000 +0300,market_open,15,3.6600000858306885,3.3499999046325684,412.2200012207031,413.010009765625,-0.084699501073307,0.0019164731031546998,-0.08661597417646169
ECOR,"electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules","ROCKAWAY, N.J., July  31, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to certain institutional and accredited investors an aggregate of 1,675,914 registered shares of common stock (or common stock equivalents) and unregistered warrants to purchase up to an aggregate of 837,955 shares of common stock. Each share of common stock is being sold together with one-half of one warrant at a combined effective offering price of $4.4125 per share and related warrant. The warrants will be exercisable commencing six months after the date of issuance at a price of $4.35 per share and will expire five years after they first become exercisable.",2023-07-31 16:29:00.000 +0300,"ROCKAWAY, N.J., July  31, 2023  (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced that it has agreed to issue and sell to certain institutional and accredited investors an aggregate of 1,675,914 registered shares of common stock (or common stock equivalents) and unregistered warrants to purchase up to an aggregate of 837,955 shares of common stock. Each share of common stock is being sold together with one-half of one warrant at a combined effective offering price of $4.4125 per share and related warrant. The warrants will be exercisable commencing six months after the date of issuance at a price of $4.35 per share and will expire five years after they first become exercisable.",https://www.globenewswire.com/news-release/2023/07/31/2714982/0/en/electroCore-Inc-Announces-8-145-Million-Registered-Direct-Offering-and-Concurrent-Private-Placements-Priced-At-Market-Under-Nasdaq-Rules.html,,Changes in company's own shares,biotech,2023-07-31 11:29:00.000 +0300,pre_market,8,4.389999866485596,4.0,456.9200134277344,457.4100036621094,-0.0888382410812712,0.0010723763896861916,-0.08991061747095738
ONCT,Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial Results,"SAN DIEGO, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2023 financial results.",2023-08-10 23:01:00.000 +0300,"SAN DIEGO, Aug.  10, 2023  (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today provided a business update and reported second quarter 2023 financial results.",https://www.globenewswire.com/news-release/2023/08/10/2723118/0/en/Oncternal-Therapeutics-Provides-Business-Update-and-Announces-Second-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-08-10 18:01:00.000 +0300,market_open,15,0.3799999952316284,0.3400000035762787,448.19000244140625,445.9100036621094,-0.10526313725600916,-0.005087125475528537,-0.10017601178048063
ELOX,Eloxx Pharmaceuticals to Host Investor and Analyst Call on Alport Syndrome,Globally renowned Alport syndrome experts will provide key insights,2023-06-21 20:30:00.000 +0300,Globally renowned Alport syndrome experts will provide key insights,https://www.globenewswire.com/news-release/2023/06/21/2692434/0/en/Eloxx-Pharmaceuticals-to-Host-Investor-and-Analyst-Call-on-Alport-Syndrome.html,,Health,biotech,2023-06-21 15:30:00.000 +0300,market_open,12,5.03000020980835,4.429999828338623,436.1600036621094,434.94000244140625,-0.11928436509798623,-0.002797141439975438,-0.1164872236580108
ECOR,electroCore Announces Second Quarter 2023 Financial Results,"Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022",2023-08-09 23:05:00.000 +0300,"Record second quarter 2023 net sales of $3.6 million, an increase of approximately 65% over second quarter 2022",https://www.globenewswire.com/news-release/2023/08/09/2722096/0/en/electroCore-Announces-Second-Quarter-2023-Financial-Results.html,,Earnings Releases and Operating Results,biotech,2023-08-09 18:05:00.000 +0300,market_open,15,6.25,5.429999828338623,449.0299987792969,445.75,-0.13120002746582032,-0.00730463173554921,-0.12389539573027111
TTOO,T2 Biosystems Receives FDA 510(k) Clearance for the T2Biothreat Panel,The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company,2023-09-19 16:00:00.000 +0300,The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company The only FDA-cleared multi-target biothreat product developed and manufactured by a U.S. owned company,https://www.globenewswire.com/news-release/2023/09/19/2745682/32489/en/T2-Biosystems-Receives-FDA-510-k-Clearance-for-the-T2Biothreat-Panel.html,,Product / Services Announcement,biotech,2023-09-19 11:00:00.000 +0300,pre_market,8,0.45899999141693115,0.4000000059604645,443.6300048828125,442.67999267578125,-0.12854027572927387,-0.0021414516524467307,-0.12639882407682715
FBIO,Fortress Biotech Announces Reverse Stock Split,"MIAMI, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. Fortress expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on October 10, 2023.",2023-10-09 19:50:00.000 +0300,"MIAMI, Oct.  09, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or the “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, announced that it will effect a 1-for-15 reverse stock split of its issued and outstanding common stock. Fortress expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on October 10, 2023.",https://www.globenewswire.com/news-release/2023/10/09/2756959/28889/en/Fortress-Biotech-Announces-Reverse-Stock-Split.html,,Changes in share capital and votes,biotech,2023-10-09 14:50:00.000 +0300,market_open,11,4.949999809265137,4.349999904632568,427.5799865722656,432.2900085449219,-0.12121210661655413,0.011015534217152153,-0.13222764083370628
KA,"Kineta, Inc. Announces $6 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","SEATTLE, April  20, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 1,425,179 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.21 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 1,425,179 shares of common stock with an exercise price of $4.08 per share which will be immediately exercisable for a period of five years following issuance. The closing of the offering is expected to occur on or about April 24, 2023, subject to the satisfaction of customary closing conditions.",2023-04-20 15:38:00.000 +0300,"SEATTLE, April  20, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 1,425,179 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $4.21 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 1,425,179 shares of common stock with an exercise price of $4.08 per share which will be immediately exercisable for a period of five years following issuance. The closing of the offering is expected to occur on or about April 24, 2023, subject to the satisfaction of customary closing conditions.",https://www.globenewswire.com/news-release/2023/04/20/2651011/0/en/Kineta-Inc-Announces-6-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html,,Changes in company's own shares,biotech,2023-04-20 10:38:00.000 +0300,pre_market,7,4.75,4.010000228881836,414.1400146484375,411.2099914550781,-0.15578942549856087,-0.007074957960405408,-0.14871446753815545
FBIO,Fortress Biotech Announces Pricing of $13.9 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules,"MIAMI, Feb.  08, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has entered into definitive agreements for the issuance and sale of 16.6 million shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share is $0.835.",2023-02-08 15:00:00.000 +0200,"MIAMI, Feb.  08, 2023  (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or monetizing promising therapeutic products and product candidates, today announced that it has entered into definitive agreements for the issuance and sale of 16.6 million shares of its common stock in a registered direct offering priced at-the-market under Nasdaq rules. The purchase price of each share is $0.835.",https://www.globenewswire.com/news-release/2023/02/08/2603922/28889/en/Fortress-Biotech-Announces-Pricing-of-13-9-Million-Registered-Direct-Offering-Priced-At-the-Market-under-Nasdaq-Rules.html,,Prospectus/Announcement of Prospectus,biotech,2023-02-08 10:00:00.000 +0200,pre_market,8,12.600000381469727,10.649999618530273,415.19000244140625,413.1300048828125,-0.1547619606271786,-0.004961577943786032,-0.14980038268339255
TTOO,T2 Biosystems Announces Preliminary Second Quarter 2023 Financial Results,Received record quarterly sepsis test panel orders and strengthened balance sheet Received record quarterly sepsis test panel orders and strengthened balance sheet,2023-07-12 15:30:00.000 +0300,Received record quarterly sepsis test panel orders and strengthened balance sheet Received record quarterly sepsis test panel orders and strengthened balance sheet,https://www.globenewswire.com/news-release/2023/07/12/2703505/32489/en/T2-Biosystems-Announces-Preliminary-Second-Quarter-2023-Financial-Results.html,,Pre-Release Comments,biotech,2023-07-12 10:30:00.000 +0300,pre_market,7,0.15000000596046448,0.12800000607967377,442.4599914550781,446.3900146484375,-0.14666666004392861,0.008882211429862988,-0.1555488714737916
BIOR,Biora Therapeutics Announces $8 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules,"SAN DIEGO, June  13, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, will be exercisable upon issuance, and will expire three years following issuance. The closing of the offering is expected to occur on or about June 14, 2023, subject to the satisfaction of customary closing conditions.",2023-06-13 15:00:00.000 +0300,"SAN DIEGO, June  13, 2023  (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery (“Biora” or the “Company”), today announced that it has entered into a definitive agreement for the purchase and sale of 1,509,434 shares of the Company’s common stock at an offering price of $5.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a concurrent private placement, the Company will issue unregistered warrants to purchase up to 3,018,868 shares of common stock. The warrants have an exercise price of $5.05 per share, will be exercisable upon issuance, and will expire three years following issuance. The closing of the offering is expected to occur on or about June 14, 2023, subject to the satisfaction of customary closing conditions.",https://www.globenewswire.com/news-release/2023/06/13/2687091/0/en/Biora-Therapeutics-Announces-8-Million-Registered-Direct-Offering-Priced-At-the-Market-Under-Nasdaq-Rules.html,,Initial Public Offerings,biotech,2023-06-13 10:00:00.000 +0300,pre_market,7,6.230000019073486,5.0,433.79998779296875,435.32000732421875,-0.1974317841585512,0.003503963978845085,-0.2009357481373963
TTOO,T2 Biosystems Announces Second Quarter 2023 Financial Results,"Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders and received second largest sepsis driven T2Dx® Instrument order",2023-08-07 23:05:00.000 +0300,"Received FDA Breakthrough Device Designation for Candida auris test, achieved record quarterly sepsis test panel orders and received second largest sepsis driven T2Dx® Instrument order",https://www.globenewswire.com/news-release/2023/08/07/2720129/32489/en/T2-Biosystems-Announces-Second-Quarter-2023-Financial-Results.html,,Conference Calls/ Webcasts,biotech,2023-08-07 18:05:00.000 +0300,market_open,15,0.3149999976158142,0.24500000476837158,448.7099914550781,450.7099914550781,-0.222222201197656,0.004457221898523797,-0.2266794230961798
SNCE,Science 37 Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4),"RESEARCH TRIANGLE PARK, N.C., Aug.  11, 2023  (GLOBE NEWSWIRE) -- August 11, 2023—Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",2023-08-11 23:41:00.000 +0300,"RESEARCH TRIANGLE PARK, N.C., Aug.  11, 2023  (GLOBE NEWSWIRE) -- August 11, 2023—Science 37 Holdings, Inc. (Nasdaq: SNCE), the industry-leading Metasite™, today announced the granting of inducement equity awards under the Science 37 Holdings, Inc. 2022 Employment Inducement Incentive Award Plan (the “Plan”). The Plan was approved by Science 37’s Board of Directors in November 2022. In accordance with NASDAQ Listing Rule 5635(c)(4), the awards were approved by Science 37’s Compensation Committee and made as a material inducement to the non-executive employees' entry into employment with the Company.",https://www.globenewswire.com/news-release/2023/08/11/2723879/0/en/Science-37-Reports-Inducement-Grant-Under-NASDAQ-Listing-Rule-5635-c-4.html,,Contests/Awards,biotech,2023-08-11 18:41:00.000 +0300,market_open,15,0.5759999752044678,0.4399999976158142,443.9700012207031,445.6499938964844,-0.23611108236658596,0.0037840229546187384,-0.2398951053212047
KA,"Kineta, Inc. Announces $3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules","SEATTLE, Oct.  04, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which will be immediately exercisable for a period of five and one-half years following issuance. The closing of the offering is expected to occur on or about October 5, 2023, subject to the satisfaction of customary closing conditions.",2023-10-04 15:00:00.000 +0300,"SEATTLE, Oct.  04, 2023  (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which will be immediately exercisable for a period of five and one-half years following issuance. The closing of the offering is expected to occur on or about October 5, 2023, subject to the satisfaction of customary closing conditions.",https://www.globenewswire.com/news-release/2023/10/04/2754501/0/en/Kineta-Inc-Announces-3-Million-Registered-Direct-Offering-Priced-At-The-Market-under-Nasdaq-Rules.html,,Major shareholder announcements,biotech,2023-10-04 10:00:00.000 +0300,pre_market,7,3.950000047683716,2.8399999141693115,421.5899963378906,422.07000732421875,-0.2810126886366266,0.0011385729986425292,-0.2821512616352691
KA,Kineta Presents New Preclinical Data on Lead Anti-CD27 Agonist Antibody at AACR Special Conference on Tumor Immunology and Immunotherapy,Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors,2023-10-04 15:30:00.000 +0300,Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors,https://www.globenewswire.com/news-release/2023/10/04/2754567/0/en/Kineta-Presents-New-Preclinical-Data-on-Lead-Anti-CD27-Agonist-Antibody-at-AACR-Special-Conference-on-Tumor-Immunology-and-Immunotherapy.html,,Clinical Study,biotech,2023-10-04 10:30:00.000 +0300,pre_market,7,3.950000047683716,2.8399999141693115,421.5899963378906,422.07000732421875,-0.2810126886366266,0.0011385729986425292,-0.2821512616352691
VIR,Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating VIR-2482 for the Prevention of Seasonal Influenza A Illness,"SAN FRANCISCO, July  20, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two secondary endpoints. VIR-2482 was generally well tolerated and no safety signals were identified.",2023-07-20 15:00:00.000 +0300,"SAN FRANCISCO, July  20, 2023  (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two secondary endpoints. VIR-2482 was generally well tolerated and no safety signals were identified.",https://www.globenewswire.com/news-release/2023/07/20/2708142/0/en/Vir-Biotechnology-Announces-Topline-Data-from-Phase-2-PENINSULA-Trial-Evaluating-VIR-2482-for-the-Prevention-of-Seasonal-Influenza-A-Illness.html,,Clinical Study,biotech,2023-07-20 10:00:00.000 +0300,pre_market,7,23.049999237060547,13.699999809265137,455.20001220703125,454.1700134277344,-0.40563990183401716,-0.002262738909656306,-0.4033771629243609
